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Evasion of apoptosis is one of the main hallmarks of cancer. The BCL-2 
family of proteins are the main mediators of the intrinsic pathway of apoptosis and 
the interactions between the pro- and anti-apoptotic members of this family of 
proteins control the fate of a cell towards life or death. Anti-apoptotic members of 
the BCL-2 family, such as BCL-2, BCL-XL and MCL-1, are frequently 
overexpressed in a plethora of cancers promoting abnormal cell survival. During the 
last ten years, several small molecule inhibitors called BH3 mimetics were developed 
to inhibit these anti-apoptotic proteins. The potency and specificity of the BH3 
mimetics make them valuable tools for targeting the pro-survival pathways in 
different cancers. The first known bona fide BH3 mimetic, ABT-737, has now been 
replaced by more selective inhibitors, such as ABT-199 (BCL-2-specific inhibitor), 
A-1331852 (BCL-XL-specific inhibitor), A-1210477 and S63845 (both MCL-1-
specific inhibitors), all of which have been employed in the different experiments 
detailed in this thesis. ABT-199 has been successfully used in the treatment of 
haematological malignancies, such as chronic lymphocytic leukaemia. Experiments 
are now in progress to reproduce this success using other BH3 mimetics in a wide 
variety of cancers. 
This study is aimed at exploring (1) whether BH3 mimetic therapy can help 
improve on current therapy in certain haematological malignancies, (2) whether BH3 
mimetics can be used as single agents or in combination with existing therapy to 
target certain solid tumours, and (3) the underlying cellular and molecular 
mechanisms by which BH3 mimetics induce apoptosis. 
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In order to explore the therapeutic potential of BH3 mimetics in 
haematological malignancies, the cancer types chosen for this work were chronic and 
acute myeloid leukaemia (CML and AML). Tyrosine kinase inhibitors (TKIs) are the 
preferred drugs for treating CML, whereas AML is treated with anthracyclines such 
as daunorubicin. Using a series of genetic knockdown experiments, it was identified 
that CML is a BCL-XL dependent malignancy and that targeting BCL-XL with A-
1331852 resulted in rapid and extensive apoptosis not only in the established CML 
cell lines but also in primary patient samples. In marked contrast, using a panel of 
AML cell lines, it was shown that AML cell lines and patient samples demonstrated 
a dual dependency on BCL-2 and MCL-1 for cell survival, which was overcome by a 
combination of ABT-199 and S63845. 
These observations were extended to solid tumours, with a focus on head and 
neck squamous cell carcinoma (HNSCC) and pancreatic ductal adenocarcinoma 
(PDAC). Unlike the dependency on BCL-XL for CML and BCL-2 and MCL-1 for 
AML, these solid tumours demonstrated a dual dependency on BCL-XL and MCL-1 
for survival. In agreement, tissue microarray (TMA) analysis revealed high 
expression levels of both BCL-XL and MCL-1 in the tumour cores of these cancer 
patients. Furthermore, dual inhibition of these BCL-2 family proteins by a 
combination of A-1331852 and S63845 induced cell death and reduced clonogenic 
potential of several cell lines derived from these solid tumours, indicating that a 
combination of these inhibitors could be valuable in treating certain solid tumours. 
A closer analysis of the intracellular effects caused by exposure to BH3 
mimetics indicated that BH3 mimetic-mediated apoptosis was accompanied by 
mitochondrial ultrastructural changes. BH3 mimetics induced extensive 
mitochondrial fragmentation, which was dependent on the mitochondrial fission 
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machinery, of which DRP-1 is the major player. It was shown that BH3 mimetic-
mediated induction of key steps of the intrinsic pathway of apoptosis, such as 
cytochrome c release and BAK activation, were dependent on DRP-1. This strongly 
suggested a linkage between the regulation of mitochondrial membrane dynamics 
with the mechanisms that control cell death. 
Assessment of the involvement of the endoplasmic reticulum (ER) in BH3 
mimetic-mediated mitochondrial membrane dynamics and cell death uncovered new 
roles for ER shaping proteins, such as RTN-4 and CLIMP-63. Genetic silencing of 
these proteins indicated that, similar to DRP-1, ER shaping proteins, play an 
important role both in mitochondrial fission and also in the effective induction of 
BH3 mimetic-mediated apoptosis. 
Overall, this study highlights the potential of BH3 mimetics as therapeutic 
intervention for haematological malignancies, such as CML and AML, as well as for 
hard-to-treat solid tumours, such as HNSCC and PDAC. In addition, this study 
underscores the importance of assessing unanticipated effects of BH3 mimetics, such 
as mitochondrial fission. Finally, this study sheds light on how ER and mitochondrial 
membrane dynamics regulate key steps of the intrinsic pathway of apoptosis, by 
showing for the first time that ER shaping proteins can regulate mitochondrial fission 
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1.1 Apoptosis – Overview 
Apoptosis is a programmed cell death pathway comprised of a coordinated set of 
cellular events, all of which lead to key changes in the cell and ultimately, killing the 
cell. The etymology of the word derives from an antient Greek term that translates to 
“falling off”,1 coined due to the resemblance of apoptotic cells to leaves falling off a 
tree. Apoptosis is crucial for the maintenance of homeostasis, occurring in aging, for 
cellular turnover; during development for the recycling of unnecessary vestigial parts 
of the body, such as the tadpole tail metamorphosis and digit formation in several 
animals; during clearance of cells that are infected/damaged by disease or noxious 
agents.2 Morphologically, apoptotic cells undergo shrinkage and pyknosis (excessive 
chromatin condensation), DNA and nuclear fragmentation,3 followed by blebbing of 
cell fragments into “apoptotic bodies”, consisting of organelles and cytoplasm bodies 
tightly packed by the plasma membrane, which are then cleared by macrophage 
phagocytosis. This ensures that the cells are eliminated with no triggers for 
inflammation or cytokine mediated responses.4 
Apoptosis is initiated via either an extrinsic (death receptor) pathway or intrinsic 
(mitochondrial) pathway (Figure 1.1). The extrinsic pathway occurs at the level of 
cell surface, and is executed by the recruitment of death ligands on transmembrane 
death receptors of the tumour necrosis factor (TNF) superfamily.5 This results in the 
recruitment of adaptor proteins, like FADD, and initiator caspases, such as caspase-8 
to a death inducing signalling complex (DISC), leading to the apoptotic cascade. In 
contrast, the intrinsic pathway occurs at the level of mitochondria and is tightly 
regulated by different members of the BCL-2 family of proteins (discussed in detail 
later). This apoptotic pathway is initiated by disruptions to the mitochondrial 
membrane integrity, characterised by the formation of a pore in the outer 
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mitochondrial membrane (OMM) in a process known as mitochondrial outer 
membrane permeabilisation (MOMP), typically considered as the “point of no 
return”  on the apoptotic pathway, which is mediated by proteins such as BAX and 
BAK.6,7 This results in the release of cytochrome c, from being initially trapped 
within the mitochondrial cristae into the cytosol, where it interacts with and induces 
the oligomerisation of APAF-1 (apoptotic protease activating factor 1), which in turn 
recruits pro-caspase-9.8 APAF-1 bound to cytochrome c and pro-caspase-9 forms a 
structure called apoptosome. By interacting with the apoptosome,9 caspase-9 
undergoes dimerization and activation.10,11 This often accompanies the cleavage of 
pro-caspase-9, which is thought to regulate the activity of the apoptosome.12 Upon 
activation, caspase-9 initiates the so-called caspase cascade, a powerful signalling 
pathway that activates the executioner caspases-3 and -7.13 These executioner 
caspases, namely capsase-3, caspase-7 and caspase-6 are activated by dimerization 
followed by cleavage of their pro-domain.14,15 The active caspase then induces the 
cleavage of several different protein substrates, including PARP (poly ADP ribose 
polymerase), culminating in an organised mechanism of cell death.2,13,16 
1.2 BCL-2 family of proteins 
BCL-2 family of proteins coordinate the initial stages of the intrinsic pathway by 
regulating mitochondrial integrity. The BCL-2 family of proteins is comprised by 
over 25 different members, which are categorised according to their function as 
either anti-apoptotic (prevent apoptosis) or pro-apoptotic (promote apoptosis). The 
pro-apoptotic members are further subdivided according to their specific functions as 
activators, sensitisers and effectors. The balance between the expression levels of the 




Figure 1.1 Pathways of apoptosis. The extrinsic pathway of apoptosis is initiated in by 
death receptors and ligands in the plasma membrane, whilst the intrinsic pathway occurs at 
the level of mitochondria via proteins of the BCL-2 family. Upon binding of death ligand to 
a death receptor, DISC is assembled to trigger the auto-catalytic activation of procaspase-8 
and procaspase-10.18 Active capase-8 cleaves procaspase-3 and BID to form the executor 
caspase-3, and a truncated form called tBID, respectively. tBID translocates to the 
mitochondria to facilitate BAX/BAK-mediated release of cytochrome c. In the intrinsic 
pathway, stress signals induce BAX/BAK activation and oligomerisation at the OMM to 
release cytochrome c and form the apoptosome. Another molecule called Smac19 is also 
released from the mitochondria, to bind and inhibit the inhibitor of apoptotic proteins (IAPs) 
to relieve their repression of caspase activation.20 Both apoptotic pathways culminate in the 
activation of the executioner caspases, ultimately promoting organised cell death. 
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All BCL-2 family of proteins share conserved BCL-2 homology (BH) domains, 
which are short amino acid sequences and classified into distinct motifs, numbered 
BH1-BH4. Of these, the BH3 domains share a signature sequence of LXXXGDE,21 
which is highly conserved and often exploited in cancer therapy. 
1.3 The antiapoptotic members of the BCL-2 family of proteins 
The main function of the anti-apoptotic members of the BCL-2 family in 
apoptosis lies in binding and inhibiting the activity of their pro-apoptotic 
counterparts, thus antagonising apoptosis. Not surprisingly, the anti-apoptotic 
members of the BCL-2 family are often overexpressed in different kinds of cancers, 
which become addicted to these proteins, as they are required for tumour cell 
survival. For these reasons, the anti-apoptotic members have been identified as 
promising targets for cancer therapy. Five members of the anti-apoptotic BCL-2 
family, namely BCL-2, BCL-XL, MCL-1, BCL-w and BCL-2A1 have been 
recognised so far. Of these, the first three have been heavily characterised in a wide 
range of malignancies. Inhibitors that selectively target these members are currently 
available, either for use in patients or at least in clinical trials. 
1.3.1 BCL-2 
BCL-2, as the name suggests, is the founder member of the BCL-2 family and 
was the first pro-survival protein to be discovered22 and characterised in follicular 
lymphomas with a t(14;18) chromosomal translocation.23 Overexpression of BCL-2 
has been shown to play important survival roles in several solid tumours, such as 
brain,24 bladder,25 breast,26 colorectal,27 lung28 and prostate29 cancer and also in 
haematological malignancies such as acute myeloid leukaemia (AML),30 chronic 
lymphocytic leukaemia (CLL)31 and non-Hodgkin’s lymphoma.32 BCL-2 exists as 
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two isoforms: BCL-2α, which corresponds to the widely known anti-apoptotic 
protein and BCL-2β, that is found overexpressed in blood and bone marrow cells of 
chronic myeloid leukaemia (CML) patients, however with no described function 
until now.33 BCL-2 is a 26 kDa protein that is mainly localised mainly within the 
membranes of endoplasmic reticulum (ER), and outer mitochondrial membrane 
(OMM), with no apparent re-localisation upon apoptotic stimuli.17 In addition to its 
well-established role in apoptosis, BCL-2 has been shown to play a role in 
autophagy, via its interaction with Beclin-1.34 
1.3.2 BCL-XL 
BCL-XL (B-cell lymphoma extra-large) shares 44% amino acid identity to 
BCL-2 and has been linked to several tumours, such as CML,35,36 head and neck,37 
colorectal38 and prostate cancer.39,40 The gene that codes for BCL-XL (BCL-X) also 
codes for another isoform, BCL-XS, by alternative splicing. While BCL-XL is anti-
apoptotic, BCL-XS has pro-apoptotic functions.
41,42 BCL-XL prevents BAX and BAK 
activation, whereas BCL-XS disrupts BAK interaction with VDAC2 (voltage-
dependent anion channel 2) facilitating BAK activation.43 Under reducing conditions, 
BCL-XL can be detected as a doublet at approximately 28 and 30 kDa which 
represent BCL-XL and its phosphorylated form respectively.
44 BCL-XL is normally 
localised in the cytosol and to some extent, in the OMM. During apoptosis, most 
cytosolic BCL-XL gets translocated to the ER and OMM.
17 In the cytosol, BCL-XL 
exerts its anti-apoptotic functions by mediating BAX retrotranslocation from 
mitochondria to cytosol, thus inhibiting BAX activation and subsequent anchoring in 





MCL-1 (myeloid cell leukaemia 1) was firstly discovered as a proliferation 
inducer in ML-1 myeloid leukaemia cells.46 MCL-1 is one of the most overexpressed 
genes with oncogenic potential in several cancers.47 highly expressed or mutated in 
solid tumours such breast,48–50 lung,51,52 ovaries,53 head and neck,54 thyroid,55 
pancreas56 and prostate cancer57 as well as in haematological malignancies, such as 
multiple myeloma58 and AML.59 Furthermore, MCL-1 is also linked to 
chemoresistance to cisplatin54,60 and radiotherapy.56,61 MCL-1 has 3 isoforms, MCL-
1L (long isoform), which is the “classic” anti-apoptotic isoform and the pro-
apoptotic, MCL-1S (short) and MCL-1ES (extra-short) isoforms, which have not 
been studied extensively so far.33 Moreover, other isoforms of MCL-1 have been 
identified in the OMM, mitochondrial matrix and even nucleus.62,63 In addition to 
these subcellular locations, MCL-1 has also been detected in the cytosol, ER and the 
inner mitochondrial membrane (IMM).17 Under reducing conditions, MCL-1 is 
detected as three main bands at approximately 40, 38 and 36 kDa, which correspond 
to full-length MCL-1 and two isoforms, one cleaved at isoleucine-10 and localised at 
the OMM and the shorter one cleaved at leucine-33 localised in the IMM/matrix.62 
MCL-1 has a N-terminus motif that has not been identified in other members of the 
BCL-2 family. This region is enriched with proline (P), glutamic acid (E), serine (S) 
and threonine (T), which confers its name, PEST.46 This motif is commonly found in 
short-living proteins and confers a labile feature to MCL-1.64 The rapid turnover of 
MCL-1 (attributed to post-translational modifications, such as ubiquitination and 
proteasomal degradation)65,66 has been exploited in cancer therapy by translationally 




1.3.4 Other anti-apoptotic BCL-2 family members 
Besides the above-mentioned members of the BCL-2 family, other anti-
apoptotic members, such as BCL-w and BCL-2A1 also are expressed in several 
cancers. BCL-w overexpression has been correlated with various kinds of cancers, 
such as breast,69 melanoma,70 colorectal71 and B cell malignancies.72 Similarly, BCL-
2A1 (BCL-2 related protein A1) also known as BFL-1 (BCL-2 related gene 
expressed in foetal liver) is another protein of the BCL-2 family, commonly 
associated with breast73,74 and stomach cancers,74 acute lymphoblastic leukaemia 
(ALL)75 and CLL.76,77  
1.4 BAX and BAK, the pro-apoptotic effectors of the BCL-2 family of proteins 
Of the pro-apoptotic members of the BCL-2 family, the effector proteins have 
been extensively investigated due to their critical function in the intrinsic pathway of 
apoptosis. The effector proteins, BAX and BAK are known for their ability to homo 
or heterodimerise to form pores that permeabilise the OMM to release cytochrome c 
from the IMM.78 In gastric and colon cancers, BAX and BAK have been found to be 
potentially mutated, thereby driving enhanced cell survival.79–81 
BAX (BCL-2 associated X), was originally identified as a BCL-2 associated 
protein,82 and later characterised to possess specific functions in the permeabilisation 
of mitochondria.83–85 Since then, several studies have focused in elucidating the 
intricate molecular mechanisms behind BAX activation, oligomerisation and pore 
formation (reviewed in 86). Soon after, BAK (BCL-2-homologous antagonist killer) 
was identified by three distinct groups and published as back-to-back articles in 




87–89 BAX also has been shown to interact with all anti-apoptotic BCL-2 
family members,90 whereas BAK binds all but BCL-w.17,90,91 
Under normal conditions, BAX shuttles back and forth between the cytosol and 
mitochondria with the help of proteins such as BCL-XL,
45 preventing BAX activation 
and thus, keeping control on MOMP and apoptosis. Upon activation, BAX also 
undergoes conformational changes, including the exposure of the 6A7 epitope in its 
1 and BH3 domains,92 which can be used as marker to assess BAX activation in 
cells.93 Although to a lesser extent than BAX, BAK also shuttles between the cytosol 
and mitochondria, however due to lower shuttling rates BAK is normally found 
inserted into the OMM,94,95 presumably via its 9 helix (Figure 1.2).96 Upon 
interaction with pro-apoptotic members of the BCL-2 family to the BH3 domain of 
BAK, it becomes activated and undergoes conformational changes such as exposure 
of AB1 epitope which can be as marker to assess BAK activation in cells.92 
Once activated, BAX and BAK oligomerise at the OMM, by engaging their BH3 
domain with their hydrophobic surface groove and exposing lipophilic residues, 
which in turn can penetrate the OMM and displace phospholipids to form a puncture 
in the membrane, in a similar fashion to certain bacterial toxins such as melittin 
(Figure 1.2).97,98 
In addition, BOK (Bcl-2-related ovarian killer), a less well understood pro-
apoptotic effector of the BCL-2 family, plays unclear roles in the intrinsic pathway 
of apoptosis, as it has been shown to promote cell death when overexpressed99–102 











Figure 1.2. Mechanisms of BAX and BAK activation and oligomerisation. Under normal 
conditions, BAX, and to a lesser extent, BAK, shuttles between cytosol and mitochondria.95 
Upon apoptotic stimuli, after interactions via its BH3 domain, BAX/BAK gets inserted in the 
OMM by release of its α9 helix. Activated BAX/BAK changes its conformation allowing for 





Primarily localised at the ER, BOK is constitutively bound to IP3Rs (inositol 
1,4,5-triphosphate receptors), where it seems to stabilise ER-mitochondria 
interactions and regulate mitochondrial fusion.104  
1.5 Protein-protein interactions within the BCL-2 family of proteins 
The anti-apoptotic members, such as BCL-2 and BCL-XL was originally thought 
to antagonise apoptosis by just binding and inhibiting BAX.105 However, with the 
discovery of new members of the BCL-2 family, this simple model has been 
revisited with further improvements in our understanding of their mechanisms. 
Besides the effector proteins, BAX and BAK, there exists a collection of pro-
apoptotic activators and sensitisers, all of which regulate the different interactions 
and interplay among the different members of the BCL-2 family of proteins. Unlike 
the other members of the BCL-2 family, the activators and sensitisers possess only 
the BH3 domain and hence, are collectively known as the BH3-only proteins. 
Two distinct models detailing possible mechanisms by which the anti-apoptotic 
BCL-2 family members, pro-apoptotic effectors (BAX and BAK) and BH3-only 
members come together to execute the apoptotic pathway have been proposed. In the 
‘direct’ model, the activators (BH3-only proteins) bind and directly activate effectors 
(BAX and BAK) to induce apoptosis, while the anti-apoptotic members sequester 
and inhibit the function of these activator proteins, thus antagonising apoptosis. In 
this model, the sensitisers (another group of the BH3-only proteins) facilitate 
apoptosis by disrupting the interactions between the anti-apoptotic members and the 
activators, thus liberating the activators to activate BAX and BAK (Figure 1.3) 106–109  
In the indirect model, the anti-apoptotic members are thought to interact with the 
effectors (BAX and BAK), which is disrupted by the BH3-only members to result in 
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apoptosis (Figure 1.3).110–112 Later, a unified model has been proposed to integrate 
the pre-existing direct and indirect models to include three different “modes of 
action”.113 In mode 1 (derived from the direct model), anti-apoptotic members inhibit 
the function of the BH3-only members to prevent BAX and BAK activation. In mode 
2 (derived from the indirect model), anti-apoptotic members interact and inhibit 
BAX and BAK. In a new mode 0, anti-apoptotic members mediate BAX 
translocation to mitochondria, thus affecting how BAX may interact with other BCL-
2 family members to induce apoptosis (Figure 1.3).7 The probability of these three 
modes to occur concomitantly is high, as the complexity of these molecules are still 
being uncovered. 
1.6 The pro-apoptotic activators of the BCL-2 family of proteins 
Three major proteins – BIM, BID and PUMA are categorised as pro-apoptotic 
factors of the BCL-2 family. Of these, BIM (BCL-2 interacting mediator of cell 
death) is a major player in apoptosis due to its ability to bind multiple members of 
the BCL-2 family of proteins (Figure 1.4). BIM expression is found altered in some 
malignancies such as lung cancers, which present low expression of BIM.114–116 In 
addition, BIM deletions have been reported in mantle cell lymphoma.117 BIM exists 
as three main different isoforms, extra-long (BIMEL), long (BIML) and short (BIMS). 
Under normal conditions, both BIMEL and BIML are associated to microtubules, 
translocating to the OMM upon apoptotic stimuli,17 while BIMS is constitutively 
mitochondrial.118 All these three isoforms of BIM present pro-apoptotic functions, 












Figure 1.3. Models of interactions among the BCL-2 family members for the dictation 
of cell fate. Several models for the activation of BAX and BAK have been proposed. The 
direct model suggests that the activators of BCL-2 family activate the effectors BAX/BAK to 
induce apoptosis when not being repressed by the anti-apoptotic members. The indirect 
model proposes that the anti-apoptotic members interact with BAX/BAK, inhibiting their 
activation. The BH3-only proteins release this inhibition, inducing activation of the effectors. 
The unified model, encompasses the first two models, using modes as different ways for 
BAX and BAK being activated. Mode 1 derives from the direct model, mode 2 derives from 
the indirect model and a new mode 0, suggests that the anti-apoptotic members can prevent 






Unlike BIM, BID (BH3 interacting-domain death agonist), is cleaved by caspases 
8 and 10 (in the extrinsic apoptotic pathway) to tBID, which facilitates BAX120 and 
BAK121 translocation to the OMM, thus serving as a mediator between the extrinsic 
and intrinsic pathways of apoptosis.122–124 Normally cytosolic, BID translocates to 
OMM upon cleavage, binding preferentially to BCL-XL and BCL-w, but BID also 
interacts with MCL-1 and BCL-2 to induce apoptosis (Figure 1.4).17 BID expression 
has been found altered in different malignancies, such as gastric cancer, in which a 
frameshift mutation in BID promoted resistance to chemotherapy,125 and in ovarian 
cancer, inhibition of BID expression led to resistance to TRAIL-induced 
apoptosis.126 
In contrast to BIM and BID, PUMA (p53 upregulated modulator of apoptosis) is 
regulated by p53, which is the most mutated gene in cancer.127 PUMA has been 
reported to be localised mostly in the cytosol and in the OMM to some extent,17 
interacting with all anti-apoptotic members of the BCL-2 family (Figure 1.4). PUMA 
expression in cancer is often dysregulated, either via p53 regulation or by other 
pathways. Furthermore, PUMA downregulation has been linked to chemoresistance 
in lung128 and colorectal cancer.129  
1.7 The pro-apoptotic sensitisers of the BCL-2 family of proteins 
Five major proteins – BAD, HRK, NOXA, BIK and BMF are categorised as 
sensitisers in the BCL-2 family of proteins (Figure 1.4). Of these, BAD (BCL-2-
associated agonist of cell death) is mainly localised in the cytosol, where it is bound 
to 14-3-3 proteins,130 which in turn prevent BAD from binding to its anti-apoptotic 
counterparts BCL-2 and BCL-XL.
17,131 Upon apoptotic stimuli, BAD is 
dephosphorylated and translocated to OMM to specifically inhibit BCL-2, BCL-XL 
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and BCL-2, but not BCL-2A1 or MCL-1.17,132 In cancer, BAD phosphorylation and 
overexpression was found to be associated with chemoresistance in ovarian133 and 
prostate cancer.134 Similar to PUMA, NOXA (also known as PMAIP, Phorbol-12-
myristate-13-acetate-induced protein 1) is another BCL-2 family protein regulated by 
p53.135 Both in normal and apoptotic conditions, NOXA is located in the OMM, 
where is binds exclusively with MCL-1 and BFL-1 (Figure 1.4). HRK (harakiri) 
interacts almost exclusively to BCL-XL in the OMM.
17,90,136 HRK inactivation has 
been associated with reduced apoptosis in glioblastomas,137 ovarian 138 and prostate 
cancer.139 Localised mainly at the ER, BIK (BCL-2 interacting killer) plays 
important roles in breast cancer140–142 and facilitates Ca2+ release from ER to 
mitochondria.143,144 BMF (BCL-2 modifying factor) interacts with the cytoskeleton 
compartment, promoting apoptosis via stress in the cellular morphology and changes 
in the extracellular matrix.145 Of the BCL-2 family members, BMF inhibits BCL-2 
BCL-w and BCL-XL (Figure 1.4).
17 
1.8 Targeting the BCL-2 family in cancer – BH3 mimetics 
During the last 30 years, the study of cell death has become an important field of 
investigation in relation to cancer therapy. With the discovery of the BCL-2 family 
of proteins and the development of a deeper understanding of the mechanisms by 
which cells undergo apoptosis, researchers started to focus on identifying ways to 
disrupt the interactions between the anti- and pro-apoptotic BCL-2 family members 
to induce cell death in cancer cells. As the BH3-only proteins displace the anti-
apoptotic members of the BCL-2 family from BAK/BAX to induce apoptosis, it was 
hypothesised that designing a compound that could occupy the BH3 domain of the 
anti-apoptotic BCL-2 family proteins could  displace the pro-apoptotic BH3-only 








Figure 1.4 The network of interactions among the major BCL-2 protein family 
members. Anti-apoptotic BCL-2 family proteins (yellow) are proposed to interact with 
activators (blue), sensitisers (green) and effectors (red) of the BCL-2 family for the induction 
of apoptosis. The activators BIM, BID and PUMA are promiscuous and can interact with all 
major anti-apoptotic members, while the sensitisers perform specific interactions with 
different anti-apoptotic members. For instance, NOXA can only bind to MCL-1 and BCL-
2A1, while BAK strongly interacts with all major anti-apoptotic members but BCL-w. Full 
lines represent a strong interaction between different proteins and dashed lines represent no 
interaction (used only for graphical purposes). Note that some of these interactions were 





inhibitors called BH3 mimetics were developed. Early attempts to generate specific 
and potent BH3 mimetics were not highly successful, as most putative inhibitors 
were ineffective at low concentrations and required high micromolar concentrations 
to induce apoptosis. Moreover, apoptosis induced as a result appeared to occur in a 
BAX/BAK-independent manner, thus making the inhibitors both ineffective and 
toxic.146–149 Continuous efforts to develop promising BH3 mimetics carried on, 
which led to the development of the first bona fide BH3 mimetic called ABT-737. 
Developed by Abbot Laboratories (now AbbVie Inc.), ABT-737 was initially 
discovered by screening of a compound library to identify small molecules capable 
of binding to the BH3 groove of BCL-XL.
150 From the screen, were selected two 
distinct molecules that exhibited binding affinities, similar to that of BH3-only 
peptides, to BCL-XL.
151 By substituting regions and linking proximal fragments of 
these two molecules, the newly generated structure showed improved affinity with 
BCL-XL, which was further enhanced by subsequent structural modifications to 
reduce serum binding. After a final modification, to promote better binding to BCL-
2,  ABT-737, with a chemical structure similar to that of the BH3-only protein BAD, 
was generated.150 Similar to BAD, ABT-737 is capable of binding and inhibiting 
BCL-2, BCL-XL and BCL-w, and it was shown to singlehandedly induce apoptosis 
in haematological malignancies and solid tumours at nanomolar concentrations in 
cell lines and in xenograph mice models.150 To this date, there are approximately 700 
publications in PubMed exploring the effects of ABT-737. However, despite its high 
potency and specificity, ABT-737 did not present good prospects to be employed as 
a therapeutic agent due to its poor oral bioavailability and low aqueous solubility, 
rendering the clinical translatability of ABT-737 challenging. For that reason a new 
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compound, ABT-263, which is both structurally similar to ABT-737 and also orally 
available and equally potent, was generated in 2008.149 
ABT-263 (also known as Navitoclax) like ABT-737, binds and inhibits BCL-2, 
BCL-XL and BCL-w promoting effective cytochrome c release and apoptosis in solid 
tumours and haematological malignancies in a BAX/BAK-dependent manner.149 In 
addition, ABT-263 is also effective in reducing tumour burden in mice xenograph 
models at clinically relevant doses.149 Soon after its discovery, ABT-263 was 
extensively investigated in approximately 400 studies, with many of these 
highlighting an obstacle to the employment of ABT-263 in cancer therapy. Patients 
administered with ABT-263 demonstrated thrombocytopenia, which was later 
identified to be due to enhanced platelet apoptosis, as platelets depend on BCL-XL 
for survival and ABT-263 by also inhibiting BCL-XL resulted in on-target 
toxicity.152,153 This undesired toxicity threatened the potential of ABT-263 to be used 
in the clinic and led to the development of another BH3 mimetic by AbbVie in 2013, 
called ABT-199. 
Also called Venetoclax, ABT-199 was developed to specifically inhibit BCL-2 to 
be used in CLL, as the malignancy is highly dependent on BCL-2 for survival.154,155 
The success of ABT-199 as a therapeutic compound started to rise when it was 
shown to induce apoptosis in several BCL-2-dependent malignancies and in non-
Hodgkin’s lymphoma cell lines.154,155 Furthermore, in vivo studies with xenograph 
mice models have shown that ABT-199 can be used in combination with other agents 
to reduce chemoresistance and remission.155 Since its development, ABT-199 has 
been investigated in approximately 600 publications and 200 clinical trials. 
Furthermore, it has recently been approved by the FDA for the treatment of 
refractory CLL156 and is currently being trialled in other malignancies, such as 
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AML,157 multiple myeloma158,159 and non-Hodgkin's lymphoma160 In addition to 
AbbVie, other pharmaceutical companies have also been developing BCL-2 
inhibitors. In 2018, Servier released a new BH3 mimetic called S55746 (or BCL201), 
which is specific for BCL-2, orally active and induces apoptosis in a BAX/BAK-
dependent manner at nanomolar concentrations in CLL and mantle cell lymphoma 
patients.161 Moreover, S55746 interacts with a different binding pocket of BCL-2 
than ABT-199, which could be beneficial in the case of development of resistance 
due to mutations in BCL-2.161 S55746 has been, so far, used in 2 clinical trials 
(Clinicaltrials.gov; identifiers NCT02920697 and NCT02603445). 
After the successful development of ABT-263 and ABT-199, efforts have been 
focused on the inhibition of other anti-apoptotic members of the BCL-2 family. In 
case of BCL-XL inhibition, several compounds were released by different companies. 
The first of them, WEHI-539, came from the Walter and Elisa Hall Institute of 
Medical Research.162 The compound presented nanomolar affinity for BCL-XL and 
induced apoptosis in a BAK-dependent manner in MCL-1-defficient mouse 
embryonic fibroblasts.162 As expected from a strong BCL-XL inhibitor, WEHI-539 
induced high levels of apoptosis in platelets. One year later, AbbVie released two 
BCL-XL inhibitors, A-1155463
163 and A-1331852164 which interacted with BCL-XL 
at nanomolar concentrations. Of these two compounds, A-1331852 performed better, 
being 50-fold more potent than A-1155463, while still being orally available.164 Up 
until this date, both WEHI-539 and A-1331852 have been reported in 15 publications 
according to PubMed. No clinical trials have been carried out so far using these 
compounds. 
With the development of specific and potent BCL-2 and BCL-XL inhibitors, 
MCL-1 emerged as the next protein to be targeted. However, the development of a 
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reliable inhibitor for MCL-1 has been a challenge. As previously mentioned, MCL-1 
has molecular characteristics that differ from the other anti-apoptotic members of the 
BCL-2 family. These include a more rigid conformation of its hydrophobic binding 
groove and a higher affinity to its BH3-only protein binding partners.165 In spite of 
these difficulties, AbbVie successfully developed the first MCL-1 inhibitor, A-
1210477,166 which specifically displaced ligands from the binding groove of MCL-1, 
inducing apoptosis in MCL-1-dependent cell lines. Furthermore, A-1210477 was 
shown to synergise with ABT-263 to promote cell death in multiple cancer cell 
lines.166 However, A-1210477 was only effective in vivo at micromolar 
concentrations, curbing its potential for translation into clinical trials.166 Since the 
release of A-1210477, other companies have started to release their own MCL-1 
inhibitors. In 2018, Amgen Inc. released AMG-176, a compound with picomolar 
affinity for MCL-1, capable of promoting rapid apoptosis in several haematological 
cancer cell lines, patient samples and tumour xenograft mouse models.167 In addition, 
AMG-176 presented synergy with other BH3 mimetics, such as Venetoclax.167 Due 
to its high specificity to MCL-1 and good success in reducing tumour burden in vivo, 
AMG-176 is currently being used in 2 clinical trials to treat relapsed or refractory 
multiple myeloma as well as AML, non-Hodgkin lymphoma and diffuse large B-cell 
lymphoma in combination with venetoclax (Clinicaltrials.gov; identifiers 
NCT03797261 and NCT02675452). Servier also released their MCL-1 inhibitor, 
S63845, soon after the initial A-1210477 publication. S63845, has been shown to 
effectively bind to the BH3 groove of MCL-1 to induce rapid apoptosis, in a 
BAX/BAK-dependent manner, at nanomolar concentrations in several cell lines and 
in mouse models of haematological malignancies, while being well tolerated in mice 
at efficacious doses.168 Until now, S63845 has been reported in approximately 20 
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publications, some of which have demonstrated that S63845 can be potentially used 
in combination with other chemotherapeutic agents in various cancers, such as breast 
cancer50 and AML.169  
Despite the successful development of specific and potent BH3 mimetics, it is not 
surprising that limitations of their use are starting to emerge, as the knowledge about 
these compounds increases. Indeed, the development of resistance to ABT-199 has 
been reported in haematological malignancies, which has been attributed to 
overexpression of MCL-1 or BCL-XL
170,171 and to downregulation or mutations in 
BCL-2.172,173 As mentioned before, a marked limitation of BCL-XL inhibition is the 
development of thrombocytopenia, due to its crucial role in the survival of 
platelets.152,153 The limitations of inhibiting MCL-1 arise from the great diversity of 
functions that MCL-1 and its isoforms appear to regulate.62,174 Furthermore, MCL-1 
is highly expressed in cardiomyocytes, which could increase toxicity. For instance, 
genetic knockout of MCL-1 in mice has showed pronounced cardiotoxicity, which is 
linked to MCL-1 involvement in mitochondrial bioenergetics.175,176 However, the 
recently developed BH3 mimetics were shown to be highly potent and specific, with 
great potential for being used in the clinic, especially in lower concentrations. 
Furthermore, the use of BH3 mimetics in combination with existing therapy can 
potentially lower toxicity, while targeting diverse pathways for a more effective 







1.9 Aims of the study 
The anti-apoptotic members of BCL-2 family of proteins are often overexpressed 
in cancer. During the last ten years, efforts to generate molecules to inhibit these 
anti-apoptotic proteins have been successful with the development of potent and 
specific BH3 mimetics, which have been successfully used in treating patients with 
CLL, as well as investigated in experimental models of myelomas, lymphomas, 
breast, ovarian and colorectal cancers.177 In this study, it was intended to extend this 
knowledge to AML and to two hard-to-treat solid tumours, such as HNSCC and 
PDAC. In addition, despite the mechanistic understanding of how BH3 mimetics 
exert their functions at the molecular level, a deeper understanding on how BH3 
mimetics can affect other facets of the apoptotic pathway, such as mitochondrial 
membrane dynamics remains elusive. Therefore, this study aims: 
1. To investigate the potential of BH3 mimetics in enhancing the effectiveness 
of current treatments in CML and AML. 
2. To assess the potential of BH3 mimetics in enhancing the effectiveness of 
current treatments in head and neck and pancreatic cancer. 
3. To examine whether BH3 mimetics induce mitochondrial structural changes, 
either upstream/downstream/independent of the apoptotic cascade and how 
such structural perturbations could relate to apoptosis. 
4. To investigate the involvement of endoplasmic reticulum in BH3 mimetic-
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2.1 Cell culture 
All cells were obtained from American Type Culture Collection (ATCC, 
Manassas, VA, USA) or from Deutsche Sammlung von Mikroorganismen und 
Zellkulturen (DSMZ, Braunschweig, Germany), unless otherwise specified in Table 
2.1. Cells were grown in appropriate cell culture media obtained from Life 
Technologies Inc (Paisley, UK) and supplemented with 10% foetal bovine serum 
(FBS) (Table 2.1). Cells were grown at 37°C, 5% CO2 until they reached ~80% 
confluence. Sub-culturing adherent cell lines was carried out by aspirating the spent 
media, washing with warmed PBS (ThermoFisher Scientific, MA, USA) and then 
incubating with 0.05% trypsin-EDTA (Gibco, ThermoFisher Scientific) at 37°C for 5 
min. Trypsinised cells were collected and then distributed into multiple plates. 
Suspension cell lines had media changed every 48 - 72 h.  
Primary CML and AML patient samples were obtained from Liverpool 
Biobank and approved by the Liverpool Central Ethics Committee. All patients gave 
informed consent. Patient mononuclear cells from chronic phase CML were 
separated by density-dependent centrifugation (Lymphoprep Axis-Shield, Oslo, 
Norway), then washed in RPMI 1640 and resuspended in 10% dimethyl sulfoxide 
(DMSO), 10% FBS in RPMI at 4°C and cryopreserved in liquid nitrogen. Cells were 
cultured with StemSpan SFEMII media (Stemcell Technologies, Cambridge, UK). 
Primary AML patient samples were thawed by adding 4 ml of IMDM complete 
media (Gibco, ThermoFisher Scientific) supplemented with 10% FBS, 1% 
penicillin/streptomycin and 1% L-glutamine Sigma-Aldrich/Merck (Darmstadt, 
Germany) dropwise over 3 minutes. Further 8 ml of IMDM media was added over 3 
more minutes. Cells were centrifuged at 2000 rpm for 5 minutes and pellet 
resuspended in IMDM media for culture. 
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2.2 Cell lines 
Table 2.1 – Cell lines, growing media and additional information. “NSCLC” 
stands for non-small cell lung carcinoma, “AML” stands for acute myeloid 
leukaemia, “CML” stands for chronic myeloid leukaemia, “MCL” stands for mantle 
cell lymphoma, “MM” stands for multiple myeloma, “BC” stands for breast cancer, 
“CEC” stands for cervical carcinoma, “PC” stands for pancreatic carcinoma, 
“PDAC” stands for pancreatic adenocarcinoma, “SCC” stands for squamous cell 
carcinoma, “COC” stands for colon carcinoma. “RPMI” stands for Roswell Park 
Memorial Institute (RPMI) 1640, “HCM” stands for Hybri-Care medium (ATCC 46-
X), “EMEM” stands for Eagle’s minimum essential medium, “DMEM” stands for 
Dulbecco’s modified Eagle Medium, “MC5A” stands for McCoy’s 5A Modified. 
“NEAA” stands for non-essential amino acids, “BME” stands for 2-mercaptoethanol.  
All culture media were supplemented with 10% FBS (Gibco, ThermoFisher 
Scientific).  
 
Cell line Tumour origin Culture media Source 
H1299 NSCLC RPMI ATCC 
H23 NSCLC RPMI ATCC 
MV-4-11 AML RPMI ATCC 
OCI-AML3 AML RPMI ATCC 
HL-60 AML RPMI ATCC 
U937 AML RPMI ATCC 
THP-1 AML RPMI ATCC 
MOLM-13 AML RPMI ATCC 
K562 CML RPMI Prof. R. Clark 
(University of 
Liverpool) KCL22 CML RPMI 
MAVER-1 MCL RPMI 





H929 MM RPMI + 0.02% BME ATCC 
AU565-A BC RPMI 
Prof. C. Palmieri 
(University of 
Liverpool) 
HCC1937D BC RPMI 
BT-474 BC HCM+1.5 g/L NaHCO3 
HCC70 BC RPMI 
Prof. P. Meier 
(Institute of 
Cancer Research) 
MCF7 BC EMEM + 1% NEAA ECCAC 
HeLa CEC DMEM ATCC 




BxPC-3 PDAC DMEM 
PANC-1 PC DMEM 
Dr. A. Mielgo 
(University of 
Liverpool) 
UM-SCC-1 oral cavity SCC DMEM + 1% NEAA 
Prof. T. Carey 
(University of 
Michigan, USA) 
UM-SCC-11B laryngeal SCC DMEM + 1% NEAA 
UM-SCC-17A laryngeal SCC DMEM + 1% NEAA 
UM-SCC-17AS laryngeal SCC DMEM + 1% NEAA 
UM-SCC-74A tongue SCC DMEM + 1% NEAA 




Dr. X. Luo 
(University of 
Nebraska, USA) 
SW48 COC MC5A 











2.3 Reagents and compounds 
Reagents, chemicals and buffers, were obtained from Sigma-Aldrich/Merck 
(Darmstadt, Germany) unless otherwise specified. Compounds used are indicated in 
Table 2.3. 
 
Table 2.3 – Compounds, targets and sources. Selleck stands for Selleck Chemicals 
Co (Houston, TX, USA), Abbvie stands for Abbvie (Chicago, IL, USA), AB stands 
for Active Biochem (New Jersey, USA), Stratech stands for Stratech Scientific Ltd. 
(Suffolk, UK), Sigma stands for Sigma-Aldrich/Merck (Darmstadt, Germany). 
Inhibitor Target Source 
ABT-199 BCL-2 Selleck 
ABT-737 BCL-2, BCL-XL, BCL-w Selleck 
A-1331852 BCL-XL Abbvie 
A-1210477 MCL-1 Abbvie 
S63845 MCL-1 Selleck 
MG-132 Proteasome AB 
Z-VAD-FMK Caspases Selleck 
Dinaciclib Cyclin-dependent kinases Stratech 
CCCP Mitochondria Sigma 
Cisplatin DNA (alkylating agent) Selleck 
Gemcitabine DNA (anti-metabolite)  Selleck 
Imatinib Tyrosine-kinase  Selleck 
Nilotinib Tyrosine-kinase  Selleck 





Table 2.4 – Antibodies specifications. Clone numbers (brackets, when available), 
epitopes, applications, sources and catalogue numbers of antibodies used. “AA” 
stands for Amino acids, “IB” stands for immunoblotting, “ICC” stands for 
immunocytochemistry, “IF” stands for immunofluorescence, “IHC” stands for 
immunohistochemistry, “IP” stands for immunoprecipitation, “SC” stands for Santa 
Cruz Biotechnology (CA, USA), “CST” stands for Cell Signalling Technologies 
(MA, USA), Abcam (Cambridge, UK), “BD” stands for BD BioSciences (CA, 
USA), “MP” stands for Millipore/Merck (Darmstadt, Germany), “Enzo” stands for 
Enzo Biochem. Inc (NY, USA), “Calbio” stands for Calbiochem Research 
Biochemicals (now Merck), “Upstate” stands for Upstate USA Inc (NY, USA). 
Antibody Epitope Application Source Cat. # 
BCL-2 family 
BCL-2 N/A IB CST 4223 
BCL-2 (124) AA 41-54 IHC CST 15071 
BCL-XL Around Asp61 IB and IHC CST 2762 
BCL-XL (E-18] AA 1-100 IP Abcam ab32370 
MCL-1 (S-19) AA 89-139 IB SC sc-819 
MCL-1 (Y-37) AA 100-200 IP Abcam ab32087 
MCL-1 (D5VL5) Around L210 IHC CST 39224 
BCL-w (31H4) Around Ala39 IB CST 2724 
BIK (N-19) N-terminal IB SC sc-1710 




PUMA C-terminal IB CST 4976 
BIM (C34C35) Around Pro25 IB CST 2933 
BAD Around Ser112 IB CST 9292 
BMF Around Gly81 IB CST 5889 
HRK AA 30-50 IB SC sc-6971 
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NOXA (114C307) FL protein IB Calbio. OP180 
BID Cleavage site IB CST 2002 
BAK (AB-1) Active Site IF (FACS) Calbio. AM-03 
BAK Internal IB SC sc-832 
BAX (C3) AA 55-178 IB BD 610983 
Apoptosis 
Cytochrome c Around AA 62 ICC and IB BD 556432 
Caspase-3 N/A IB CST 9662 
Cleaved caspase-9 Around Asp315 IB CST 9505 
Caspase-7 FL protein IB CST 9494 
Cleaved PARP 
(D64E10) 
Around Asp214 IB CST 5625 
Mitochondrial fusion and fission 
DRP-1 (8/DLP-1) AA 601-722 IB and ICC BD 611113 
DRP-1 S616 Around Ser616 IB CST 3455 
DRP-1 S367 Around Ser637 IB CST 4867 
MFN1 (D6E2S) C-terminal IB CST 13196 
MFN2 (D2D10) Around Val573 IB CST 9482 
OPA-1 (18/OPA1) AA 708-830 IB BD 612607 
Endoplasmic reticulum shaping proteins 
RTN-1 AA 159-208 IB Abcam ab83049 
RTN-4 AA 1-50 IB Abcam ab47085 
LNP-1 AA 304-426 IB Sigma HPA014205 
CLIMP-63 
(G1/296) 




Tubulin (6-11B-1) Around Lys40 IB Abcam ab24610 
GAPDH (FL-335) AA 1-335 IB SC sc-25778 





2.5 RNA interference 
siRNAs (small interfering RNA oligoduplexes) obtained from Qiagen 
(Cambridge, UK) or Ambion (Austin, TX, USA) were transfected in cells at a final 
concentration of 10 nM, using OptiMEM Reduced Serum Media (Life Technologies) 
and Interferin transfection reagent (Polyplus, Illkirch, France). 
Table 2.5 – siRNAs targets, catalogue numbers, source and target regions. 
siRNA catalogue number with source between brackets and the sequence targeted. 
(Q) stands for Qiagen and (A) stands for Ambion obtained siRNAs. 
Protein targeted Cat. # (source) Sequence Targeted 
BCL-XL SI03025141 (Q) TTGGCTTTGGATCTTAGAAGA 
MCL-1 (#1) SI02781205 (Q) CCCGCCGAATTCATTAATTTA 
MCL-1 (#2) S102781205 (Q) CCCGCCGAATTCATTAATTTA 
BAX 1299001 (A) CCCACCAGCUCUGAGCAGAUCAUGA 
BAK 4390824 (A) GGUUUUCCGCAGCUACGUUTT 
BIM 4427038 (A) CAUGAGUUGUGACAAAUCATT 
BID S102654568 (Q) TAGGGACTATCTATCTTAATA 
PUMA 4390828 (A) GGAUAGGUUGCAGUCCAUCTT 
NOXA SI00129430 (Q) TGGGCTATATACAGTCCTCAA 
HRK 4427037 (A) GAGCGAUCGUAGAAACACATT 
BMF 16104 (A) GCUAAGUGACUUUUAGAGUTT 
BIK 4390824 (A) GGACUUCGAUUCUUUGGAATT 
BAD SI00299348 (Q) ACGAGTTTGTGGACTCCTTTA 
BCL-w 4390824 (A) CAGACUUUGUAGGUUAUAATT 
BFL-1 AM16104 (A) GAGTTCATAATGAATAACACA 
DRP-1 S104274235 (Q) CACGGTGGGCGCCGACATCAT 
DRP-1 SI02661365 (Q) CAGGAGCCAGCTAGATATTAA 
OPA-1 SI03019429 (Q) CCGGACCTTAGTGAATATAAA 
RTN-1 SI04178545 (Q) CACGGACTGCCTGCAGTTCTA 
RTN-4 4392420 (A) CCAUCAGCUUUAGGAUAUATT 
RTN-4 s32767 (A) GGCCACCCGGGGAGTACCCA 
LNP-1 SI00460355 (Q) CACGATGTTCTTGATGATAAT 
CLIMP-63 SI00347242 (Q) CCAAGTGGAGGCGGACTTGAA 
CLIMP-63 4427037 (A) CTCTTCAAATCAGGCAACTTCCA 
Non-targeting 
control 
1027310 (Q) AACTGGGGGAGGATTGTGGCC 
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2.6 Overexpression studies 
For transient transfections of DRP-1 K38A plasmid (gift from Dr. E. Bampton, 
University of Leicester), cells were seeded at a determined density to reach 80% of 
confluency in 3-4 days. On the day after seeding, cells were transfected using 
TransIT-LT-1 transfection reagent (Mirus Bio LLC, Madison, WI, USA) in a 3:1 
ratio (DNA:LT-1) with 10% of final media volume of OptiMEM serum free media. 
Transfection rates were observed in an EVOS FLoid Cell Imaging Station 
(ThermoFisher Scientific, MA, USA) under the green channel. 
2.7 Immunoblotting (SDS-PAGE) 
Immunoblotting was performed using acrylamide gels made in-house with 
Protogel acrylamide (30%) (National Diagnostics, Atlanta GA, USA), lower gel 
buffer (1.5 M Tris-HCL, 0.4% SDS, pH 8.8), upper gel buffer (Tris-HCL 0.5 M, 
0.4% SDS, pH 6.8), 10% ammonium persulphate and TEMED. Cells were collected, 
centrifuged and pellets were lysed in radioimmunoprecipitation assay (RIPA) buffer 
(10 mM Tris-Cl (pH 8.0), 1 mM EDTA, 0.5 mM EGTA, 1% Triton X-100, 0.1% 
sodium deoxycholate, 0.1% SDS, 140 mM NaCl) with 20 µM MG-132 and one 
protease inhibitor tablet (Roche, Basel, Switzerland). For lysis, cells were incubated 
on ice for 15 min in RIPA lysis buffer and sonicated with a Bandelin SONOPULS 
ultrasonic homogeniser (Bandelin, Berlin, Germany). Colorimetric Bradford assay 
(BioRad Protein Assay Dye Reagent, BioRad, CA, USA) was used to determine 
protein concentration. Samples optical density at 600 nm (OD600) were measured 
with a spectrophotometer (Eppendorf, Hamburg, Germany) and standardised with a 
solution of bovine serum albumin (BSA) which concentration was pre-determined to 
obtain samples protein concentrations.  
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Protein lysates with concentrations ranging from 10-50 µg were added to 4x 
NuPAGE LDS sample buffer (Life Technologies) and boiled for 5 min at 70°C 
(ThermoFisher Scientific). Samples were loaded in acrylamide gels alongside 5 µl of 
protein ladder SeeBlue™ Plus2 Pre-stained Protein Standard (ThermoFisher 
Scientific) and subjected to SDS-PAGE in electrode buffer (25 mM Tris-HCL, 192 
mM glycine, 10% SDS) at 130 V for 100 min and then transferred to Amersham 
ProTran nitrocellulose membranes (VWR, Radnor, PA, USA) in transfer buffer (25 
mM Tris-HCL, 192 mM glycine, 20% methanol) at 100 V for 90 min. Membranes 
were blocked in non-fat 5% milk in TBS-T (Tris-buffered saline with 0.1% Tween, 
20 mM Tris-HCL, 150 mM NaCl, 0.1% Tween-20) for 30 min, incubated overnight 
at 4°C with the indicated primary antibodies, with a 1:1000 dilution in TBS-T. Next, 
membranes were rinsed with TBS-T and incubated with anti-mouse or anti-rabbit 
IgG HRP-linked secondary antibodies (Cell Signalling Technology) for 1 h, then 
washed three times in TBS-T before revealing of protein bands with ECL reagents 
(GE Healthcare, IL, USA) either by X-ray film (GE Healthcare) or via ChemiDoc 
Imaging system (BioRad). 
2.8 Immunoprecipitation 
Protein G Dynabeads (ThermoFisher Scientific) (30 µl/sample) were washed 
three times with PBS-T (0.05% Tween-20 in PBS) and resuspended with 5 µg of 
antibody against BCL-XL or MCL-1 (see Table 2.4). Beads with antibodies were 
incubated under rotation for 4 h at 4°C, followed by two washes with triethanolamine 
(0.2 M). Beads were crosslinked to antibodies using dimethylpimelidate (5.4 mg/ml) 
at room temperature for 30 min. Crosslinking reaction was neutralised with Tris-
HCL pH 7.5 (50 mM) at room temperature for 15 min. Beads-antibody conjugates 
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were washed three times with PBS-T and resuspended in 500 µg of cell lysate for a 
total volume of 100 µl per sample. 
Cells were collected, centrifuged and lysed in 1% CHAPS lysis buffer (150 
mM KCl, 50 mM HEPES (pH 7.4), 1% CHAPS) added with 20 µM MG-132 and a 
protease inhibitor tablet (Roche, Basel, Switzerland) for 1 h on ice and centrifugated 
at 14,000 RPM for 10 min at 4°C. 500 µg of protein from the supernatant was 
incubated overnight with beads-antibody conjugate, under rotation at 4°C. Beads 
were collected, washed three times with PBS-T and protein was eluted from beads 
using 2x NuPAGE LDS sample buffer (Life Technologies) at 55°C for 10 min under 
constant shaking. Samples were loaded into gels for immunoblotting analysis of 
protein levels. A lane with bead control (beads with no antibody) was added to assess 
for antibody specificity. 
2.9 Clonogenicity assay 
Cells were seeded at a 500, 1000 or 2000 cells per well of a 12 well plate and 
monitored daily for the formation of colonies. On the first day after seeding, cells 
were exposed to different compounds used throughout the studies. Upon reaching 
~50 cells per colony (at around day 7) cells were washed with PBS, fixed with fixing 
solution (1:7 v/v ratio acetic acid to methanol) for 5 min at room temperature and 
stained with staining solution (20 ml methanol, 80 ml H2O, 0.5 g crystal violet) for 2 
h at room temperature. Next, cells were de-stained under running water and left for 
drying for 1 day. Colonies were counted using a GelCount instrument (Oxford 
Optronix, Oxford, UK). Surviving fraction was determined by the following 
equation:                                         𝑆𝑢𝑟𝑣𝑖𝑣𝑖𝑛𝑔 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 =
#𝑐𝑜𝑙𝑜𝑛𝑖𝑒𝑠 𝑓𝑜𝑟𝑚𝑒𝑑
#𝑐𝑒𝑙𝑙 𝑠𝑒𝑒𝑑𝑒𝑑




2.10 Tissue micro array analysis 
Tissue micro array (TMA) slides were obtained from Liverpool Biobank, 
(University of Liverpool). TMA analysis was performed using QuPath software.178 
Electronic scans of TMAs were uploaded to the software and the basic wizard 
protocol was used to assess for the intensity of staining of BCL-2, BCL-XL and 
MCL-1 in the tissues and H-scores were obtained from the final analysis. H-score 
values were then used in conjunction with patient data to generate Kaplan-Meier 
estimators. 
2.11 Flow cytometry - apoptosis 
Suspension cells were collected directly in tubes, washed and pelleted, while 
adherent cells were trypsinised and washed in PBS before being pelleted. Cell pellets 
were resuspended in 500 µl of 1x Annexin Binding Buffer (10 mM HEPES, 140 mM 
NaCl, 2.5 mM CaCl2, pH 7.4) with Annexin-V-FITC (1:20,000 dilution, made in-
house) and incubated at room temperature for 7 min. 5 µl of propidium iodide (PI) 
(Sigma-Aldrich/Merck, Darmstadt, Germany) was added to cell suspension just 
before analysis. For assessment of the extent of Annexin-V/PI labelling, cells were 
passed through an Attune NxT flow cytometer (ThermoFisher) using the red and 
blue lasers for PI and Annexin V staining respectively. 10,000 events per sample 
were recorded and a minimum of 3 replicates were assessed for each experiment.  
2.12 Flow cytometry – BAK activation 
BAK activation by FACS was performed by collecting cells and fixing them 
with 2% paraformaldehyde (PFA) at room temperature for 10 min. Fixed cells were 
washed with PBS and re-suspended in FACS buffer (0.1% saponin, 0.5% BSA in 
PBS) for 10 min. Primary antibody anti-BAK AB-1 (0.1 mg/ml) was added to the 
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cells at a volume FACS buffer and cells were incubated for 1 h at 4°C. Cells were 
pelleted by centrifugation and goat-anti-mouse IgG-AlexaFluor-488 conjugated 
secondary antibody was then added to cells in FACS buffer and incubated for 1 h at 
4°C. The extent of BAK activation was detected by flow cytometry using a blue 
(BL1) laser (530/30 nm emission filter) as recommended for AlexaFluor-488 
secondary antibodies. 
2.13 Immunocytochemistry 
Cells were seeded on sterile coverslips in a 24 well plate to reach 80% 
confluency by the day of treatment and fixation. On the determined day, media was 
removed from wells and coverslips were washed with PBS twice. Cells were fixed 
with 4% (w/v) paraformaldehyde for 10 min at room temperature and permeabilised 
in 0.5% (v/v) Triton X-100 in PBS for 10 min at room temperature. Coverslips were 
removed from wells and incubated in a humidified chamber with primary antibody 
diluted in 3% BSA in PBS for 1 h. Next, coverslips were incubated with species-
specific AlexaFluor (Life Technologies) secondary antibody diluted 1:1000 in 3% B 
BSA in PBS. Next, coverslips were washed in dH2O three times, dried with lint-free 
paper towels and mounted in glass slides with Polymount (Polysciences, PA, USA) 
mounting solution. Finally, cells were imaged in a 3i Marianas spinning disk 
confocal microscope, fitted with a Plan-Apochromat × 63/1.4 NA Oil Objective, 
M27 and a Hamamatsu ORCA-Flash4.0 v2 sCMOS Camera (Intelligent Imaging 
Innovations, GmbH, Gottingen, Germany). For quantitation of mitochondrial 
fragmentation using HSP70 antibody, only cells with fine punctate mitochondrial 





Explants, surgically resected from patients, were acclimatized overnight to 
the culture conditions before exposure to BH3 mimetics for 48 h. Explants were 
fixed in 4 % paraformaldehyde at 4 C for 24 h and processed using a HistoCore 
PEARL Tissue Processor (Leica). Following paraffin embedding, tissues were cut 
into 5 m sections. Sections from TMAs were processed and stained using the 
Bond RXm autostainer (Leica). TMA sections were deparaffinised, subjected to 
heat induced epitope retrieval and incubated with the relevant primary antibodies 
and a non-species-specific linker and HRP, which was detected using DAB+ 
chromogen. Sections were counterstained with hematoxylin, dehydrated, cleared 
and mounted using EcoMount (Biocare Medical). Images were acquired at 20x 
magnification using a Nikon Eclipse E800 microscope and MetaMorph 6.3r7 
software or by scanning at 40x magnification using an Aperio slide scanner 
(Leica). Antibody staining intensity was analyzed using QuPath software.178 The 
cytoplasmic DAB optical density was measured for each tumor cell within a tissue 
sample, and a histo-score (H-score; a quantitative measurement of the intensity of 
staining for a particular antibody) generated for that sample. The H-score was 
averaged between two or three tissue samples available per patient and thresholds 
applied to designate each patient’s overall H-score as low, moderate or high for 
the appropriate antibody. Explant staining was quantified by counting the HNSCC 
nuclei in each image and determining the percentage of positively stained cells.  
2.15 Transmission Electron Microscopy 
Cells were fixed in 2.5% (w/v) glutaraldehyde and 2 mM calcium chloride in 
0.1 M cacodylate buffer (pH 7.4), followed by heavy metal staining, consisting of 
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two consecutive osmium tetroxide steps (2% (w/v) OsO4 in ddh2O), followed by 1% 
(w/v) aqueous uranyl acetate. All fixation and staining steps were performed in a 
Pelco Biowave®Pro (Ted Pella Inc., Redding, California, USA) at 100w 20Hg, for 3 
min and 1 min, respectively. Dehydration steps were conducted in a graded ethanol 
series before filtration and embedding in medium premix resin (TAAB, Reading, 
UK). 70- 74 nm serial sections were cut using a UC6 ultra micro- tome (Leica 
Microsystems, Wetzlar, Germany) and collected on Formvar (0.25% (w/v) in 
chloroform (TAAB, Reading, UK) coated Gilder 200 mesh copper grids (GG017/C; 
TAAB, Reading, UK). Images were acquired using a 120 kV Tecnai G2 Spirit 
BioTWIN (FEI, Hillsboro, Oregon, USA) with a MegaView III camera and analySIS 
software (Olympus, Germany).  
2.16 Serial block face scanning electron microscopy (3view microscopy) 
Cells were fixed in 2.5% (w/v) glutaraldehyde with 2 mM calcium chloride in 0.1 
M cacodylate buffer (pH 7.4). Heavy metal staining consisted of reduced osmium 
(2% (w/v) OsO4, 1.5% (w/v) potassium ferrocyanide in ddh2O), 1% (w/v) 
thiocarbohydrazide (RT), 2% OsO4 (w/v in ddh20), then 1% (w/v) aqueous uranyl 
acetate overnight at 4°C. The next day cells were stained with Walton’s lead 
aspartate (0.02 M lead nitrate, 0.03 M aspartic acid, pH 5.5) at RT. Fixation and 
staining steps were performed in a Pelco Biowave®Pro (Ted Pella Inc.Redding 
California, USA) at 100 w 20 Hg, for 3 mins and 1min respectively. Dehydration 
was performed in a graded series of ethanol before filtration and embedding in hard 
premix resin (TAAB, Reading, UK). Images were obtained from Gatan 3View serial 
block-face system (Gatan, Pleaseanton, CA) installed on a FEI Quanta 250 FEG 
scanning electron microscope (FEI Company, Hillsboro, OR). Each z-section had a 
thickness of 75 nm and the images had a resolution of ~20 nm. Images were double 
40 
 
binned for faster render and were processed, analysed and quantified using Thermo 
Scientific Amira Software 6. For quantification of ER-mitochondria contact points, 
we considered the number of times that an ER membrane overlapped with a 
mitochondrial membrane in the same 3D reconstruction for the chosen 
mitochondrion. 
2.17 Synergy studies 
Synergistic analysis was carried out using a multiple-ray experimental design 
with a fixed order of magnitude increase between the assessed compounds. Cell 
death output from FACS analysis was fed to the Combenefit179 software to generate a 
Bliss Independence score heatmap. Bliss Independence scores range from -100 to 
100, representing at -100, antagonistic effects, at 0, additive effects and at 100, 
synergistic effects for the combination of the two compounds tested. 
2.18 Statistics 
Two-way ANOVA was performed for studies using two numerical variables. 
For studies involving a single numerical variable, one-way ANOVA was performed. 
Multiple comparison tests were conducted using Fisher’s LSD test. For continuous 
variables, Mann-Whitney U-test was used to compare independent samples. For 
estimation of survival function from lifetime data, Kaplan-Meier estimator was used. 
Asterisks depicted correspond to the following p values:  * for p ≤ 0.05, ** for p ≤ 
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Chronic myeloid leukaemia (CML) is a disorder that arises from the myeloid 
lineage of haematopoietic stem cells. The disease is characterised by abnormal 
growth and accumulation of granulocytes and their precursors in the bone marrow. In 
a typical case, the disease begins at the chronic phase, which comprises around 85% 
of diagnosed patients. In the absence of successful treatment, the disease can evolve 
to the accelerated phase, characterised by a gradual increase (10-20%) of immature 
blast cells in peripheral blood. This signals for rapid disease progression and 
imminent transition to blast crisis (with blast cell count in peripheral blood  
>20%).180 Blast crisis is the last phase of CML, progressing rapidly and ultimately 
leading to bone marrow failure by massive undifferentiated cell infiltration.  
The main genetic feature of CML is a reciprocal chromosomal translocation 
between chromosomes 9 and 22, which results in the formation of the Philadelphia 
chromosome coding for BCR-ABL, a chimeric tyrosine kinase signalling protein. 
This aberrant protein is constitutively active and signals downstream targets resulting 
in uncontrolled cell proliferation.181 The mRNA transcript of BCR-ABL is found in 
more than 90% of CML cases, and therefore targeting the kinase activity of this 
protein is a major approach for therapy.181 The first tyrosine kinase inhibitor (TKI) – 
Imatinib – discovered by Novartis in 1992, acts by preventing ATP from binding its 
site in the ABL pocket, blocking the catalytic function of the enzyme (Figure 3.1). 
Although treatment with imatinib achieved low relapse and high response rates, with 
overall survival rates of ~80% after 8 years, some patients developed resistance to 
imatinib, through accumulation of mutations in the BCR-ABL protein or through 
independent mechanisms, such as drug efflux or activation of alternative signalling 
pathways.182 To circumvent imatinib resistance, second generation TKIs – nilotinib 
44 
 
and dasatinib - were developed and shown to directly inhibit specific mutant forms of 
BCR-ABL.183 However, in spite of being effective against the great majority of 
mutations associated with imatinib resistance, the second generation TKIs do not 
target the T315I mutant of BCR-ABL (often referred to as the gatekeeper 
mutation).184 In 2010, a new compound named ponatinib addressed this issue by 
effectively binding to the pocket of the BCR-ABL T315I mutant and also to other 
known mutants. Ponatinib has recently been approved for phase II clinical trials.185 
Acute myeloid leukaemia (AML), like CML, also derives from the myeloid 
lineage of haematopoietic stem cells compartment. The malignancy is the most 
common acute leukaemia in adults, accounting for ~80% of cases.186 In AML, the 
undifferentiated myeloid cells accumulate in the bone marrow, peripheral blood and 
other organs, leading to anaemia, thrombocytopenia and bone marrow failure.187 The 
stratification of different risk groups in AML is based primarily on the expression 
levels of fusion proteins, such as RUNX1-RUNX1T1 and PML-PARA, which occur 
as a consequence of the chromosomal translocations, t(8;21) and t(15;17) 
respectively.187,188 In addition to chromosomal abnormalities, FLT3 (FMS-like 
tyrosine kinase 3) receptor gene mutations are the most common somatic mutations 
in AML, leading to a constitutive activation of this protein and consequently 
cytokine-independent proliferation of myeloblasts. The presence of a mutated FLT3 
receptor has been linked to poor prognosis.189 The current main line of treatment for 
AML consists of a combination of cytarabine and anthracyclines.187 In the last 







Figure 3.1. Scheme representing the mechanism of action of TKIs. In CML, the BCR-
ABL tyrosine kinase is constitutively active by binding to ATP, leading to a signalling 
cascade that promotes cell division and inhibition of apoptosis. The TKIs bind to the ATP 




The members of the BCL-2 family of proteins are key regulators of the intrinsic 
pathway of apoptosis. These proteins are highly expressed in CML. Furthermore, it 
has been shown that cells that express BCR-ABL have high levels of the anti-
apoptotic members, BCL-XL and MCL-1, as well as the pro-apoptotic BIM.
193 
Resistance to TKIs in CML has been attributed to the increased expression/activity 
of BCL-2, BCL-XL and MCL-1.
36 Moreover, BCR-ABL modulates the expression 
levels and/or the phosphorylation status of several BCL-2 family members, thus 
exerting important regulatory effects on apoptosis.194–196 In addition, high expression 
levels of BCL-2 have been connected to a bad prognostic in AML,30 posing ABT-
199 as a good candidate for therapy.197 These findings suggest that BH3 mimetic 
therapy could be beneficial in the treatment of CML and AML. 
In this chapter, using a panel of BH3 mimetics, the potential of targeting distinct 
members of the BCL-2 family of proteins to enhance the effectiveness of current 





3.2.1 CML cell lines undergo TKI-mediated apoptosis in a concentration-
dependent manner 
Since TKI-mediated cell death has been observed in CML cell lines36 and 
TKIs are commonly used in therapy,198 the extent of apoptosis in CML cell lines 
following exposure to first (imatinib) and second (nilotinib and dasatinib) generation 
TKIs was compared. Apoptosis was assessed by measuring the extent of 
phosphatidylserine (PS) externalisation following caspase activation in these cells. 
Since the protein Annexin-V specifically recognises the externalised PS molecules, 
the cells were stained with Annexin V, conjugated to FITC and the extent of FITC 
fluorescence (indicative of PS externalisation) was measured by flow cytometry. For 
the following experiments, two CML cell lines, K562 and KCL22, which were 
originally derived from blast crisis patients, were chosen.199,200 The cells were 
exposed for 48 h to a concentration range of imatinib (10 nM - 10 µM), nilotinib (1 
nM - 3 µM), dasatinib (0.1 nM - 10 nM) and assessed for PS externalisation (Figure 
3.2). In both cell lines, dasatinib was most effective in inducing apoptosis, followed 
by nilotinib and imatinib, possibly due to its higher affinity for the ATP binding site 
of the BCR-ABL protein.201 In addition, KCL22 cells were slightly more sensitive to 
all the TKIs used. This experiment was used to identify appropriate concentrations of 
the different TKIs for further studies. Imatinib (1 µM), nilotinib (50 nM) and 
dasatinib (3 nM) induced comparable levels of apoptosis (Figure 3.2) and hence 

















Figure 3.2. CML cell lines undergo TKI-mediated apoptosis in a concentration-
dependent manner. (A) K562 and (B) KCL22 cells were exposed for 48 h to a 
concentration range of TKIs, imatinib (bold lines with filled circle), nilotinib (dotted lines 
with hollow square) and dasatinib (bold lines with filled triangle) and assessed for the extent 
of PS positivity by flow cytometry. In the graph, the extent of apoptosis in untreated cells is 
represented by a red circle. Error bars represent standard error of mean (S.E.M.) from at least 




3.2.2 TKIs induce apoptosis in a BAX/BAK-dependent manner 
 The induction of the intrinsic pathway of apoptosis is initiated by the release 
of the pro-apoptotic BCL-2 family members from their anti-apoptotic counterparts, 
which in turn activates BAK and/or BAX in the OMM to facilitate cytochrome c 
release and apoptosis. Since TKIs induced apoptosis in a concentration-dependent 
manner, studies were performed to assess if TKI-mediated apoptosis was BAK and 
BAX-dependent. For this, K562 and KCL22 cells, were transfected with siRNAs 
against both BAK and BAX for 48 h and the extent of TKI-mediated apoptosis 
assessed. In both cell lines, BAK and BAX knockdown did not enhance basal cell 
death, with less than 10% of the cells exhibiting basal apoptosis (Figure 3.3 A). 
Downregulation of BAX and BAK resulted in a significant decrease of TKI-
mediated apoptosis (Figure 3.3 B - E). These results indicate that TKIs induce the 
intrinsic pathway of apoptosis in a BAX and/or BAK-dependent manner. 
 
3.2.3 TKIs induce the intrinsic pathway of apoptosis in a BIM, BID and 
PUMA-dependent manner  
Next, to assess the involvement of the pro-apoptotic activators, BIM, BID 
and PUMA in TKI-mediated apoptosis, K562 and KCL22 cells were transfected for 
48 h with siRNAs against BIM, BID and PUMA and TKI-mediated apoptosis 
assessed. In both cell lines, downregulation of BIM, BID or PUMA significantly 
reduced the extent of TKI-mediated apoptosis. This was more evident following 
exposure to nilotinib and dasatinib than imatinib (Figure 3.4 B - E). These results 














Figure 3.3. TKIs induce BAX and BAK dependent-intrinsic pathway of apoptosis. K562 
and KCL22 cells were transfected with siRNAs against BAK and BAX for 48 h and further 
exposed for 48 h to (A) DMSO, (B) imatinib (1 µM), (C) nilotinib (50 nM) or (D) dasatinib 
(3 nM) and assessed for PS positivity by flow cytometry (E) Western blots confirming the 
knockdown efficiency of siRNA targeting mRNAs of the indicated proteins. GAPDH was 
used as loading control. Error bars represent standard error of mean (S.E.M.) from at least 
three independent biological replicates. Western blots were performed 72 h after siRNA 
transfection. Statistical analysis was conducted using one-way ANOVA and multiple 











Figure 3.4. TKIs induce apoptosis in a BIM, BID and PUMA-dependent manner. K562 
and KCL22 cells were transfected with siRNAs against BIM, BID or PUMA for 48 h and 
exposed for a further 48 h to (A) DMSO, (B) imatinib (1 µM), (C) nilotinib (50 nM) or (D) 
dasatinib (3 nM) and assessed for PS positivity by flow cytometry (E) Western blots 
confirming the knockdown efficiency of siRNA. GAPDH was used as loading control. Error 
bars represent standard error of mean (S.E.M.) from at least three independent biological 
replicates. Western blots were performed 72 h after siRNA transfection. Statistical analysis 
was conducted using one-way ANOVA and multiple comparison tests were conducted using 
Fisher’s LSD test (***p≤0.001; ** p≤0.01; * p≤0.05).  
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3.2.4 TKIs induce apoptosis in HRK- and BAD-dependent manner 
The sensitisers BH3-only members, NOXA, HRK, BMF, BIK and BAD, do 
not interact with BAX and BAK but can bind specifically to anti-apoptotic BCL-2 
family members to release BH3-only activators and induce apoptosis. Therefore, 
K562 and KCL22 cells were transfected with siRNAs against NOXA, HRK, BMF, 
BIK and BAD for 48 h, and assessed for TKI-mediated apoptosis. Downregulation of 
HRK and BAD, but not NOXA, BMF or BIK inhibited TKI-mediated apoptosis in 
both K562 and KCL22 cells (Figure 3.5 B - E). Although HRK levels were not 
clearly detected by western blot, HRK mRNA levels were detected by qPCR (data 
shown in the published version and in Appendix). 
 
3.2.5 BCL-XL is an essential requirement for CML cell lines survival  
The sensitisers, BAD (binds BCL-2, BCL-XL and MCL-1) and HRK 
(specifically binds BCL-XL) share BCL-XL as their common binding partner (Figure 
1.3).202 Data demonstrating that TKI-mediated apoptosis occurred in a BAD- and 
HRK-dependent manner highlight a possible role for BCL-XL in TKI-mediated cell 
death in CML. Therefore, K562 and KCL22 cells were transfected with siRNAs 
against BCL-2, BCL-XL, BCL-W, BFL-1 and MCL-1 for 48 h and assessed for 
changes in TKI-mediated apoptosis. Downregulation of BCL-XL but not the other 
members resulted in high levels of apoptosis in both K562 and KCL22 cells (Figure 
3.6 A and B). Furthermore, silencing of BCL-XL also increased TKI-mediated cell 






Figure 3.5. TKIs induce apoptosis in an HRK and BAD-dependent manner. K562 and 
KCL22 cells were transfected with siRNAs against NOXA, HRK, BMF, BIK or BAD for 48 
h and further exposed for 48 h to (A) DMSO, (B) imatinib (1 µM), (C) nilotinib (50 nM) or 
(D) dasatinib (3 nM) and assessed for PS positivity by flow cytometry (E) Western blots 
confirming the knockdown efficiency of siRNAs. Levels of BMF and BIK were undetectable 
in the experiments. GAPDH was used as loading control. Error bars represent standard error 
of mean (S.E.M.) from at least three independent biological replicates. Western blots were 
performed 72 h after siRNA transfection. Statistical analysis was conducted using one-way 
ANOVA and multiple comparison tests were conducted using Fisher’s LSD test 






Figure 3.6. BCL-XL is critical for the survival of CML cell lines. (A) K562 and (B) 
KCL22 cells were transfected with siRNAs against BCL-2, BCL-XL, BCL-W, BFL-1 or 
MCL-1 for 48 h and further exposed for 48 h to either DMSO, imatinib (1 µM), nilotinib (50 
nM) or dasatinib (3 nM) and assessed for PS positivity by flow cytometry (C) Western blots 
confirming the knockdown efficiency of siRNAs. GAPDH was used as loading control. 
Error bars represent standard error of mean (S.E.M.) from at least three independent 
biological replicates. Western blots were performed 72 h after siRNA transfection. Statistical 
analysis was conducted using one-way ANOVA and multiple comparison tests were 




3.2.6 The BCL-XL inhibitor, A-1331852, induces apoptosis in CML cell lines 
 As CML cells appeared to depend on BCL-XL for survival (Figure 3.6), K562 
and KCL22 cells were exposed to increasing concentrations of ABT-737 (a BAD 
mimetic that inhibits BCL-2, BCL-XL and BCL-w), ABT-199 (a BCL-2 inhibitor), 
A-1331852 (a BCL-XL inhibitor) and A-1210477 (a MCL-1 inhibitor) and assessed 
for PS positivity. In accordance with previous results (Figures 3.5 and 3.6), inhibition 
of BCL-XL by A-1331852 was by far the most effective in promoting apoptosis in 
both cell lines compared to the other inhibitors (Figure 3.7).  
 
3.2.7 TKI-induced apoptosis is enhanced by chemical or genetic inhibition of 
BCL-XL 
 After establishing that the CML cell lines require BCL-XL for apoptosis, 
experiments were performed to verify how pharmacological or genetic inhibition of 
BCL-XL would affect TKI-induced apoptosis. Downregulation of BCL-XL resulted 
in 50-60% apoptosis, which was greatly increased when exposed to the different 
TKIs (Figure 3.8 A and B). To assess whether A-1331852 enhanced TKI-mediated 
apoptosis, K562 cells were exposed to a sub-lethal concentration of A-1331852              
(1 nM), which did not induce any apoptosis. The three different TKIs alone induced 
~50% of apoptosis, which was significantly increased when cells were exposed to a 
sub-lethal concentration (1 nM) of A-1331852 (Figure 3.8 C). These results further 
confirmed that A-1331852 induced extensive apoptosis in CML cell lines and also 










Figure 3.7. A BCL-XL inhibitor induces apoptosis in CML cell lines. (A) K562 and (B) 
KCL22 cells were exposed for 4 h to a concentration range of BH3 mimetics: ABT-737 
(dotted lines with cross), ABT-199 (dotted lines with hollow square), A-1331852 (bold lines 
with filled triangle) and A-1210477 (bold lines with filled circle) and assessed for PS 
positivity by flow cytometry. In the graph, the extent of apoptosis in untreated cells are 
represented by a red circle. Error bars represent standard error of mean (S.E.M.) from at least 










Figure 3.8. Inhibition of BCL-XL enhances TKIs-induced apoptosis in CML cell lines. 
(A) K562 and (B) KCL22 cells, transfected with siRNA against BCL-XL for 48 h, were 
further exposed to DMSO, imatinib (1 µM), nilotinib (50 nM) or dasatinib (3 nM) for 48 h 
and assessed for PS positivity by flow cytometry. (C) K562 cells, exposed to DMSO, 
imatinib (1 µM), nilotinib (50 nM) or dasatinib (3 nM) for 48 h, were further exposed to     
A-1331852 (1 nM) for 1 h and assessed for PS positivity by flow cytometry. Error bars 
represent standard error of mean (S.E.M.) from at least three independent biological 
replicates. Statistical analysis was conducted using one-way ANOVA and multiple 






3.2.8 Inhibition of BCL-XL induces rapid apoptosis in primary CML cells with 
no effect in normal mononuclear cells (MNC) 
To extend the observations in cell lines to primary patient samples, CD34+ 
(haematopoietic stem cell marker) progenitor CML cells and MNCs from healthy 
volunteers were exposed to increasing concentrations of A-1331852 and the extent of 
PS positivity assessed. At low concentrations (1 nM), A-1331852 resulted in 
enhanced apoptosis in CD34+ progenitor cells within 1 h of exposure, with higher 
concentrations (10 nM) further increasing the extent of apoptosis (Figure 3.9 A). In 
contrast, survival of MNCs from healthy volunteers was not affected by A-1331852 
(Figure 3.9 B). Thus A-1331852 could selectively kill CML cells while sparing 
normal cells.  
 
3.2.9 AML cell lines depend on MCL-1 and BCL-2 but not BCL-XL for 
survival  
Several studies have shown that AML cells can be targeted by inhibiting 
BCL-2 and/or MCL-1.170,203–205 However, some reports indicate that AML cells 
depend primarily on BCL-2 for survival.197,206 To study this further, 6 AML cell 
lines, namely MV-4-11, MOLM-13, THP-1, AML-3, U937 and HL-60, were 
exposed to increasing concentrations of the different BH3 mimetics, namely ABT-
199, A-1331852 and S63845 to inhibit BCL-2, BCL-XL  and MCL-1, respectively. 
S63845 was used instead of A-1210477 in these experiments, as it was recently 
reported as the most potent and specific MCL-1 inhibitor.168 Of the six cell lines 
used, MV-4-11 and MOLM-13 exhibited marked sensitivity to either ABT-199 (IC50 
~ 100 nM) or S63845 (IC50 ~ 10 nM). THP-1 and AML-3 cells were highly sensitive 













Figure 3.9. Inhibition of BCL-XL induces rapid apoptosis in primary CML cells but not 
in normal MNC. (A) Primary CD34+ cells from CML patients (n=3) and (B) MNCs from 
healthy volunteers (n=8) were exposed to 0, 1 or 10 nM of A-1331852 for 1 h and assessed 
for PS positivity by flow cytometry. In the graphs, each line represents the same pool of 






Figure 3.10. Inhibitors of BCL-2 and/or MCL-1 induces apoptosis in AML cell lines. 
(A) MV-4-11, (B) MOLM-13, (C) THP-1, (D) AML-3 (OCI), (E) U937 and (F) HL-60 cell 
lines were exposed to a concentration range of ABT-199 (BCL-2 inhibitor), S63845 (MCL-1 
inhibitor) or A-1331852 (BCL-XL) inhibitor for 24 h and assessed for PS positivity by flow 
cytometry. Results are shown as Mean ± SEM (standard error of the mean) from at least 
three independent experiments. Statistical analysis was conducted using two-way ANOVA 
and multiple comparison tests were conducted using Fisher’s LSD test (***p≤0.001; ** 




cells showed mild resistance to S63845 (IC50 ~ 1 µM) and great resistance to ABT-
199. HL-60 cells were the most resistant cells from the panel. None of the cells 
showed sensitivity to BCL-XL inhibition by A-1331852 (Figure 3.10). 
 
3.2.10 Inhibition of both MCL-1 and BCL-2 exhibits synergy in the induction of 
apoptosis in AML cell lines 
Single inhibition of MCL-1 or BCL-2, but not BCL-XL, induced varying 
levels of apoptosis in most of the AML cell lines used, indicating that these cells 
might depend on either MCL-1 or in some cases, BCL-2 for survival. Based on a 
multiple-ray experimental design to achieve an ideal concentration ratio between 
S63845 and ABT-199, the cells were exposed to varying concentrations of a 
combination of the two inhibitors and assessed for PS positivity. Cell death 
percentages were fed to the Combenefit software179 to generate a Bliss Independence 
score heatmap. The Bliss Independence model is based on the assumption that the 
effects of the drugs used are due to a probabilistic chance, and a zero interaction is 
comparable to a probabilistic independence. This synergy model works analogously 
to the concept of epistasis in molecular biology, which is the phenomenon where the 
effect of a particular gene is dependent on the presence of at least one other 
gene.207,208 Using this approach, the effect of the two BH3 mimetics were compared 
to answer whether the presence of one of them affects the extent of apoptosis 
mediated by the other and vice-versa. Although all cell lines showed differing levels 
of synergy between S63845 and ABT-199, MV-4-11 and MOLM-13 exhibited better 
synergy at lower concentrations, which was not apparent in the most resistant U937 
and HL-60 cells (Figure 3.11). It is important to note that MV-4-11 and MOLM-13 








Figure 3.11. Inhibitors BCL-2 and MCL-1 synergise with each other to induce 
apoptosis in AML cell lines. (A) MV-4-11, (B) MOLM-13, (C) THP-1, (D) AML-3 (OCI), 
(E) U937 and (F) HL-60 cell lines were exposed to a combination of varying concentrations 
of ABT-199 and S63945 for 24 h and assessed for PS positivity by flow cytometry. The 
Bliss score ranging from 0 (white) to 100 (dark blue) depicts the strength of the synergistic 
effect and the extent of PS positivity for the different combinations is shown inside each 





alone, which affected the calculation of synergy, since the effect of one compound by 
itself can explain the amount of cell death observed. 
 
3.2.11 Dual inhibition of MCL-1 and BCL-2 in primary AML cells induces 
apoptosis in an additive manner 
Next, primary AML cells isolated from patients, were exposed to increasing 
concentrations of S63845 and/or ABT-199 for 4 h, and the extent of PS positivity 
subjected to Bliss score analysis (Figure 3.12). ABT-199 in combination with 
S63845 induced apoptosis in primary AML cells in an additive manner for all the 
samples tested, with some cells being similarly to sensitive to both ABT-199 and 
S63845 (#3621 and #3624), while the rest being more sensitive to S63845 than to 
ABT-199. Taken together, these results indicate that a combination therapy, 








Figure 3.12. Exposure to ABT-199 and S63845 in primary AML cells induces apoptosis 
in an additive manner. Primary AML cells isolated from patients (A-D) were exposed to a 
combination of varying concentrations of ABT-199 and S63945 for 4 h and assessed for PS 
positivity. The Bliss score ranging from -100 (red) to 100 (green) depicts antagonistic (red), 
additive (yellow) or synergistic (green) effects by the inhibitors. The extent of PS positivity 
for the different combinations is shown inside each quadrant. The Bliss score was calculated 





The constitutively active kinase activity of BCR-ABL1 contributes to disease 
progression in CML and hence has been exploited in the design and successful use of 
TKIs. Several TKIs display great potency in inhibiting BCR-ABL1 kinase activity 
and reducing the frequency of CML disease progression to blast crisis. Although 
imatinib has greatly improved patient outcome, approximately one third of patients 
still fail treatment.209 In this study, using RNA interference in CML cell lines, 
specific members of the BCL-2 family, such as BAX/BAK, BIM, BID, PUMA, BAD 
and HRK, have been identified to be critical in the induction of apoptosis following 
exposure to TKIs (Figures 3.3-3.5). Intriguingly, these findings also appeared to 
extend to CML patients, as increased expression of specific pro-apoptotic BH3-only 
members PUMA, HRK and possibly BIM correlated with progression free survival in 
CML patients.35 This was the first study to link several pro-apoptotic BCL-2 family 
members to progression free survival in imatinib–treated CML patients. 
Targeting the BCL-2 family of proteins with selective antagonists may offer 
novel therapeutic approaches in this malignancy. BCL-XL has been associated with 
the development and maintenance of TKI resistance as well as disease progression in 
CML.36,194,210–212 In agreement, A-1331852 displayed remarkable potency, both as a 
single agent and in combination with TKIs, to facilitate apoptosis both in cell lines 
and in the progenitor CD34+ primary cells. Notably, the insensitivity of these 
quiescent CD34+ progenitor cells has limited the potential of imatinib to cure CML 
and is a major factor in the recurrence of the disease on discontinuation of therapy. 
Previous studies have shown a BCL-XL dependence of stem cell survival for human 
embryonic stem cells as well as non-small cell lung cancer cells.213,214 The sensitivity 
of CD34+ progenitor cells to BCL-XL inhibition offers much promise towards the 
66 
 
introduction of BH3 mimetic therapy in CML. The results presented in this study 
indicate that targeting of BCL-XL in CML in combination with TKIs could be a very 
beneficial adjunct to current therapy, taking into consideration the effects of BCL-XL 
inhibition for platelet survival.215 
Chromosomal abnormalities and mutations in the FLT3 receptor gene are 
responsible for the onset of the great majority of AML types.187,216 Besides the 
common cytarabine and anthracycline therapy, TKIs have been developed to inhibit 
the FLT3 receptor.187 The potential of BH3 mimetic therapy in AML has been 
explored in conjunction with standard chemotherapy, such as sorafenib,217 HDAC 
inhibitors218 and MEK inhibitors.219 Recent reports suggest that AML is a BCL-2 
dependent cancer,197,206 although recently developed MCL-1 inhibitors have entered 
clinical trials to treat AML.220 In addition, ABT-199 has been used in combination 
with MEK inhibitors and TKIs, unveiling new ways to target AML.197,219,221,222 The 
data presented in this chapter indicate that dual inhibition of BCL-2 and MCL-1 is 
remarkably synergistic to induce cell death in AML cell lines and additive in primary 
cells derived from AML patients, which could be due to the sample number 
limitation and patient to patient variability. Taken together, these results show that 
using BH3 mimetics to tackle AML could be a very appealing strategy. Moreover, it 
is important to emphasise that a prior knowledge on BCL-2 family member 
dependency would be required for a more specific and personalised therapy in the 
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4.1 Introduction  
 BH3 mimetics have been successfully used in several haematological 
malignancies. While the use of ABT-199 in CLL has been extensively 
studied,164,223,224 leading to the approval of ABT-199 for treatment against 
chemorefractory CLL,225 findings from the previous chapter revealed the potential of 
BH3 mimetic therapy in CML and AML. To extend these observations to solid 
tumours, two different tumour types were chosen. 
The first tumour type was from Head and neck squamous cell carcinoma 
(HNSCC), a highly prevalent cancer worldwide, with ~600,000 new cases every 
year.226 Although the most important risk factors are alcohol consumption and 
tobacco use, human papillomavirus (HPV) infection has been linked to a subset of 
high-risk HNSCC, as HPV type-16 E6 oncogene inactivates p53. In addition, TP53 is 
also mutated in 60-80% of HNSCC cases which are linked to poor prognosis.227  The 
main line of chemotherapy for head and neck cancer is cisplatin, often combined 
with surgery and/or radiotherapy.228  However, HNSCC treatment is hampered by 
development of resistance to cisplatin as well as enhanced toxicity.229 Therefore, 
assessment of new promising candidates for HNSCC therapy is essential. On that 
note, the first successful targeted therapy for HNSCC was the use of antibodies 
targeting EGFR,230 as EGFR expression has been associated with poor prognosis.231 
Studies pertaining to the BCL-2 family of proteins in HNSCC are focused on 
chemoresistance, which has been attributed to high expression of anti-apoptotic 
members of the BCL-2 family, especially BCL-XL in HNSCC.
232 In support of this, 
BH3 peptides and ABT-737 have been previously used in HNSCC to enhance the 
extent of apoptosis following cisplatin and etoposide,233,234 highlighting that the use 
of BH3 mimetics could be beneficial for the treatment of HNSCC. 
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The second choice of tumour type was from pancreatic ductal 
adenocarcinoma (PDAC), one of the most deadly tumours, responsible for ~20-25% 
of all cancer deaths worldwide.235 It presents a very poor prognosis as < 20% of 
patients achieve cure and the 5-year survival rate is < 5%.236 Although several 
environmental factors have been likely linked to PDAC, a causative role only exists 
for tobacco use.237 In addition, KRAS2 mutations and inactivation of CDKN2A are 
present in ~90% of all fully established pancreatic tumours.238 Gemcitabine, a 
nucleoside analogue of deoxycytidine, is widely used as the first line treatment for 
pancreatic cancer, however response rates to gemcitabine treatment is as low as 25% 
and many patients develop resistance.239 Gemcitabine resistance has been attributed 
to several factors, such as upregulation of the ribonucleotide reductase RRM1,240 
enhanced activity of the DNA repair endonuclease ERCC1,241 or via miRNA 
regulatory pathways.239 In addition, resistance to gemcitabine has been linked to 
overexpression of BCL-XL and MCL-1.
242,243 Of interest, some reports have shown 
that targeting BCL-2, BCL-XL or MCL-1 with BH3 mimetics can potentially 
increase gemcitabine sensitivity in PDAC, and induce caspase-dependent cell death, 
highlighting the potential of using BH3 mimetics in PDAC therapy.244–247  
In this chapter, using cell lines and patient material derived from cancers of 
the head and neck and pancreas, the potential of BH3 mimetic therapy in these 





4.2.1 Several solid tumour cell lines depend on both MCL-1 and BCL-XL for 
survival  
 Haematological malignancies generally depend on a single anti-apoptotic 
member of BCL-2 family for survival.35,155,248 However, several reports indicate that 
the majority of solid tumours depend on both BCL-XL and MCL-1 for survival,
249 
thus requiring inhibition of the two anti-apoptotic proteins to undergo 
apoptosis.250,251 To confirm that, cell lines derived from different solid tumours, 
namely breast, pancreas, lung and colon, were exposed to S63845 and/or A-1331852 
and PS positivity assessed. All cell lines exhibited marked PS externalisation when 
exposed to a combination of S63845 and A-1331852 but not when exposed to either 
of those BH3 mimetics individually (Figure 4.1), indicating these cell lines depend 
on both BCL-XL and MCL-1 for survival. The 4 h exposure to BH3 mimetics in 
these experiments was chosen based on hourly observations under a light microscope 
for detached and apoptotic cells.  
4.2.2 Several HNSCC cell lines express high levels of BCL-XL and MCL-1 
 In order to check the expression levels of BCL-2, BCL-XL and MCL-1 in 
HNSCC, several head and neck cancer cell lines derived from distinct anatomical 
sites, namely oral cavity (UM-SCC-1), larynx (UM-SCC-11B, UM-SCC-17A and 
UM-SCC-17AS) and oropharynx (UM-SCC-74A and UM-SCC-81B), were 
immunoblotted for the major BCL-2 anti-apoptotic proteins. The chosen cells 
showed varying levels of BCL-2, but high expression levels of both MCL-1 and 
BCL-XL (Figure 4.2), indicating that inhibiting these proteins could potentially 






Figure 4.1. MCL-1 and BCL-XL inhibition induces apoptosis in several solid tumours 
cell lines. Breast cancer cell lines, AU-565A, HCC-70, HCC-1937D and BT-474; a colon 
cancer cell line, SW-48; a pancreatic cancer cell lines, MIA PaCa-2, BxPC-3 and PANC-1 
and a non-small cell lung cancer cell line, H1299 were exposed to S63845 (100 nM), A-
1331852 (100 nM) or a combination of both for 4 h and assessed for the extent of PS 
















Figure 4.2. BCL-2 anti-apoptotic family members protein expression levels in several 
HNSCC cell lines. Immunoblot of several HNSCC cell lines derived from different head 
and neck tissues showing expression levels of BCL-1, BCL-XL and MCL-1. GAPDH was 







4.2.3 BCL-2 is poorly expressed in the oral cavity tissue of HNSCC patients 
 As some of the HNSCC cell lines expressed varying levels of BCL-2, studies 
were carried out to confirm whether this result translated to patient samples. Oral 
cavity (OC) TMA (tissue microarray) cores from normal, tumour core and advancing 
front of HNSCC patients were immunostained with BCL-2 antibody and the staining 
intensity (H-score) quantified to assess BCL-2 expression levels. Normal cores from 
healthy patients, tumour cores from HNSCC patients as well as tumour tissues from 
the advancing front of the tumour core from HNSCC patients exhibited similar H-
scores, averaging below 100, which is considered a low value.178 Statistical analysis 
showed that there were no significant differences between BCL-2 expression levels 
of normal, tumour core and tumour advancing front TMAs. A representative image 
of each category illustrates BCL-2 expression levels of the tissues analysed (Figure 
4.3). 
  
4.2.4 BCL-XL is highly expressed in HNSCC oral cavity tissue 
 Similarly, the expression levels of BCL-XL in normal and HNSCC patients 
were assessed in the relevant TMAs. In contrast to the expression profile of BCL-2, 
BCL-XL expression levels were overall high. Normal patient cores showed 
considerably lower levels of BCL-XL expression when compared to tumour cores 
and tumour advancing front (Figure 4.4), in agreement with previous data showing 
high levels of BCL-XL expression in HNSCC cell lines (Figure 4.2). This indicated 
that BCL-XL may be a good marker for HNSCC prognosis and that it could be 















Figure 4.3. BCL-2 is poorly expressed in HNSCC oral cavity. TMAs of oral cavity (OC) 
obtained from normal patients, tumour core and tumour advancing front (AF) stained with 
anti-BCL-2 antibody and counter-stained for haematoxylin. Scale bar: 50 µm. TMA cores 
were assessed for the intensity of BCL-2 antibody staining using QuPath software (H-score). 
Yellow hollow circles represent the core section chosen as a representative image. Statistical 
analysis was conducted using one-way ANOVA and multiple comparison tests were 














Figure 4.4. BCL-XL is highly expressed in HNSCC oral cavity. TMAs of oral cavity (OC) 
obtained from normal patients, tumour core and tumour advancing front (AF) stained with 
anti-BCL-XL antibody and counter-stained for haematoxylin. Scale bar: 50 µm. TMA cores 
were assessed for the intensity of BCL-XL antibody staining using QuPath software (H-
score). Yellow hollow circles represent the core section chosen as a representative image. 
Statistical analysis was conducted using one-way ANOVA and multiple comparison tests 








4.2.5 MCL-1 is highly expressed in HNSCC oral cavity tissue 
 Similar to BCL-XL, MCL-1 expression levels were higher in the tumour core 
and advancing front than normal tissues. In addition, oral cavity tumour cores 
exhibited higher levels of MCL-1 expression than advancing front cores, which 
could indicate that the role of MCL-1 in this cancer might be involved in precursor 
tumour cells (tumour core) but not so much in the derived cells (advancing front) 
(Figure 4.5). These data confirm that HNSCC tumours express high levels of MCL-1 
and therefore MCL-1 could be a good target for potential BH3 mimetic therapy. 
 
4.2.6 BH3 mimetics do not accentuate the effects of cisplatin in reducing the 
clonogenic potential of HNSCC cell lines 
 Since cisplatin is the first-line chemotherapy for HNSCC, the specified cell 
lines were exposed to cisplatin in combination with the different BH3 mimetics and 
assessed for changes in their clonogenic potential. This was performed by 
quantifying the percentage of colonies that survived the specific treatments 
(surviving fraction). Cisplatin exposure alone greatly reduced clonogenicity of UM-
SCC-11B, -17A and -74A, however this was not exacerbated when combined with 
BH3 mimetics. UM-SCC-1 cells exhibited mild reduction of clonogenicity by 
cisplatin and A-1331852 was the only BH3 mimetic capable of further reducing the 
clonogenic potential of this cell line. UM-SCC-17AS and 81B were the most 
resistant cells, showing a small reduction of clonogenic potential by cisplatin alone, 
which was not exacerbated when combined with any of the BH3 mimetics (Figure 
4.6). These results indicate that co-administration of BH3 mimetics with cisplatin 












Figure 4.5. MCL-1 is highly expressed in HNSCC oral cavity. TMAs of oral cavity (OC) 
obtained from normal patients, tumour core and tumour advancing front (AF) stained with 
anti-MCL-1 antibody and counter-stained for haematoxylin. Scale bar: 50 µm. TMA cores 
were assessed for the intensity of MCL-1 antibody staining using QuPath software (H-score). 
Yellow hollow circles represent the core section chosen as a representative image. Statistical 
analysis was conducted using one-way ANOVA and multiple comparison tests were 
















Figure 4.6. Single inhibition of BCL-2, BCL-XL or MCL-1 does not affect native or 
cisplatin-induced clonogenic survival of several head and neck cancer cell lines. Several 
head and neck cancer cell lines were exposed to ABT-199 (100 nM), A-1331852 (100 nM) 
or S63845 (100 nM) alone or in combination with cisplatin (1 µM) for 7 days and assessed 
for clonogenic survival. Error bars represent the S.E.M. for at least three independent 
biological replicates. Statistical analysis was conducted using one-way ANOVA and 






4.2.7 Inhibition of both BCL-XL and MCL-1 induce apoptosis in HNSCC cell 
lines 
 Since exposure to individual BH3 mimetics did not reduce clonogenic 
potential of HNSCC cells, these studies were extended to assess whether exposing 
the HNSCC cell lines to a combination of BH3 mimetics could induce apoptosis. As 
expected, BH3 mimetics, when used as single agents, were not capable of promoting 
apoptosis in these cells, confirming that these cells must depend on more than one 
anti-apoptotic member of the BCL-2 family (Figure 4.7 A). Similarly, inhibiting both 
BCL-2 and BCL-XL (by ABT-199 and A-1331852, respectively) or both BCL-2 and 
MCL-1 (by ABT-199 and S63845, respectively) did not induce apoptosis in any of 
the cell lines (Figure 4.7 B and C). However, a dual inhibition of BCL-XL and MCL-
1 (by A-1331852 and S63845, respectively) greatly induced apoptosis in all HNSCC 
cell lines (Figure 4.7 D). These results are in accordance to the initial findings on 
several solid tumour cell lines, showing dependence on both BCL-XL and MCL-1 for 
survival and indicate that HNSCC cells also depend on these two proteins. 
 
4.2.8 The clonogenic survival of HNSCC cell lines is greatly impaired by 
inhibition of both BCL-XL and MCL-1 
 As inhibition of both BCL-XL and MCL-1 induced apoptosis, experiments 
were performed to investigate whether a combination of A-1331852 and S63845 
would also decrease clonogenic potential of these cells. Indeed, targeting both BCL-
XL and MCL-1 with A-1331852 and S63845, respectively greatly reduced the 
clonogenic potential of all HNSCC cell lines used in this study (Figure 4.8), further 
confirming the dual dependency on BCL-XL and MCL-1 of HNSCC cells and 









Figure 4.7. HNSCC cell lines depend on both BCL-XL and MCL-1 for survival. HNSCC 
cell lines were exposed to ABT-199 (100 nM), A-1331852 (100 nM), S63845 (100 nM) 
alone or in combination for 24 h and assessed for the extent of PS externalisation by FACS. 
(A) Single BH3 mimetics exposure. (B) Inhibition of BCL-2 and BCL-XL (C) Inhibition of 
BCL-2 and MCL-1. (D) Inhibition of BCL-XL and MCL-1. Error bars represent the S.E.M. 
for at least three independent biological replicates. Statistical analysis was conducted using 














Figure 4.8. Inhibition of both BCL-XL and MCL-1 greatly impairs clonogenic survival 
of several HNSCC cell lines. Indicated HNSCC cell lines were exposed to A-1331852 (100 
nM), S63845 (100 nM) or a combination of both for 7 days and assessed for clonogenic 
survival. Error bars represent the S.E.M. for at least three independent biological replicates. 
Statistical analysis was conducted using one-way ANOVA and multiple comparison tests 




4.2.9 Inhibition of both BCL-XL and MCL-1 induce apoptosis in primary 
tumours derived from head and neck cancer patients 
 To corroborate the previous observations that targeting both BCL-XL and 
MCL-1 induced apoptosis in HNSCC cell lines, and thus could form a new potential 
therapy in HNSCC, similar treatments of the specific BH3 mimetics were carried out 
on the ex-vivo explant cultures of the tumour tissues, freshly resected from patients. 
The tumour tissues, post-surgery, were collected, treated with BH3 mimetics, fixed, 
processed, sectioned and stained for apoptosis markers (cleavage of PARP) by Dr. 
Rachel Carter in our research group. I assisted Dr. Carter in quantifying the cleaved 
PARP-positive tumour nuclei, and the results from these studies were plotted. As 
expected, A-1331852 and S63845, when used in combination but not as singe agents, 
resulted in pronounced apoptosis in patient tissues (Figure 4.9), further confirming 
the rationale for using this combination therapy in HNSCC. 
 
4.2.10 Several PDAC cell lines express similar levels of the anti-apoptotic BCL-
2 family of proteins 
Following a similar strategy used to investigate the potential of BH3 mimetic 
therapy in head and neck cancer, efforts were made to extend these observations to 
pancreatic cancer. Firstly, the expression levels of BCL-2, BCL-XL and MCL-1 were 
assessed in 3 pancreatic cell lines, MIA PaCa-2, PANC-1 and BxPC-3. All 3 cells 
showed similar expression levels of the proteins (Figure 4.10). Although these cells 
express considerable amounts of BCL-2, as already demonstrated in Figure 4.1, these 







Figure 4.9. Inhibition of both BCL-XL and MCL-1 induces apoptosis in HNSCC patient 
tissues. (A) Freshly resected patient tissues of HNSCC were obtained from Aintree 
University Hospital, cut to 1 mm3 pieces and exposed to A-1331852 (1 µM), S63845 (1 µM) 
or a combination of both for 48 h and processed for immunohistochemistry with cleaved 
PARP antibody (brown staining) and counterstained with haematoxylin (blue staining). Scale 
bar: 50 µm. (B) The percentage of cells positively stained for cleaved PARP was quantified 
for different patient-derived tissues (colour coded for each patient). Statistical analysis was 
conducted using one-way ANOVA and multiple comparison tests were conducted using 

















Figure 4.10. Protein expression levels of the anti-apoptotic BCL-2 family members in 
several PDAC cell lines. Immunoblot of several pancreatic cancer cell lines showing 














4.2.11 BCL-2, BCL-XL and MCL-1 are highly expressed in pancreatic cancer 
 Similar to the TMA analysis that was carried out using HNSCC patient 
samples, pancreatic cancer TMAs obtained from Liverpool biobank were 
immunostained with BCL-2, BCL-XL and MCL-1 antibodies and H-score was 
determined using QuPath analysis. Expression levels of BCL-2 were variable among 
the TMA cores, with slightly more cores expressing low levels of the protein (Figure 
4.11). In contrast, BCL-XL was highly expressed in the great majority of the cores, 
with a few cores showing moderate staining and no core exhibiting low staining 
(Figure 4.12). MCL-1 expression levels were also variable, with most of the cores 
expressing moderate amounts of the protein (Figure 4.13).  
 
4.2.12 Expression levels of BCL-2, BCL-XL and MCL-1 in pancreatic cancer 
TMAs do not correlate with overall patient survival  
Next, the expression levels of BCL-2, BCL-XL and MCL-1 were correlated 
with overall survival in the corresponding pancreatic cancer patients. Using data 
obtained from TMA analysis and patient data obtained from Liverpool biobank, 
Kaplan-Meier estimators were generated to verify whether expression levels of BCL-
2, BCL-XL and MCL-1 would be good estimators of overall patient survival. 
Statistical analysis by logrank test indicated that expression levels of BCL-2, BCL-
XL and MCL-1 are not good estimators for overall patient survival (Figure 4.14). 
These results suggested that expression levels of these anti-apoptotic BCL-2 family 
of proteins may not necessarily contribute to disease progression in pancreatic 
cancer. Nevertheless, targeting these proteins have been shown to be effective in 










Figure 4.11. BCL-2 expression is evenly distributed among the tumour cores of PDAC 
patients. TMAs from PDAC patients were stained with anti-BCL-2 antibody, counter-
stained for haematoxylin and H-score on QuPath software. (A) TMA cores were assessed for 
the intensity of antibodies staining using QuPath software (H-score). Yellow hollow circles 
represent the core section chosen as a representative image (B) Representative images of 




















Figure 4.12. BCL-XL expression is generally high in the tumour cores of PDAC 
patients. TMAs from PDAC patients were stained with anti-BCL-XL antibody, counter-
stained for haematoxylin and H-score on QuPath software. (A) TMA cores were assessed for 
the intensity of antibodies staining using QuPath software (H-score). Yellow hollow circles 
represent the core section chosen as a representative image (B) Representative images of 
TMA cores for BCL-XL staining levels and respective n numbers for each stratum. Cores 



















Figure 4.13. MCL-1 expression is evenly distributed among the tumour cores of PDAC 
patients. TMAs from PDAC patients were stained with anti-MCL-1 antibody, counter-
stained for haematoxylin and H-score on QuPath software. (A) TMA cores were assessed for 
the intensity of antibodies staining using QuPath software (H-score). Yellow hollow circles 
represent the core section chosen as a representative image (B) Representative images of 















Figure 4.14. Kaplan-Meier plots reveal no correlation between the overall survival of 
patients and expression levels of anti-apoptotic BCL-2 family members. Low, moderate 
and high expression levels of (A) BCL-2 (B) BCL-XL and (C) MCL-1 obtained from H-
scores of TMA cores of pancreatic cancer patients (showed in Figures 4.11, 4.12 and 4.13), 
were analysed against patient survival time after diagnostic. Stratification for low, moderate 
and high expression levels were obtained from QuPath recommendations for 3 bins based on 





4.2.13 BH3 mimetics may enhance gemcitabine-mediated apoptosis in PDAC 
 In order to assess whether targeting BCL-XL or MCL-1 would synergise with 
a standard treatment such as gemcitabine in inducting apoptosis in pancreatic cancer, 
MIA PaCa-2, PANC-1 and BxPC-3 cells were exposed to increasing concentrations 
of gemcitabine alone or in combination with A-1331852 or S63845 and assessed for 
changes in the extent of apoptosis. While A-1331852 but not S63845 in combination 
with gemcitabine enhanced apoptosis in BxPC-3 cells, no such effects were observed 
in MIA Paca-2 and PANC-1 cells (Figure 4.15).  
 
4.2.14 Inhibition of BCL-XL in combination with gemcitabine decreases the 
clonogenic potential of PDAC cell lines 
 Next, the treatments mentioned above were carried out in the same cell lines 
to measure their clonogenic potential. Exposure to A-1331852 diminished the ability 
of the cells to form distinct colonies, especially when gemcitabine was 
simultaneously administered (Figure 4.16). This effect was more pronounced in 
BxPC-3 cells compared to the other two cell lines, indicating that inhibiting BCL-XL 
in combination with gemcitabine treatment could be beneficial to some pancreatic 
cancer patients. However, this study could not be extended to tumour samples from 














Figure 4.15. Gemcitabine-mediated apoptosis is enhanced by inhibition of BCL-XL or 
MCL-1. The PDAC cell lines (A) MIA PaCa-2, (B) BxPC-3 and (C) PANC-1 were exposed 
to different concentrations of gemcitabine alone (black line) or in combination with S63845 
(100 nM; red line) or A-1331852 (100 nM; blue line) for 24 h and assessed for the extent of 
















Figure 4.16. Gemcitabine-mediated decrease in clonogenic potential is further 
decreased by inhibition of BCL-XL or MCL-1. The PDAC cell lines (A) MIA PaCa-2, (B) 
BxPC-3 and (C) PANC-1 were exposed to different concentrations of gemcitabine alone 
(black line) or in combination with S63845 (10 nM; red line) or A-1331852 (10 nM; blue 
line) for 7 days and assessed for clonogenic survival. Statistical analysis was conducted 








4.3 Discussion  
HNSCC and PDAC comprise together approximately 20,000 new cases per 
year in the UK.252 Main line of chemotherapy for both of these cancers are agents 
that target DNA (antimetabolites and alkylating agents) that have been used for more 
than 25 years. The problems associated with such therapy (resistance/toxicity) 
emphasise the need for newer, more specific and more potent treatments.229,239,253,254 
Screening several cell lines from HNSCC and PDAC to assess dependencies on the 
different anti-apoptotic BCL-2 family members revealed that BCL-XL and MCL-1 
are promising therapeutic targets (Figure 4.1). Furthermore, protein expression 
analysis of head and neck cell lines showed high expression levels of BCL-XL and 
MCL-1 (Figure 4.2), which was confirmed by patient TMA analysis (Figures 4.3 - 
4.5), thus raising the potential of BH3 mimetic therapy in HNSCC.  
BH3 mimetics such as ABT-737 and gossypol have been studied as potential 
therapy for head and neck cancer, especially when used in combination with 
cisplatin.234,255 However, the data presented here suggests that targeting BCL-XL, 
MCL-1 or BCL-2 with more specific BH3 mimetics does not improve cisplatin-
mediated decrease in clonogenicity of HNSCC cell lines (Figure 4.6). Nevertheless, 
inhibition of both BCL-XL and MCL-1 drastically reduced clonogenic potential and 
induced apoptosis in all HNSCC cell lines tested (Figure 4.7 and 4.8), indicating that 
co-administration of these inhibitors could be valuable to head and neck cancer 
patients. Moreover, this strategy could potentially benefit patients by reducing 
cisplatin-related toxicity side effects such as myelosuppression, nephrotoxicity, 
vomiting and others.228 
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Similarly, expression profile of pancreatic cancer cell lines and TMAs 
revealed that MCL-1 and BCL-XL were highly expressed in PDAC (Figures 4.12 and 
4.13). In pancreatic cancer, the use of BH3 mimetics has been studied more 
extensively in comparison to head and neck cancer. BH3 mimetics such as 
sabutoclax and apogossypol have been shown to enhance the sensitivity if pancreatic 
cancer cells to gemcitabine.256,257 However, these BH3 mimetics are much less 
specific than the recently developed inhibitors, such as A-1210477 and 
S63845.168,251,258 Moreover, a recent study showed that ABT-199 alone enhanced 
sensitivity to gemcitabine by reducing BCL-2 protein expression, indicating BCL-2 
could also be an important target in pancreatic cancer.245 This is not in line with the 
results presented in this chapter, as expression levels of BCL-2 were generally low in 
the PDAC patient TMAs  (Figure 4.11). Nevertheless, genetic inhibition of BCL-XL 
and MCL-1 has been shown to induce apoptosis in pancreatic cancer cells,250 in 
agreement to the data shown here (Figures 4.12 and 4.13), suggesting that these two 
proteins could be potentially targeted to improve therapy. 
Taken together, the results presented in this chapter show that using BH3 
mimetics in solid tumours and more specifically in head and neck and pancreatic 
cancer, could be beneficial and that BCL-XL and MCL-1 play an important role in 
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5.1 Introduction  
Having emerged as an endosymbiont from ancient bacteria,259 the subcellular 
organelle, the mitochondrion, possesses its own DNA, proteins and division 
processes.260 Recent studies have redefined the intricacies around mitochondrial 
structure and function, and confirmed that the mitochondrial network acts in tight 
conjunction with the host cell, sharing proteins and processes that are fundamental 
for cellular homeostasis. This complex mitochondrial dynamic network that spreads 
throughout the cell is organised and maintained by a balance of mitochondrial fission 
and fusion events, named mitochondrial membrane dynamics.260  
Mitochondrial membrane dynamics are orchestrated by GTPases proteins of 
the dynamin superfamily. Fission events are catalysed mainly by DRP-1, which is 
recruited transiently from the cytosol to its receptors, MFF, MiD49, MiD51 and Fis1, 
at the mitochondrial fission sites.261 DRP-1 contains a highly conserved N-terminal 
GTPase domain that homodimerizes in the presence of GTP.262 This self-assembly 
mechanism continues to recruit additional DRP-1 molecules in a ring like structure 
transversally around the mitochondria. In the following steps, this newly assembled 
DRP-1 ring undergoes further conformational changes, tightening the target 
membrane and inducing fission of the mitochondrial membrane.261 Notably, DRP-1 
overexpression does not directly induce mitochondrial fission, as DRP-1 activity is 
dependent of different post-translational modifications, such as phosphorylation, 
which is controlled by proteins regulating different pathways within the cell. Of 
those, kinases such as cyclin-dependent kinases phosphorylate DRP-1 at Ser616, 
inducing activity of the GTPase.263 On the other hand, DRP-1 activity can be 
inhibited by phosphorylation at Ser637 by protein kinase A,264 which in turn can be 
counteracted by calcineurin.265  
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Fusion events are catalysed by mitofusins 1 and 2 (MFN1 and MFN2), 
responsible for outer mitochondrial membrane fusion and OPA-1, responsible for 
inner mitochondrial membrane fusion (Figure 5.1).261 After mRNA splicing OPA-1 
exists as 2 long (L-OPA-1) and 3 short (S-OPA-1) variants266 which control the 
closure and maintenance of the structure of the mitochondrial cristae, crucial for 
trapping cytochrome c in the electron transport chain and for proper functioning of 
mitochondrial oxidative phosphorylation.267 Upon mitochondrial stress, membrane-
bound L-OPA-1 can be proteolysed by the metalloproteases YME1L (ATP-
dependent metalloprotease YME1L1) and OMA1 (Oma1 zinc metallopeptidase), 
which cleave L-OPA-1 to produce S-OPA-1.268,269 Notably a balance between the 
long and short isoforms of OPA-1 is a pre-requisite for a healthy mitochondria, while 
a shift towards the short isoforms promotes mitochondrial dysfunction.266 Moreover, 
it has been shown that inhibition of ATP-synthase reduces OPA-1 processing by 
OMA1, altering mitochondrial remodelling dynamics induced by DRP-1 and 
hindering mitochondrial fission in an attempt to prevent cell death.270,271 In addition, 
DRP-1 function can be regulated by mitochondrial redox status. Enhanced 
mitochondrial respiration induces production of ROS which stimulates DRP-1 
phosphorylation at Ser616, promoting mitochondrial fission.272 Moreover, 
mitochondrial membrane dynamics also play an important role during cell death, as 
mitochondria constitute the initiation sites of the intrinsic apoptotic pathway. It has 
been known that cytochrome c release requires inner mitochondrial membrane 
remodelling and OPA-1 proteolysis for a successful release to the intermembrane 









Figure 5.1. The main processes of mitochondrial membrane dynamics. Mitochondrial 
fusion is mediated by MFN1 and MFN2 in the OMM and by OPA-1 in the IMM, whereas 
mitochondrial fission is mediated by binding of DRP-1 to its receptors in the OMM, which 




These studies have focussed on unravelling the mechanisms of mitochondrial 
membrane dynamics and multi-organelle interplay by monitoring the molecular 
changes of mitochondrial membranes, fission/fusion proteins and ionic exchange 
with other organelles.275–278 However, most of these studies lack detailed information 
on how these events relate to apoptosis. In addition, the assessment of mitochondrial 
membrane dynamics and cell death, in the context of BH3 mimetics has been 
minimal. Previously, it has been shown that ABT-737 induces OMM breaks in 
primary B-cell malignancies cell lines independently of caspase activity, which could 
be due to changes in the mitochondrial ionic influx.279 Furthermore, putative MCL-1 
inhibitors such as sabutoclax, BI112D1 and maritoclax have been shown to induce 
mitochondrial fragmentation independently of MCL-1, DRP-1, BAX or BAK by a 
mechanism not yet elucidated.68,280 
There is clearly a lack of clear understanding on the mitochondrial 
ultrastructural changes that occur during BH3 mimetic-mediated apoptosis. This 
chapter is aimed at understanding whether BH3 mimetics induce mitochondrial 
structural changes, either upstream/downstream/independent of the apoptotic 
cascade. The study further extends to answer whether such mitochondrial changes, if 












Figure 5.2. Control of cristae structure by OPA-1. (A) Under normal conditions, BAX 
and BAK are inactive and OPA-1 is engaged in trapping cytochrome c within mitochondrial 
cristae. (B) Under apoptotic conditions, OPA-1 is proteolysed, which facilitates the release 




5.2.1 BH3 mimetics induce rapid mitochondrial structural perturbations  
BH3 mimetics were designed to specifically induce apoptosis via the intrinsic 
pathway,281 therefore experiments were performed to verify how these small 
molecules affect mitochondrial structure and function in different cell lines. For this, 
three haematological cancer cell lines that depend on distinct BCL-2 family members 
for survival were chosen. The cell lines were - H929 (derived from multiple 
myeloma and depend on MCL-1 for survival), K562 (derived from CML and depend 
on BCL-XL) and MAVER-1 (derived from mantle cell lymphoma and depend on 
BCL-2).248 Those three cell lines were exposed to the corresponding BH3 mimetics 
and subjected to electron microscopy to observe mitochondrial structural changes. In 
the control cells exposed to DMSO, mitochondria appeared intact with a defined 
double membrane and organised cristae. Upon exposure to specific BH3 mimetics, 
these cells showed marked OMM breaks, as well as cristae remodelling, as 
evidenced by the excessive swelling of the mitochondrial matrix (Figure 5.3, yellow 
arrowheads). 
Since these structural changes were observed following exposure to a single 
BH3 mimetic in a single-dependent cell line, studies were carried out to assess 
whether mitochondrial changes would be evident in dual-dependent cell lines derived 
from solid tumours. The cell lines - H1299 (derived from NSCLC) and HCT-116 
(derived from colon cancer), both dependent on BCL-XL and MCL-1 for survival, as 
detailed in the previous chapter – were exposed to a combination of A-1210477 and 
A-1331852 and assessed them for mitochondrial ultrastructural changes. In both cell 
lines, similar structural perturbations to mitochondria were observed (Figure 5.4), 
similar to those seen in haematological cell lines, indicating that BH3 mimetics 
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induce profound mitochondrial structural changes in multiple cell lines. It is 
important to note that all these experiments were performed in the presence of Z-
VAD.FMK, a broad-spectrum caspase inhibitor, to ensure that the observed 
mitochondrial changes were not due to caspase activation or downstream the 
apoptotic cascade. 
5.2.2 BH3 mimetic-mediated mitochondrial changes are BAX- and BAK-
dependent 
To further characterise the involvement of BAK and BAX in BH3 mimetic-
mediated mitochondrial ultrastructural changes, HCT-116 – both WT (wildtype) and 
BAX/BAK DKO (double knockout) were exposed to a combination of A-1210477 
and A-1331852 and assessed for mitochondrial ultrastructural changes by electron 
microscopy. WT HCT-116 cells exposed to BH3 mimetics showed extensive 
mitochondrial deformation, outer membrane breaks and matrix swelling, whereas 
mitochondria of DKO HCT-116 cells exposed to BH3 mimetics were not affected, 
showing a similar phenotype to untreated cells (Figure 5.4). These results indicate 
that BAX and BAK are important for BH3 mimetic-mediated mitochondrial 
ultrastructural changes and could potentially couple these changes to the intrinsic 
pathway of apoptosis. 
5.2.3 BH3 mimetic-mediated mitochondrial fission occurs before apoptosis 
 Previous results clearly demonstrate that BH3 mimetics induce drastic 
perturbations to mitochondrial structure at the level of electron microscopy. 
However, since the technique is both time consuming and expensive, other avenues 
were explored to study BH3 mimetic-mediated mitochondrial changes. 










Figure 5.3. BH3 mimetics induce marked mitochondrial ultrastructural changes. H929, 
K562 and MAVER-1 cells were exposed to A-1210477 (10 µM), A-1331852 (100 nM) or 
ABT-199 (100 nM) respectively for 4 h and assessed by EM for mitochondrial structural 
changes. Yellow arrowheads: outer mitochondrial membrane breaks and matrix swelling. 











Figure 5.4. BAX and BAK are required for BH3 mimetic-mediated apoptosis-related 
mitochondrial ultrastructural changes. H1299 and WT or DKO (BAX and BAK 
deficient) HCT-116 cells were exposed to a combination of A-1210477 (10 µM) and A-
1331852 (100 nM) for 4 h and processed for EM for mitochondrial structural changes. Scale 




as HSP70 was used to characterise mitochondrial structural changes using confocal 
microscopy. To assess whether BH3 mimetics mediate mitochondrial structural 
changes upstream of or independent of apoptosis, the dual (BCL-XL and MCL-1-) 
dependent H1299 cells were transfected with siRNAs against BCL-XL (to render 
them MCL-1-dependent) or MCL-1 (to render them BCL-XL-dependent), exposed to 
either A-1210477 or A-1331852 and subjected to immunocytochemistry and 
confocal microscopy. Immunolabeling with HSP70 antibody revealed a filamentous 
mitochondrial network in the control as well as in the BCL-XL or MCL-1-
downregulated cells. However, exposure to A-1210477 induced mitochondrial 
fragmentation in the cells independently of MCL-1 or BCL-XL (Figure 5.5). This is 
line with the extensive mitochondrial fragmentation previously observed with several 
putative inhibitors of MCL-1.68,280 Exposure to A-1331852 also resulted in 
mitochondrial fragmentation but this occurred only when H1299 cells were rendered 
BCL-XL-dependent by the removal of MCL-1 (Figure 5.5). Moreover, the 
fragmented mitochondria in this instance appeared more swollen unlike the more 
punctate-distribution of mitochondria, observed following A-1210477. These results 
suggested that A-1210477-mediated mitochondrial fragmentation could be distinct 
from the mitochondrial fragmentation observed during apoptosis, following the 
neutralisation of both MCL-1 and BCL-XL in the H1299 cells. 
5.2.4 A-1210477 induces extensive mitochondrial fission in several cell lines, 
most likely in an MCL-1-dependent but BH3 only-independent manner. 
Since A-1210477 induced mitochondrial changes in H1299 cells, studies 








Figure 5.5. Mitochondrial fragmentation mediated by different BH3 mimetics appear 
to exhibit distinct structural characteristics. H1299 cells were transfected with control, 
MCL-1 or BCL-XL siRNA and exposed to DMSO, A-1210477 (10 µM) or A-1331852 (100 
nM) for 4 h in the presence of Z-VAD-FMK (30 µM) and assessed for mitochondrial 
integrity by immunofluorescence with HSP70 antibody. Areas inside dashed line boxes have 




be replicated in several cancer cell lines. Exposure of H23 (a NSCLC cell line), 
HeLa (a cervical adenocarcinoma cell line) and MCF7 (a breast cancer cell line) to 
A-1210477 also showed extensive mitochondrial fission compared to the control 
cells (Figure 5.6). In order to resolve if the mitochondrial fragmentation mediated by 
A-1210477 was solely due to inhibition of MCL-1 or other nonspecific effect(s), 
three different strategies were employed to downregulate MCL-1, following which 
mitochondrial structural changes were assessed. The first strategy involved 
downregulation of MCL-1 using a genetic knockdown (RNA interference), while the 
second strategy utilised the short half-life of MCL-1,64 involving transcriptional 
repression of MCL-1 using the CDK inhibitor, Dinaciclib.68 The final strategy was to 
perform similar studies with the more potent and specific inhibitor of MCL-1, 
S63845, which has been established to inhibit MCL-1 and induce apoptosis at low 
nanomolar concentrations.168,249 
Downregulation of MCL-1 using two different MCL-1-targeting siRNAs or 
transcriptional repression by Dinaciclib failed to mimic A-1210477 in inducing 
mitochondrial fragmentation, despite effectively depleting MCL-1 protein levels 
(Figure 5.7). This suggested that mitochondrial fragmentation observed following 
exposure of cells to A-1210477 could be due to potential off-target effects of A-
1210477, or an on-target activity on MCL-1 affecting protein-protein interactions as 
part of a large scaffold in which MCL-1 could play a vital role. The latter possibility 
is speculated to be more likely as multiple putative inhibitors of MCL-1 have 
previously been reported to induce such mitochondrial fragmentation.68,280 To gain 
more clarity on this issue, the third strategy of inhibiting MCL-1 using S63845 was 















Figure 5.6. A-1210477 induces mitochondrial fragmentation in several cell lines. H23, 
HeLa and MCF7 cells were exposed to A-1210477 (10 µM) for 4 h and assessed for 








Figure 5.7. Mitochondrial ultrastructural network is not altered by genetic or 
translational inhibition of MCL-1. (A) Immunoblotting showing silencing efficiency for 
the MCL-1 siRNAs and MCL-1 downregulation by Dinaciclib. (B) H1299 cells were 
transfected with control siRNA and two different MCL-1-targeting siRNAs for 72 h or 
exposed to Dinaciclib (30 nM) for 4 h and assessed for mitochondrial integrity by 




concentration (1 µM), sufficient to induce apoptosis in a MCL-1-dependent 
manner,168 failed to demonstrate extensive mitochondrial fragmentation (Figure. 5.8). 
In addition, A-1210477 when used in conjunction with A-1331852 resulted in 
mitochondrial structural changes that resembled the swollen mitochondria observed 
during apoptosis, as previously observed (compare Figures 5.8 and 5.5). Taken 
together, these results suggested that mitochondrial fission mediated by A-1210477 
and induction of apoptosis induction are distinct effects. 
5.2.5 Expression levels of mitochondrial fusion/fission proteins are not affected 
by A-1210477 
 Next to assess whether A-1210477-mediated mitochondrial fragmentation 
was due to changes in the levels of key mitochondrial fission and fusion proteins, 
H1299 cells were exposed to A-1210477 for 4 h, and the expression levels of the 
mitochondrial fusion proteins OPA-1, MFN1, MFN2 and fission protein, DRP-1 
were assessed. Since no major changes were detected in the total levels of these 
proteins (Figure 5.9), efforts were carried out to assess the phosphorylation states of 
these proteins, in particular DRP-1, as DRP-1 has been shown to be phosphorylated 
at Ser 616 to induce mitochondrial fission282 and at Ser 637 to inhibit mitochondrial 
fission.282–284 Surprisingly, despite the extensive induction of mitochondrial 
fragmentation in these cells, A-1210477 did not result in any consistent changes to 
the phosphorylation status of DRP-1 (Figure 5.9), thus negating a role for DRP-1 
phosphorylation in A-1210477-induced mitochondrial fission. It must be noted that 
these studies were not performed using higher concentrations of S63845, as the 












Figure 5.8. S63845 induces mitochondrial fragmentation only at high concentrations. 
(A) H1299 cells were exposed to A-1210477 (10 µM) or S63845 (1 µM, 10 µM) for 4 h and 
assessed for mitochondrial integrity by immunofluorescence with HSP70 antibody. Areas 
inside dashed line boxes have been zoomed. Scale bar: 10 µm. (B) Quantification for the 















Figure 5.9. A-1210477 does not appear to alter expression levels of mitochondrial 
fission-fusion proteins. H1299 cells were exposed to A-1210477 (10 µM) for 0, 1, 2 or 4 h 
and assessed for mitochondrial fission and fusion protein levels by immunoblotting. Letters 











5.2.6 DRP-1 foci localise at A-1210477-mediated mitochondrial fission sites 
 DRP-1 is the master regulator of mitochondrial fission and is recruited from 
the cytosol to the mitochondrial membrane to execute fission.285 A-1210477, despite 
not changing DRP-1 protein levels or phosphorylation status, could still be dictating 
DRP-1 translocation to mitochondrial membrane resulting in excessive 
fragmentation. To assess that, H1299 cells were exposed to A-1210477 and 
processed for immunocytochemistry staining with antibodies against DRP-1 and 
HSP70. In control cells, DRP-1 appeared as punctate structures distributed between 
cytosol and mitochondrial membranes (Figure 5.10). Following A-1210477, DRP-1 
did not undergo remarkable redistribution. DRP-1 punctae were clustered around the 
fragmented mitochondria, suggesting that DRP-1 could be involved in A-1210477-
mediated mitochondrial fragmentation. However, as DRP-1 activity depends on 
different post-translational modifications, further analysis such as assessment for the 
phosphorylation status of DRP-1 will be valuable for an accurate evaluation of the 
role of DRP-1 in A-1210477-mediated mitochondrial fragmentation. 
5.2.7 Mitochondrial fragmentation mediated by MCL-1 inhibitors occurs in a 
DRP-1-dependent manner 
 To assess whether DRP-1 is required for A-1210477-mediated mitochondrial 
fragmentation, H1299 cells were transfected with control or two different DRP-1 
targeting siRNAs which were used on the following experiments (data shown for 
only one of them). On the following day, cells were exposed to A-1210477 or 
S63845 and immunostained for HSP60 to assess for mitochondrial ultrastructure. 
Indeed, mitochondrial fragmentation mediated by both these inhibitors was 
significantly prevented in cells lacking DRP-1, indicating that DRP-1 is necessary 






Figure 5.10. DRP-1 localises at A-1210477-induced mitochondrial fission sites. H1299 
cells were exposed to A-1210477 (10 µM) for 4 h and assessed for mitochondrial 
ultrastructure and DRP-1 localisation by immunofluorescence. Areas inside dashed line 








Figure 5.11. DRP-1 is required for BH3 mimetic-induced mitochondrial fragmentation. 
(A) H1299 cells were reverse transfected with control or DRP-1 siRNA for 72 h, exposed to 
A-1210477 (10 µM) or S63845 (1 µM, 10 µM) for 4 h and assessed for mitochondrial 
integrity by immunofluorescence with HSP70 antibody. Areas inside dashed line boxes have 
been zoomed. Scale bar: 10 µm. (B) Quantification for the extent of mitochondrial 
fragmentation showed in A. At least 100 cells were counted for 3 independent experiments. 




5.2.8 DRP-1 is not required for mitochondrial structural changes that occur 
during apoptosis 
 Although A-1210477-mediated fragmentation appeared structurally different 
from mitochondrial fission following BH3 mimetics, the requirement of DRP-1 for 
the former could potentially delineate these ultrastructural changes. To elucidate that, 
H1299 cells were transfected with DRP-1 siRNA in combination with suitable 
apoptotic stimuli (as previously shown in Figure 5.5, which forms the negative 
control for this experiment) and subjected to immunocytochemistry and confocal 
microscopy. The apoptotic stimuli used here was a combination of siRNA against 
either MCL-1 or BCL-XL (to render the cells depend on one or the other member for 
survival) and BH3 mimetics, targeting BCL-XL or MCL-1 (to neutralise both 
proteins and induce apoptosis). The results indicated that downregulation of DRP-1, 
despite preventing A-1210477-mediated mitochondrial fragmentation (as previously 
shown in Figure 5.11), does not alter mitochondrial fragmentation induced by 
apoptotic stimuli (Figure 5.12). Collectively, this data revealed that DRP-1 is not 
required for these early mitochondrial fission events observed during apoptosis.   
5.2.9 BH3 mimetic-induced apoptosis is DRP-1-dependent 
 Although DRP-1 does not seem to be required for early mitochondrial fission 
events observed during apoptosis, it is extensively characterised as a fission GTPase, 
with implications in apoptosis (Figure 5.13 A). In support, a recent study has shown 
that DRP-1 could play a role in apoptosis by preventing staurosporine-induced 
cytochrome c release.275 To investigate the role of DRP-1 in BH3 mimetic-mediated 
apoptosis, H1299 cells were transfected with control or two different DRP-1 siRNA, 







Figure 5.12. Pre-apoptotic mitochondrial fragmentation is independent of DRP-1. 
H1299 cells were transfected with control, MCL-1 or BCL-XL siRNA in combination with 
DRP-1 siRNA and exposed to DMSO, A-1210477 (10 µM) or A-1331852 (100 nM) for 4 h 
in the presence of Z-VAD-FMK (30 µM) and assessed for mitochondrial integrity by 









DRP-1 silencing prevented A-1210477 and A-1331852-mediated PS externalisation 
(Figure 5.13 B) and caspase-3 processing, evident by a marked decrease of the 
cleaved band at ~20 kDa (Figure 5.13 C). The protective effects of DRP-1 depletion 
against cell death were more striking when cells were observed under bright-field 
microscopy, following exposure to BH3 mimetics (Figure 5.13 D). Taken together 
these results indicate that DRP-1 plays an important anti-apoptotic role in BH3 
mimetic-mediated apoptosis. 
5.2.10 BH3 mimetics-induced MOMP and cytochrome c release is DRP-1-
dependent 
 To further investigate the precise step at which DRP-1 could be exerting its 
anti-apoptotic role, early apoptotic events were monitored. MOMP was the next 
logical step to analyse, as it precedes PS externalisation and caspase processing in 
the intrinsic pathway. MOMP was assessed by cytochrome c release from 
mitochondria to the cytosol (Figure 5.14 A). H1299 cells were transfected with DRP-
1 siRNA or with a DRP-1 K38A plasmid (the K38A mutation at the GTPase domain 
of DRP-1 renders a kinase dead protein, non-functional and dominant-negative 
protein)286 and exposed to a combination of A-1210477 and A-1331852. Cytochrome 
c release was then assessed by immunocytochemistry and immunoblotting. The 
combination of BH3 mimetics induced cytochrome c release from the mitochondria 
to the cytosol, which was greatly reduced by DRP-1 silencing or by K38A mutant 
overexpression (Figure 5.14 B-D). Interestingly, mitochondria in cells that lack DRP-
1 appeared swollen following BH3 mimetics (Figure 5.14 B), possibly indicating that 
in the absence of DRP-1, mitochondria that has received the apoptotic insult 





Figure 5.13. DRP-1 is required for BH3 mimetic-induced apoptosis. (A) Flowchart 
representing the findings of this study hitherto. (B) H1299 cells were transfected with control 
siRNA and DRP-1 siRNA, exposed to a combination of A-1210477 (10 µM) and A-1331852 
(100 nM) for 4 h and assessed for the extent of PS externalisation by flow cytometry. 
Statistical analysis was conducted using one-way ANOVA (***P≤0.001). (C) Caspase-3 
processing and DRP-1 silencing efficiency by immunoblotting and (D) overall cell death by 





Figure 5.14. DRP-1 is required for BH3 mimetic-induced cytochrome c release. (A) 
Flowchart representing the findings of this study hitherto. (B) H1299 cells were transfected 
with control siRNA, DRP-1 siRNA or DRP-1 K38A plasmid and assessed for the extent of 
cytochrome c release by immunofluorescence upon exposure to a combination of A-1210477 
(10 µM) and A-1331852 (100 nM) for 4 h. Areas inside the dashed line boxes have been 
zoomed. Scale bar: 10 µm. (C) Quantification of the extent of cytochrome c release showed 
in A. At least 100 cells were counted for 3 independent experiments. Statistical analysis was 
conducted using one-way ANOVA (***P≤0.001). (D) Immunoblot showing silencing 
efficiency of DRP-1 siRNA used in A and the extent of cytochrome c release from 
mitochondria to cytosol upon exposure to a combination of A-1210477 (10 µM) and A-
1331852 (100 nM) for 4 h. GAPDH was used as loading control. 
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5.2.11 BH3 mimetic-induced BAK activation is DRP-1-dependent 
 Since BH3 mimetic-mediated mitochondrial swelling occurred in a 
BAX/BAK-dependent manner (Figure 5.4), it is possible that BAK and BAK are 
already activated by BH3 mimetics to facilitate mitochondrial fission, which then 
requires DRP-1 to induce fission and MOMP (Figure 5.15 A). Since H1299 cells 
(ATCC, 5803-CRL H1299) neither express BAX nor p53,287 these experiments were 
altered to only assess BAK activation in the presence and absence of DRP-1. For 
this, H1299 cells were transfected with control or DRP-1 siRNA, exposed to a 
combination of A-1210477 and A-1331852 and assessed for BAK activation by 
FACS with anti-BAK AB1 antibody, specific for the active conformation of BAK.288 
Interestingly, DRP-1 silencing greatly reduced BH3 mimetic-mediated BAK 
activation in H1299 cells (Figure 5.15 B), thus placing DRP-1 upstream of BAK 
activation during BH3 mimetic-mediated apoptosis. 
5.2.12 BH3 mimetic-mediated release of BH3-only proteins is not altered by 
DRP-1 downregulation 
  BAX and BAK are effector proteins that can be activated either upon direct 
release from their anti-apoptotic counterparts or by the release of BH3-only proteins, 
which in turn can activate BAX and BAK.86 Immunoprecipitation of BCL-XL and 
MCL-1 in H1299 cells, following BH3 mimetics revealed that BIM, BAD and BAK 
bound to BCL-XL and NOXA that is bound to MCL-1 were released in cells, 
irrespective of the presence or absence of DRP-1 (Figure 5.16), thus suggesting that 
DRP-1 does not play a role in the protein-protein interactions between the anti- and 











Figure 5.15. DRP-1 is required for BH3 mimetic-induced BAK activation. (A) Flowchart 
representing the findings of this study hitherto. (B) H1299 cells were transfected with control 
or DRP-1 siRNA and assessed for the extent of BAK activation by flow cytometry upon 
exposure to a combination of A-1210477 (10 µM) and A-1331852 (100 nM) for 4 h. 









Figure 5.16. DRP-1 is not required for BH3 mimetic-release of BH3-only proteins. 
H1299 cells were reverse transfected with control or DRP-1 siRNA for 72 h before exposed 
to DMSO or a combination of A-1210477 (10 µM) and A-1331852 (100 nM) for 4 h and 
processed for immunoprecipitation with MCL-1 or BCL-XL antibodies. IP indicates 





5.2.13 DRP-1 is not required for BH3 mimetic-induced mitochondrial cristae 
remodelling 
 Previous results indicate that BAK released from the anti-apoptotic members 
is somehow not activated in the absence of DRP-1 (even when all other BH3-only 
proteins are released from both BCL-XL and MCL-1) (Figures 5.15 B and 5.16). 
Since BAK is normally localised in the mitochondrial membrane, structural changes 
in the mitochondrial membrane following BH3 mimetics could regulate BAK 
activation, and it is possible that DRP-1 plays a role in this mechanism. At the level 
of mitochondria, BH3 mimetics result in cristae remodelling, which is largely 
dictated by OPA-1 processing and can occur upstream of BAK activation (Figure 
5.17 A).273,289 H1299 cells transfected with control or DRP-1 siRNA and exposed to 
a combination of A-1210477 and A-1331852 demonstrated clear OMM breaks, 
induced by BH3 mimetics exposure (yellow arrowhead, Figure 5.17 B), as expected 
of cells undergoing apoptosis. DRP-1 silencing induced mitochondrial elongation,290 
and following BH3 mimetics, aberrant shaped mitochondria, with extensive matrix 
swelling but intact double membranes, could be observed (Figure 5.17 B). 
Furthermore, silencing of DRP-1 neither repressed BH3 mimetic mediated cristae 
remodelling nor prevented OPA1 proteolysis (Figure 5.17 B and C). In the control 
and DRP-1 downregulated cells, exposure to BH3 mimetics induced a clear 
alteration in the levels of OPA-1 isoforms, with the long isoforms a and b of OPA1 
being proteolyzed, compatible with an induction of cristae remodelling (Figure 5.17 
C). These results indicate that the anti-apoptotic role of DRP-1 in the intrinsic 
pathway of apoptosis lies downstream of cristae remodelling, OPA-1 processing and 









Figure 5.17. BH3 mimetics induce DRP-1 independent cristae remodelling. (A) 
Flowchart representing the findings of this study hitherto. (B) Electron micrographs of 
H1299 cells transfected with control or DRP-1 siRNA and exposed to a combination of A-
1210477 (10 µM) and A-1331852 (100 nM) for 4 h. Scale bar: 10 nm. Yellow arrowhead 
points to a mitochondria outer membrane break. (C) Immunoblot showing silencing 
efficiency of DRP-1 siRNA and proteolysis of OPA-1 isoforms upon exposure to a 
combination of A-1210477 (10 µM) and A-1331852 (100 nM) for 4 h. GAPDH was used as 




5.2.14 DRP-1 acts downstream of OPA-1 in activating BAK to drive BH3 
mimetic-induced apoptosis 
 As DRP-1 silencing did not prevent BH3 mimetic-mediated OPA-1 
processing and cristae remodelling (Figure 5.18 A), it suggested that the role of 
DRP-1 in apoptosis lies downstream of OPA-1. Since OPA1 regulates the release of 
cytochrome c within the mitochondria from cristae to the inner membrane space, 
H1299 cells were transfected with siRNA against OPA-1 to induce in this 
redistribution, which was followed by exposure to A-1210477 and A-1331852 to 
induce BAK activation and cause MOMP. As expected, OPA-1 silencing followed 
by exposure to BH3 mimetics induced slightly higher levels of cytochrome c release 
and PS externalisation (most likely due to the redistribution of cytochrome c) 
compared to cells transfected with control siRNA (Figure 5.18 B - D). Interestingly, 
silencing of DRP-1 in these cells still prevented BH3 mimetic-induced cytochrome c 
release and PS externalisation (Figure 5.18 B - D), further confirming the 
requirement of active BAK to result in MOMP and PS externalisation. Thus, the 
results indicate that DRP-1 somehow activates BAK to facilitate BH3 mimetic-





Figure 5.18. DRP-1 acts downstream of OPA-1 to regulate BH3 mimetic-induced 
apoptosis. (A) Flowchart representing the findings of this study hitherto (B) H1299 cells 
were transfected with OPA-1 siRNA or OPA-1 and DRP-1 siRNA and the extent of 
cytochrome c release assessed by immunofluorescence following exposure to a combination 
of A-1210477 (10 µM) and A-1331852 (100 nM) for 4 h. Scale bar: 10 µm. (C) 
Quantification of the extent of cytochrome c release showed in B. At least 100 cells were 
counted for 3 independent experiments. Statistical analysis was conducted using one-way 
ANOVA (***P≤0.001). (D) H1299 cells were transfected with control siRNA, DRP-1 
siRNA, OPA-1 siRNA or OPA-1 and DRP-1 siRNA and assessed for PS externalisation 
following exposure to a combination of A-1210477 (10 µM) and A-1331852 (100 nM) for 4 





BH3 mimetics were developed based on the mechanism of interactions between 
the pro- and anti-apoptotic members of the BCL-2 family of proteins, which, when 
shifted towards cell death, culminates in the release of cytochrome c and activation 
of the caspase cascade.22 Mitochondrial structural changes, particularly fission, have 
been observed during apoptosis.284 Furthermore, MCL-1 inhibitors, such as A-
1210477 and S63845 induced extensive mitochondrial fragmentation in a DRP-1-
dependent manner (Figure 5.11). However, removal of MCL-1 either by genetic 
silencing or transcriptional inhibition did not affect the mitochondrial ultrastructural 
network (Figure 5.7) suggesting that the presence of MCL-1 may be critical for the 
induction of the structural changes, or that the fragmentation caused by these MCL-1 
inhibitors derive from an off-target effect, as only high concentrations of S63845 (10 
µM) but not low concentrations capable of inducing apoptosis (100 nM) promoted 
mitochondrial fragmentation (Figures 5.5 and 5.8). A recent report delving into the 
functions of different MCL-1 isoforms has shown that a truncated form of MCL-1, 
located in the mitochondrial matrix, regulates mitochondrial metabolism and 
dynamics by supporting oxidative phosphorylation and maintenance of 
mitochondrial membrane potential.62,291 Moreover, deletion of MCL-1 in 
cardiomyocytes have been shown to induce abnormal mitochondrial structure and 
defective respiration.175 Based on that, it is likely that A-1210477 could bind to these 
two isoforms to induce both apoptosis (by displacing the BH3-only members from 
the long isoform at mitochondrial outer membrane) and mitochondrial fragmentation 
(by displacing an unknown protein from the truncated isoform at the matrix).62 
Several studies have shown that DRP-1 not only acts as the master regulator of 
mitochondrial fission, but also plays a role in the induction of apoptosis.275,276,292 
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More recently, it has been shown that the RING-finger-containing protein, MAPL, 
when overexpressed, induced mitochondrial fragmentation. In addition, MAPL was 
also identified to promote SUMOylation of DRP-1,293 which is required for 
staurosporine-mediated apoptosis.276 In this study, the data indicate that silencing of 
DRP-1 prevented BH3 mimetic-mediated cytochrome c release. Furthermore, the 
involvement of DRP-1 in cell death was further confirmed by overexpression of a 
kinase-dead dominant-negative protein with a K38A mutation in the G1 motif of the 
GTPase domain of DRP-1,294 rendering DRP-1 non-functional (Figure 5.14). 
Interestingly, H1299 cells transfected with DRP-1 siRNA and exposed to BH3 
mimetics, despite having cytochrome c trapped in the mitochondria (due to the lack 
of DRP-1), showed unexpected spherical mitochondrial aggregates highly stained for 
cytochrome c (Figure 5.14). When analysed by EM, these aggregates seemed like 
bundles of altered mitochondrial cristae, localised at the periphery of the 
mitochondria and connected by a central swollen mitochondrial matrix (Figure 5.17). 
This indicates that the apoptotic effects of BH3 mimetics on mitochondria occur 
independently of DRP-1 up to the point of cristae remodelling and OPA-1 
proteolysis (Figures 5.17 and 5.18), freeing cytochrome c from the OPA-1-bound 
cristae to the intermembrane space. At this point, DRP-1 is recruited to the fission 
sites and constricts the mitochondrial membrane, leading to the release of 
cytochrome c to the cytosol. 
 The requirement of DRP-1 for BH3 mimetics to activate BAK is another 
interesting finding, as BH3 mimetics appeared to displace BAK and all BH3-only 
members from their anti-apoptotic counterparts irrespective of DRP-1. This indicates 
that the released BAK still requires DRP-1 to undergo activation and mitochondrial 
insertion to facilitate MOMP. In agreement, previous reports have linked DRP-1 and 
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BAX/BAK at the level of mitochondria to regulate MOMP, where BAX/BAK 
stabilises DRP-1 association with mitochondria via SUMOylation of DRP-1.295 
However, a few years later, the same group showed that MAPL, the protein 
responsible for SUMOylation of DRP-1, acts downstream of BAK/BAX 
activation,276 arguing that MAPL-mediated DRP-1 stabilisation could be a tipping 
point towards apoptosis for sub-lethal levels of BAX/BAK activation. Furthermore, 
it has also been shown that the dominant-negative DRP-1 K38A cannot prevent BAX 
clustering in the OMM, preventing cell death.292  
Although determination of MOMP was performed via quantitative or 
qualitative assessment of cytochrome c release, the most modern models for MOMP 
consider the initial event as the formation of BAX/BAK pores on OMM.296 This 
results in the release of other molecules, such as Smac and Omi.297 Even though 
Smac release was not assessed throughout this study, there is evidence that it can 
occur independently of DRP-1,298 indicating the complexity underlying MOMP. 
Nevertheless, the results presented here place DRP-1 immediately upstream of BAK 
activation to facilitate MOMP (cytochrome c release) and the downstream apoptotic 
cascade, reinforcing the role of DRP-1 not only in mitochondrial fission, but also in 













Figure 5.19. Scheme representing the mechanism of action of BH3 mimetics in pre-
apoptotic mitochondrial fragmentation and cell death. A-1331852 and S63845 displace 
BH3-only proteins from BCL-XL and MCL-1 respectively, inducing mitochondrial 
fragmentation that precedes apoptosis in a DRP-1-independent manner. The pre-apoptotic 
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In eukaryotic cells, the endoplasmic reticulum (ER) is formed of a highly 
interconnected network of tubules and sheets, which are present as one continuous 
membrane.299,300 The membranes of ER tubules and sheets are maintained by 
curvature stabilisation, achieved by proteins called the ER shaping proteins, mainly 
from the reticulon family.301,302 ER shaping proteins, such as RTN-4 are localised in 
the ER tubules and sheets and possess a multi-transmembrane reticulon homology 
domain (RHD), which is inserted across the ER membrane in a stitch or hairpin-like 
manner, inducing a mechanical bend in the ER membrane.303 Besides reticulons, 
other proteins, such as CLIMP-63, are responsible for the maintenance of ER 
structure. CLIMP-63 resides in the ER sheets and creates a distance between two 
apposed ER membranes, creating a cisterna via a coiled coil domain (Figure 6.1).304 
These ER shaping proteins are vital for the normal functioning of ER and for 
enabling ER to interact with other organelles, such as mitochondria at the ER-
mitochondria contact sites.301 The mitochondria-associated membranes (MAMs) are 
the connections between the ER and mitochondria. MAMs are considered to be 
contiguous with the ER, but physically connected to mitochondria.305 MAMs play 
important functions in maintaining cellular homeostasis by transferring diverse 
molecules and ions, such as Ca2+, phosphatidylserine and sterols.305,306 In addition, 
MAMs have also been implicated in other cellular processes, such as autophagy and 
mitochondrial membrane dynamics.307–310  
Recent studies show that the onset of mitochondrial fission occurs at specific 
sites where ER contacts the mitochondria.308,311 ER tubules wrap around 
mitochondria, for an initial constriction that initiates the recruitment of DRP-1 to its 
receptors, which is followed by DRP-1 oligomerisation and the assembly of the 
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constriction ring.308,311 This model further integrates the ER, components of the 
cytoskeleton and mitochondria. An initial tether occurs between ER and 
mitochondria via INF2 in the ER membrane and Spire1C in the mitochondrial 
membrane through ER-derived actin and myosin IIA filaments.312 This interaction 
tightens the tether and acts as a motor for the initial ER wrapping around 
mitochondria, which in turn recruits DRP-1 and the fission machinery.277 In addition 
to those events, some studies point to the role of dynamin 2 (Dyn2) in the final 
scission step of mitochondrial fission.275,313  
Recent studies have implicated a role of ER membranes in mitochondrial fission 
and the induction of apoptosis.276 While the involvement of ER in mitochondrial 
fission is well characterised, cell death studies have been carried out with broad-
spectrum, non-specific cell death inducers, such as staurosporine and etoposide.275 
When studying such critical pathways, it is crucial to employ specific and potent cell 
death inducing compounds, such as BH3 mimetics. To date, relatively little 
information is available regarding the effects of BH3 mimetics on ER-mitochondria 
crosstalk mechanisms. As BH3 mimetics are already being used in clinical trials for 
different cancers,281,314 it is important to understand how BH3 mimetics could affect 
mitochondrial fission/fusion dynamics, in the context of an involvement of ER 
membranes. In this chapter, using RNA interference to downregulate specific ER 
shaping proteins, such as RTN-4 and CLIMP-63, studies have been performed to 
assess the involvement of ER shape in mitochondrial fission, ER-mitochondrial 













Figure 6.1. Schematic representation of mitochondria and ER, highlighting the 
organelle localisation of ER shaping proteins used throughout this study. ER wraps 
around mitochondria to facilitate DRP-1-mediated mitochondrial fission. Mitochondrial 
proteins cytochrome c, OPA-1 and BAK are shown to illustrate the possible involvement of 
the ER in apoptosis. ER shaping proteins RTN-4 and CLIMP-63 are shown to illustrate their 





6.2.1 Silencing of ER shaping proteins alters mitochondrial ultrastructure 
 Over the last few years, several reports have highlighted the importance of 
ER membranes in regulating mitochondrial membrane dynamics.276,315,316 ER 
interacts with mitochondria via different complexes, which could facilitate and 
orchestrate DRP-1-mediated mitochondrial fission.277,312,317,318 To assess that, 
experiments were performed to elucidate how silencing some key ER shaping 
proteins, such as Reticulon-1 (RTN-1), Reticulon-4 (RTN-4), Lunapark-1 (LNP1) 
and CLIMP-63 could affect mitochondrial ultrastructure. While RTN-1/4 are 
transmembrane proteins involved in creating an ER curvature,301,319 whereas CLIMP-
63 maintains the shape of ER sheets (Figure 6.1).301,320 LNP-1 is a three-way junction 
protein that resides in the ER membranes and regulates ER membrane 
interconnectivity.321,322 To carry out this study, H1299 cells were transfected with 
siRNAs against the indicated ER shaping proteins and processed for EM. RNAi 
against DRP-1 was used as a positive control for demonstrating changes in 
mitochondrial ultrastructure. Visual analysis of EMs of these cells indicated 
increased mitochondrial elongation induced by silencing of DRP-1, as well as the 
different ER shaping proteins. Although the extent of elongation was not quantified, 
the same observation was made in multiple experiments in several, suggesting that 
DRP-1 and ER shaping proteins are playing a role in mitochondrial membrane 
dynamics (Figure 6.2). 
6.2.2.3view EM imaging reveals a detailed analysis of the mitochondrial 
network  
 Although EM is extremely useful to visualise mitochondrial ultrastructure, a 








Figure 6.2. Silencing of ER shaping proteins induces mitochondrial elongation. Electron 
micrographs of H1299 cells transfected with control, DRP-1, RTN-4 or CLIMP-63 siRNA 
for 72 h. Scale bar: 500 nm. (B) Immunoblot showing silencing efficiency of DRP-1, RTN-4 
and CLIMP-63 siRNAs in H1299 cells. GAPDH was used as a loading control. 
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filamentous mitochondria. Therefore, 3view EM analysis was used to render the 
whole mitochondrial structure from <150 serial sections (electron micrographs) of a 
single cell. This analysis demonstrated that mitochondria in the assessed cell were 
highly interconnected as the rendering revealed that the chosen mitochondrion 
spanned through several sections of the cell in a highly interconnected network 
(Figure 6.3). Furthermore, the particular cell that was analysed was rendered and 
quantified to comprise 145 mitochondria with a total volume of 220 µm3 (Figure 
6.3). Of the 145 mitochondria, only 2 had volumes greater than 50 µm3 (70 and 65 
µm3), whereas the rest were discontinuous with volumes lower than 1 µm3 (Figure 
6.3). 
6.2.3.Silencing of DRP-1 facilitates mitochondrial hyperfilamentation  
In order to assess the effect of DRP-1 and possibly ER shaping proteins on 
mitochondrial structural changes, further studies involving 3view EM imaging were 
carried out using siRNAs against DRP-1 (positive control), as well as RTN-4 and 
CLIMP-63. Downregulation of DRP-1 drastically reduced the total number of 
mitochondria (145 in the control siRNA-transfected cell versus 67 for DRP-1 
siRNA-transfected cell). Of the 67 mitochondria rendered in the DRP-1 siRNA-
transfected cell, only 1 of the mitochondria demonstrated hyperfilamentation, defined 
by a single continuous mitochondrion, and mitochondrial swelling, with a total 
volume of 203 µm3 (Figure 6.4, right panel, red dot) The rest of the mitochondria in 
this cell were discontinuous with volumes lower than 1 µm3 (Figure 6.4). 
Up to the final moments of writing this thesis, experiments are still being 
carried out for the assessment of mitochondrial volume and number in H1299 cells 










Figure 6.3. The complexity of the mitochondrial network. H1299 cells were processed for 
3view electron tomography. Mitochondria (green) and nuclei (blue) were rendered and 
quantified for volume and number of mitochondrial fragments. Red dot corresponds to the 
mitochondrion used for rendering of ER in the next experiments. vt, total volume of all 











Figure 6.4. Mitochondrial network is altered by DRP-1. H1299 cells were reverse 
transfected with DRP-1 siRNA for 72 h and processed for 3view electron tomography. 
Mitochondria (green) and nuclei (blue) were rendered and quantified for volume and number 
of mitochondrial fragments. Red dot corresponds to the mitochondrion used for rendering of 




6.2.4.A-1210477 induces mitochondrial fission only in the presence of ER 
shaping proteins 
The results shown in figure 6.2 indicated that ER shaping proteins seemed to 
play a role in mitochondrial membrane dynamics, possibly involving mitochondrial 
fission.  As silencing of DRP-1 prevented A-1210477-mediated mitochondrial 
fragmentation (Figure 5.8), experiments were carried out to assess whether silencing 
the different ER shaping proteins would demonstrate similar effects. In these and the 
following experiments two different siRNAs targeting DRP-1, RTN-4 and CLIMP-
63 were used to control for potential off-target effects. Indeed, silencing of the ER 
shaping proteins prevented A-1210477-mediated mitochondrial fragmentation 
(Figure 6.5), indicating that ER shaping proteins are important for mitochondrial 
fission, possibly by regulating the recruitment of DRP-1 to the mitochondria. 
6.2.5.DRP-1 localisation at mitochondrial fission sites does not depend on ER 
shaping proteins 
 To examine whether the localisation of DRP-1 to mitochondrial fission sites 
is dictated by ER shaping proteins, H1299 cells lacking ER shaping proteins were 
exposed to A-1210477 and immunolabeled for both HSP70 and DRP-1. As expected, 
HSP70 staining showed a filamentous network of mitochondria in untreated cells, 
which underwent extensive fragmentation in the presence of A-1210477. DRP-1 
staining in the untreated cells showed a punctate pattern and distributed evenly 
between the cytosol and mitochondrial membranes. Following A-1210477, one or 
more DRP-1 punctae were observed surrounding the fragmented mitochondrial 








Figure 6.5. ER shaping proteins are required for A-1210477-mediated mitochondrial 
fragmentation. (A) H1299 cells were transfected with control siRNA, DRP-1 siRNA, RTN-
4 siRNA or CLIMP-63 siRNA for 72h and assessed for mitochondrial shape by 
immunofluorescence with anti-HSP60 antibody upon exposure to A-1210477 (10 µM) for 4 
h. Areas inside the dashed line boxes have been zoomed. Scale bar: 10 µm. (B) 
Quantification of the extent of mitochondrial fragmentation shown in A. At least 100 cells 
were counted for 3 independent experiments. Statistical analysis was conducted using one-




Interestingly, none of the ER shaping proteins seemed to be required for A-1210477-
mediated localisation of DRP-1 to the mitochondria, as a similar distribution pattern 
of DRP-1 was observed even in cells lacking RTN-4 and CLIMP-63 (Figure 6.6). 
These results could suggest that localisation of DRP-1 to mitochondria at fission sites 
could be dictated by mechanisms independent of these ER shaping proteins. 
However, as previously mentioned, assessment of DRP-1 activity/post-translational 
modifications and/or translocation to mitochondria would be beneficial to clarify the 
role of ER shaping proteins in the fission process. In this regard, time-lapse or live-
cell imaging under these conditions could offer further insight. 
6.2.6.CCCP induces mitochondrial fission independently of ER shaping proteins 
 Next, to assess whether ER shaping proteins regulated mitochondrial fission 
induced by other stimuli or the effect was exclusive to BH3 mimetics, H1299 cells 
transfected with RTN-4, and CLIMP-63 siRNA were exposed to carbonyl cyanide 
m-chlorophenyl hydrazine (CCCP), a proton uncoupler that rapidly depolarises 
mitochondria and induces mitochondrial fragmentation. While DRP-1 
downregulation could overcome CCCP-mediated mitochondrial fragmentation, 
silencing of ER shaping proteins could not produce the same effect (Figure 6.7), 
possibly due to the ability of CCCP, but not A-1210477 to depolarise mitochondria 
in these cells.251 This result indicates that, even in the absence of RTN-4 and 
CLIMP-63, CCCP could be recruiting DRP-1 to induce mitochondrial fragmentation. 
6.2.7.Loss of mitochondrial fusion mediated by OPA-1 silencing does not 
require ER shaping proteins 
 Previous data suggested that DRP-1 played a critical role downstream of 
mitochondrial cristae remodelling and OPA-1 proteolysis in regulating apoptosis 





Figure 6.6. ER shaping proteins are not required for DRP-1 localisation at 
mitochondria fission sites. H1299 cells were transfected with control siRNA, RTN-4 
siRNA or CLIMP-63 siRNA for 72 h and assessed for mitochondrial shape and for DRP-1 
localisation by immunofluorescence with anti-HSP70 (red) and an anti-DRP-1 (green) 
antibody respectively, following exposure to A-1210477 (10 µM) for 4 h. Areas inside the 







Figure 6.7. ER shaping proteins are not required for CCCP-mediated mitochondrial 
fragmentation. (A) H1299 cells were transfected with control siRNA, DRP-1 siRNA, RTN-
4 siRNA or CLIMP-63 siRNA for 72 h and assessed for mitochondrial shape by 
immunofluorescence with an anti-HSP70 antibody following exposure to CCCP (20 µM) for 
2 h. Areas inside the dashed line boxes have been zoomed. Scale bar: 10 µm. (B) 
Quantification of the extent of mitochondrial fragmentation shown in A. At least 100 cells 
were counted for 3 independent experiments. Statistical analysis was conducted using one-







downstream of OPA-1 proteolysis, H1299 cells were transfected with RTN-4 and 
CLIMP-63 siRNA (DRP-1 siRNA was used as a positive control) in the presence and 
absence of OPA-1 siRNA and the extent of mitochondrial fragmentation was 
assessed. 
Similar to the results obtained for CCCP-induced mitochondrial 
fragmentation, fragmentation induced by OPA-1 depletion depends on DRP-1 
(Figure 6.8). This could be due to the tight connection between OPA-1, maintenance 
of cristae structure and mitochondrial polarisation. Furthermore, OPA-1 has been 
shown to stabilise different complexes of the respiratory chain, maintaining 
mitochondrial polarisation.323 In marked contrast silencing of ER shaping proteins 
did not prevent mitochondrial fragmentation induced by OPA-1 silencing (Figure 
6.8). 
Taken together with previous results (Figures 6.5 and 6.7), these findings 
indicate that altering mitochondrial cristae either by silencing of OPA-1 or by direct 
mitochondrial depolarisation, resulted in extensive DRP-1-mediated mitochondrial 
fission, which occurred independently of the ER membranes. 
6.2.8.Silencing of DRP-1 reduces the number of contact points between the ER 
and mitochondria 
 Previous results revealed that silencing of DRP-1 and ER shaping proteins 
reduced the total number of individual mitochondria in H1299 cells, resulting in a 
single, hyperfused mitochondrion (Figure 6.4). These data, combined with the model 
dictating that ER wraps around mitochondria to initiate mitochondrial fission, led to 
the hypothesis that the number of ER-mitochondria contact points could be 
significantly decreased following downregulation of the different ER shaping 
proteins. To assess this hypothesis, 3view analysis was performed in all ER 
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membranes around a chosen mitochondrion from a single cell (obtained from figure 
6.3) was labelled and rendered to generate a composite image (Figure 6.9; left panel). 
The rendered image revealed that ER membranes extensively wrap the mitochondria, 
thus potentially making numerous contacts with the mitochondria (Figure 6.9; left 
panel). To quantify, the precise number of contacts that the ER makes with 
mitochondria, the number of ER-mitochondria contact points were calculated by 
counting how many times an ER membrane was in contact with a mitochondrial 
membrane. In the control cell, there were about 604 contact points (depicted as 
nc=number of contact sites) (Figure 6.9; right panel). Due to variations in the volume 
between the selected mitochondrion in each condition, the number of contact points 
were normalised to the volume of the chosen mitochondrion. Since the volume of the 
chosen mitochondrion in the control cells was 65 µm3 (Figure 6.3, right panel, red 
dot), the contact points for this mitochondrion was normalised by dividing nc over 
mitochondrial volume to generate the number of ER-mitochondria contacts as 9.29 in 
the chosen mitochondrion (Figure 6.9; right panel). Interestingly, silencing of DRP-1 
drastically reduced the number of ER-mitochondria contact points (Figure 6.10, right 
panel), from a ratio of 9.29 for control siRNA to 1.32 for DRP-1 siRNA. These 
results indicate that DRP-1 recruitment could facilitate the interactions between ER 
and mitochondria. It will be interesting to see if silencing of RTN-4 and CLIMP-63 
would have similar effects in exhibiting decrease of ER-mitochondria contacts. 
6.2.9.BH3 mimetic-induced PS externalisation and caspase processing require 
ER shaping proteins 
Recent studies claim that ER plays a major role in the recruitment of DRP-






Figure 6.8. ER shaping proteins are not required for OPA-1 silencing-mediated 
mitochondrial fragmentation. (A) H1299 cells were transfected with control siRNA, DRP-
1 siRNA, RTN-4 siRNA or CLIMP-63 siRNA alone or in combination with OPA-1 siRNA 
for 72 h and assessed for mitochondrial shape by immunofluorescence with anti-HSP70. 
Areas inside the dashed line boxes have been zoomed. Scale bar: 10 µm. (B) Quantification 
of the extent of mitochondrial fragmentation shown in A. At least 100 cells were counted for 















Figure 6.9. ER-mitochondrial contact sites are abundant in H1299 cells. H1299 cells 
were processed for 3view electron tomography. An isolated mitochondrion, obtained from 
figure 6.3 (green), was rendered and its volume calculated. Similarly, ER (red, left panel) at 
the mitochondrion surrounding were rendered and contact points were quantified (right 









Figure 6.10. ER-mitochondrial contact sites are drastically reduced by DRP-1 silencing. 
H1299 cells were reverse transfected with DRP-1 siRNA for 72 h and processed for 3view 
electron tomography. An isolated mitochondrion obtained from figure 6.4 (green) was 
rendered and its volume calculated. Similarly, ER (red, left panel) at the mitochondrion 
surrounding were rendered and contact points were quantified (right panel, red spheroids). vi, 





BAK activation, cytochrome c release and PS externalisation (Figures 5.13 
and 5.14) and ER shaping proteins seem to be important for A-1210477-mediated 
mitochondrial fragmentation (Figure 6.5), a strategy, similar to the one used to 
identify the role of DRP-1 in apoptosis, was adopted to understand how the ER 
shaping proteins can regulate the distinct steps of the intrinsic pathway of apoptosis 
(Figure 6.11 A). H1299 cells were transfected with two different DRP-1, RTN-4 or 
CLIMP-63 siRNAs, exposed to a combination of A-1210477 and A-1331852 and 
apoptosis assessed by PS externalisation and immunoblotting. Although statistically 
significant, the protective effect of RTN-4 and CLIMP-63 silencing was not as 
effective as DRP-1 siRNA in antagonising BH3 mimetic-mediated apoptosis as 
evidenced by PS externalisation (Figure 6.11 B). However, the appearance of the 
cleaved forms of caspase-9, -3 and -7 in cells exposed to BH3 mimetics was 
markedly inhibited by silencing of DRP-1, RTN-4 and CLIMP-63 (Figure 6.11 C). 
These data indicate that DRP-1, RTN-4 and CLIMP-63 are required for an effective 
induction of BH3 mimetic-mediated apoptosis. 
6.2.10.BH3 mimetic-induced cytochrome c release requires ER shaping proteins 
  Next, the effects of silencing the ER shaping proteins on BH3 mimetic-
mediated MOMP, measured by cytochrome c release were analysed (Figure 6.12 A). 
H1299 cells were transfected with two different DRP-1, RTN-4 and CLIMP-63 
siRNAs, exposed to a combination of both A-1210477 and A-1331852 and assessed 
for the extent of cytochrome c release using immunocytochemistry. Similar to the 
results observed by PS externalisation and apoptosis silencing of CLIMP-63 
effectively prevented BH3 mimetic-mediated cytochrome c release (Figure 6.12). 




Figure 6.11. ER shaping proteins are required for BH3 mimetic-mediated apoptosis. 
(A) Flowchart representing the findings of this study hitherto (B) H1299 cells were 
transfected with control siRNA, RTN-4 siRNA or CLIMP-63 siRNA for 72 h and assessed 
for the extent of phosphatidylserine externalisation by FACS upon exposure to a 
combination of A-1210477 (10 µM) and A-1331852 (100 nM) for 4 h. Statistical analysis 
was conducted using one-way ANOVA (***P≤0.001). (C) Immunoblots of H1299 cells 
transfected with the same siRNAs and exposed to the same conditions as in (A) showing 
distinct apoptotic markers, such as PARP, Caspase-9, Caspase-3 and Caspase-7 processing. 






Figure 6.12. ER shaping proteins are required for BH3 mimetic-mediated cytochrome c 
release. (A) Flowchart representing the findings of this study hitherto (B) H1299 cells were 
transfected with control siRNA, RTN-4 siRNA or CLIMP-63 siRNA for 72 h and assessed 
for the extent of cytochrome c release by immunofluorescence following exposure to a 
combination of A-1210477 (10 µM) and A-1331852 (100 nM) for 4 h. Scale bar: 10 µm. (C) 
Quantification of the extent of cytochrome c release shown in A. At least 100 cells were 




BH3 mimetic-mediated release of cytochrome c (Figure 6.12 B and C). Nevertheless, 
these data indicate that ER shaping proteins also play a role in the regulation of 
MOMP. 
6.2.11.BH3 mimetic-induced BAK activation requires DRP-1 and CLIMP-63, 
but not RTN-4  
 Previous results showed that DRP-1, RTN-4 and CLIMP-63 were required 
for BH3 mimetic-mediated cytochrome c release and MOMP (Figure 6.12). During 
the intrinsic pathway of apoptosis, cytochrome c is released from mitochondria to the 
cytosol via BAX/BAK-mediated pores in the outer mitochondrial membrane. As 
activation of BAK is a necessary step for the formation of the pore, the block in 
cytochrome c release induced by silencing of DRP-1, RTN-4 and CLIMP-63 could 
be related to BAK activation (Figure 6.13 A). It must be noted that H1299 cells do 
not express BAX. To assess BAK activation, H1299 cells were transfected with 
control, DRP-1, RTN-4 or CLIMP-63 siRNA and exposed to a combination of both 
A-1210477 and A-1331852 and stained with anti-activated BAK specific antibody. 
While silencing of DRP-1 and CLIMP-63 prevented BH3 mimetic-mediated BAK 
activation, in agreement with measurements of PS externalisation and cytochrome c 
release, silencing of RTN-4 did not have any protective role in BH3 mimetic-
mediated BAK activation In fact, silencing of RTN-4 slightly increased the extent of 
BAK activation following exposure to BH3 mimetics in these cells (Figure 6.13 B). 
These findings uncoupled the effect of RTN-4 and CLIMP-63 in regulating the 









Figure 6.13. DRP-1 and CLIMP-63 are required for BH3 mimetic-mediated BAK 
activation. (A) Flowchart representing the findings of this study hitherto. (B) H1299 cells 
were transfected with control siRNA, DRP-1 siRNA, RTN-4 siRNA or CLIMP-63 siRNA 
for 72 h and assessed for BAK activation by FACS upon exposure to a combination of A-
1210477 (10 µM) and A-1331852 (100 nM) for 4 h. Statistical analysis was conducted using 





6.2.12.ER shaping proteins are not required for BH3 mimetic-induced 
mitochondrial cristae remodelling 
 Although only DRP-1 and CLIMP-63, but not RTN-4 silencing prevented 
BH3 mimetic-mediated BAK activation, it was important to ascertain whether ER 
shaping proteins were required for BH3 mimetic-induced cristae remodelling. To 
assess this, H1299 cells were transfected with control, DRP-1, RTN-4 or CLIMP-63 
siRNA, exposed to a combination of A-1210477 and A-1331852 and subjected to 
EM analysis. Silencing of the ER shaping proteins did not prevent BH3 mimetic-
mediated mitochondrial cristae remodelling as it did not inhibit the loss of 
mitochondrial cristae, the appearance of outer mitochondrial membrane breaks and 
the major mitochondrial ultrastructural changes (Figure 6.14). Taken together, these 
results indicate that the ER shaping proteins play a role downstream of cristae 















Figure 6.14. BH3 mimetics induce cristae remodelling independent of ER shaping 
proteins. Electron micrographs of H1299 cells transfected with control, DRP-1, RTN-4 or 
CLIMP-63 siRNA and exposed to a combination of A-1210477 (10 µM) and A-1331852 






The recent model linking mitochondrial fission and apoptosis highlights the 
interactions between ER and mitochondria as initiators of these processes.277 
According to the model, ER wraps around mitochondria to initiate the assembly of 
DRP-1 constriction ring.277 Since ER shaping proteins play an important role in the 
maintenance of ER structure and function,301,302 the roles of these proteins in 
mitochondrial fission and apoptosis were investigated in this chapter. 
The data presented here support the ER-mitochondrial fission model by 
indicating that silencing of RTN-4 and CLIMP-63 not only induced mitochondrial 
elongation (Figure 6.2), but also prevented BH3 mimetic-mediated mitochondrial 
fragmentation (Figure 6.5). Moreover, silencing of RTN-4 and CLIMP-63 did not 
seem to affect DRP-1 localisation to fission sites, although DRP-1 activity was not 
assessed (Figure 6.6). Further investigation using live-cell microscopy and 
quantitative analysis could provide further information. In this context, determination 
of the number of contact sites between ER and mitochondria in cells lacking RTN-4 
and CLIMP-63 would be extremely valuable. In addition, it is important to underline 
that, despite providing highly informative data, 3view microscopy is a technique 
based on single cell analysis. Analysing a larger dataset or using other techniques 
such as standard transmission electron microscopy could be beneficial to reduce 
sampling bias. 
Even though DRP-1 and ER shaping proteins regulate mitochondrial fission-
fusion dynamics, mitochondrial fragmentation induced by CCCP or OPA-1 silencing 
is only dependent on DRP-1, with no role evidence for ER shaping proteins in these 
processes (Figures 6.7 and 6.8). OPA-1 is a major factor in mediating mitochondrial 
fusion and maintaining cristae stability.266,289,324 The results presented in this chapter 
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also indicate that ER shaping proteins are required for BH3 mimetic-mediated OMM 
break but IMM cristae remodelling lies downstream of ER shaping proteins in the 
apoptotic pathway (Figure 6.14). Furthermore, silencing of RTN-4 and CLIMP-63 
prevented BH3 mimetic-mediated cytochrome c release and apoptosis (Figure 6.11 
and 6.12). Although there are several reports underlining the functions of RTN-4 and 
CLIMP-63 in the maintenance of ER shape, structure and function,319,325–327 there are 
few studies linking these ER shaping proteins to cell death, to date. For instance, 
silencing of RTN-1, another member of the reticulon family, has been shown to 
reduce apoptosis during cerebral ischemia by retrotranslocating BCL-XL from 
mitochondria to ER.328 Similar interaction of a related protein RTN-XS with BCL-2 
and BCL-XL in the ER has been reported to reduce the anti-apoptotic activity of these 
proteins.329 However, these studies did not focus specifically on the effects of these 
ER shaping proteins in apoptosis, and did not employ a bona fide apoptotic inducer 
like BH3 mimetics. 
Based on the findings presented in this chapter, an integrative model of ER-
mitochondrial membrane dynamics and BH3 mimetic-mediated apoptosis is shown 
for the first time. Therefore, we propose a model in which BH3 mimetics facilitate 
the recruitment of ER membranes (involving specific ER shaping proteins such as 
RTN-4 and CLIMP-63) and DRP-1 to mitochondrial fission sites, inducing enhanced 
mitochondrial fission and/or MOMP, followed by BAK activation, cytochrome c 
release and subsequent apoptosis (Figure 6.15). Further studies are required to 
understand the role of ER shaping proteins in cristae remodelling and possible 
interactions with proteins at the OMM to better characterise the effect described here. 
All in all, this is the first study to describe the roles of ER shaping proteins in 










Figure 6.15. ER shaping proteins and DRP-1 are required for BH3 mimetic-
mediated mitochondrial fission and apoptosis. (a) Upon exposure to A-1214077, 
DRP-1 is recruited and oligomerises at (b) ER-marked mitochondrial fission sites, in a 
process dependent on ER shaping proteins that culminates in (c) enhanced 
mitochondrial fission. (d) Upon exposure to both A-1210477 and A-1331852, BH3 
only members are released from MCL-1 and BCL-XL, facilitating (e) DRP-1 
oligomerisation at ER-marked mitochondrial sites, culminating in (f) BAK activation, 
cristae remodelling, cytochrome c release and apoptosis dependent on DRP-1 and ER 
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7.1 Inhibition of BCL-XL in CML as an adjunct/alternative to TKI therapy 
 As development of resistance to TKIs poses a major problem for CML 
therapy, new efforts to target other cellular pathways to induce apoptosis in cancer 
cells have been widely considered330–332 (and clinical trials NCT00006364, 
NCT00049192, NCT00381550). In chapter 3, BCL-XL has been identified as a novel 
therapeutic target for CML. Genetic and pharmacological inhibition of BCL-XL not 
only induced rapid apoptosis in CML cell lines, but also promoted cell death in 
patient-derived CML cells while sparing healthy MNCs. Although some studies have 
shown that using ABT-737 in combination with TKIs could induce apoptosis in 
CD34+ progenitor cells, it has been speculated that Imatinib could reduce MCL-1 
expression, which in combination with ABT-737 is sufficient to inhibit all major 
anti-apoptotic BCL-2 family members.193 More recent papers imply a closer link to 
BCL-XL inhibition and the induction of apoptosis in CML.
36,333,194 Using animal 
models, it has been shown that BCL-XL is not necessary for the development of 
CML but it plays a major role in disease progression.36 
The ability of A-1331852 to induce apoptosis in a BCR-ABL driven malignancy 
like CML could be attributed to STAT5, which is a critical substrate of BCR-ABL.194 
Upon phosphorylation of STAT5 by BCR-ABL, BCL-XL transcription is enhanced 
leading to an increased anti-apoptotic phenotype.194 In addition, overexpression of a 
dominant negative STAT5 ablated the increased transcription of BCL-XL even in 
BCR-ABL positive cells.194 Furthermore, decreased STAT5 activity was also linked 
to enhanced expression of BIM116 and BAD,334 further escalating the imbalance of 
the pro- and anti-apoptotic members of the BCL-2 family. Of interest, in a 
therapeutic context, a combination of ABT-263 and PP242 (a mTOR inhibitor) has 
been shown to induce selectively toxicity in CML CD34+ progenitor cells but not 
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normal progenitors cells, which has been attributed to BAD activation.36 With the 
recent introduction of more selective BH3 mimetics such as A-1331852, it is 
arguably more beneficial to directly inhibit BCL-XL using BH3 mimetics than to 
alter BCR-ABL/STAT5/mTOR signalling pathways, all of which will invariably 
have multiple downstream effects. 
Although this strategy offers much promise, it is important to consider the 
challenges imposed by the inhibition of BCL-XL. BCL-XL inhibition/depletion has 
been strongly linked to a decrease in platelet population, as these cells depend mainly 
on BCL-XL for survival.
152 Although this is a limiting factor in cancer therapy and 
has paved a way for the development of ABT-199 for the treatment of CLL, 
thrombocytopenia following BCL-XL inhibition could be managed clinically with 
platelet transfusion. Therefore, the possibility to inhibit BCL-XL in CML still 
remains, especially when used in conjunction with current TKI therapies, which may 
facilitate lower dosage and a better clinical outcome. Another issue that can emerge 
from the use of BH3 mimetics in CML is the development of resistance. Recently we 
have shown that K562 cells can rapidly acquire resistance to A-1331852, which in 
turn, can be overcome by targeting other pathways of intermediary metabolism.248 
Currently several BCL-XL inhibitors have been developed by pharmaceutical 
companies with great therapeutic potential for different cancers,162,163 however these 
inhibitors are yet to be tested in clinical trials. Given the results of this study, clinical 




7.2 Inhibition of both BCL-2 and MCL-1 in AML 
Despite the increasing body of knowledge towards understanding the 
mechanisms underlying clinical and molecular aspects of AML, an effective 
treatment for the disease remains elusive.187,216,335 So far FLT3 has been the primary 
target in AML, since FLT3 alterations that are found in 25% of AML cases which 
are most aggressive than normal. Interestingly, MCL-1 was found overexpressed in 
FLT3 mutated AML cells resistant to TKIs, and silencing of MCL-1 in these cells 
rescued sensitivity to TKIs.336 Similarly, BCL-2 has been found overexpressed in 
primary AML cell lines, and targeting BCL-2 with ABT-737 has been shown to 
synergise with FLT3 inhibitors.337 Furthermore, BCL-2 and MCL-1 seem to play 
redundant roles in AML as BCL-2-bound BIM is sequestered by MCL-1 upon BCL-
2 inhibition, thus causing resistance to apoptosis. 338 This could be overcome by dual 
inhibition of BCL-2 and MCL-1. Recent efforts have initially uncovered the potential 
of inhibiting both BCL-2 and MCL-1 in AML. An initial study using venetoclax and 
A-1210477 has shown that AML cell lines and primary patient samples underwent 
apoptosis upon exposure to both compounds.338 However, the concentrations used in 
this study were around the micromolar range, which are not translatable to the 
clinical setting. This issue has been resolved by the introduction of more potent 
MCL-1 inhibitor such as S63845 and  which induce high levels of apoptosis in AML 
cell lines and mouse xenograft models.169  
 In agreement, the results in chapter 3 show that dual inhibition of BCL-2 and 
MCL-1 by BH3 mimetics synergistically induce apoptosis in AML cell lines and 
promote cell death in AML patient cells in an additive manner. While this thesis was 
in preparation, a paper published in Leukemia also confirmed that a combination of 
BCL-2 and MCL-1 inhibition is effective in inducing apoptosis in AML.339 The 
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potential of tackling MCL-1 and BCL-2 in AML offers much promise and this drug 
combination has entered 3 clinical trials for the treatment of AML.169 In support of 
that, S63845 and AMG176 (another MCL-1 inhibitor) have entered phase I studies 
(individual drugs) in combination with venetoclax to treat AML (Clinical trials: 
NCT03672695 and NCT03797261, respectively). 
7.3 The potential of using BH3 mimetics to improve therapy in solid tumours 
 In the last 50 years, the understanding of the biology of HNSCC has been 
greatly improved. Cisplatin and/or radiotherapy remain the gold standard therapy for 
HNSCC, however these therapeutic strategies are often plagued with resistance or 
undesirable side effects.239 In HNSCC, resistance to cisplatin has been attributed to 
mutation or loss of p53, the most commonly altered gene in the malignancy.340,341 
Numerous strategies, including the inhibition of STAT3 and Chk1/2 to promote cell 
death in p53 mutated HNSCC cell lines, have been advocated to restore sensitivity to 
cisplatin.341 As previously mentioned, STAT3 has been reported to upregulate MCL-
1 in AML, and this could be the possible mechanism by which inhibition of STAT3 
is effective in HNSCC.342,336 Interestingly, a short nuclear isoform of MCL-1 
responds to DNA damage promoting phosphorylation of Chk1, therefore inhibition 
of Chk1 could also be linked to nuclear MCL-1 downregulation and enhanced 
sensitivity to cisplatin.174,343 
 Several studies have explored the role of the BCL-2 family of proteins in 
HNSCC. IHC analyses of BCL-2 levels have presented indecisive results when 
correlated with clinical outcome. In agreement with the data presented in chapter 4, 
most of these studies showed that BCL-2 expression in HNSCC was low,232,344–350 
however, others have proposed BCL-2 as an early prognostic marker of HNSCC as 
BCL-2 protein levels were considered high in 25 to 55% of the cases analysed.351–353 
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Although BCL-2 inhibition with ABT-199 is highly effective and is currently being 
employed in more than 100 clinical trials, this study indicates that targeting BCL-2 in 
HNSCC patients would not be as effective as targeting MCL-1 and BCL-XL, despite 
that only a few studies have investigated BCL-XL and MCL-1 in 
HNSCC.37,54,344,348,350 Our results showed that BCL-XL expression is higher than 
MCL-1, especially when considering the advancing front of the oral cavity tumours. 
That could be the reason as to why a recent work has shown that ABT-737, when 
combined with etoposide or cisplatin, induced apoptosis and reduced clonogenic 
potential of HNSCC, albeit in considerably high concentrations (5 µM) and over 48 h 
of exposure.234 Furthermore, the precise mechanisms dictating low MCL-1 levels in 
the advancing front could be due to a functional redundancy with BCL-XL, which 
has been shown to promote epithelial-mesenchymal transition and tumour 
metastasis.37 Nevertheless, since BCL-XL and MCL-1 have similar roles in apoptosis 
and tumour survival in HNSCC, targeting these two proteins could be beneficial for 
HNSCC therapy. 
Determination of the therapeutic index for the combination of S63845 and A-
1331852 for HNSCC patients could be highly valuable, as cisplatin therapy only 
marginally improves overall survival with high toxicity. In addition, many HNSCC 
patients in advanced stages of the disease are not suitable for a cisplatin-based 
regimen. Although, when used as single agents, the BH3 mimetics did not synergize 
with cisplatin to reduce the clonogenic potential of HNSCC cell lines, dual inhibition 
of MCL-1 and BCL-XL has proven to be highly effective, indicating that the 
combination could potentially permit lower dosage of cisplatin for patients. 
Furthermore, due to the high expression of these proteins in HNSCC patient tissue, 
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MCL-1 and BCL-XL could also be used as potential biomarkers for this kind of 
cancer, rendering MCL-1 and BCL-XL as valuable assets for HNSCC therapy. 
In PDAC, K-RAS mutations are the most frequent genetic alteration 
observed, reaching almost 100% of all cases,354 which is linked to the expression of 
anti-apoptotic BCL-2 family members via the NF-κB pathway. Furthermore, 
overexpression of a dominant-negative RAS allele abolishes NF-κB in PDAC cell 
lines,355 which has been shown to upregulate expression levels of several BCL-2 
family members.356 p53 also plays an important role in PDAC,239 as it is found 
mutated in 50 to 70% of PDAC cases, which upregulates expression levels of MCL-1 
and BCL-XL 
354,357 Gemcitabine is the first line therapy for PDAC and, as resistance 
to gemcitabine-mediated cytotoxicity has been attributed to mutations in p53, BH3 
mimetics could be a valuable tool to overcome gemcitabine resistance in PDAC 
patients. 
Initial studies with BH3 mimetics in PDAC were conducted with non-specific 
compounds such as sabutoclax, which showed inhibition of cell proliferation and 
induction of apoptosis in several PDAC cell lines.257 Similarly, ABT-737 was shown 
to enhance gemcitabine-mediated reduction of cell viability in the PDAC cell lines 
PANC-1 and BxPC-3 and in vivo models of PDAC.247,358 Accordingly, the data 
presented in chapter 4 indicates that PDAC patients could benefit from BCL-XL 
inhibition to possibly overcome gemcitabine resistance, as A-1331852 and 
gemcitabine together reduced clonogenic potential and induced apoptosis in several 






7.4 BH3 mimetics and mitochondrial membrane dynamics 
BH3 mimetics were designed to mimic specific BH3-only members of the 
BCL-2 family, binding to the BH3 groove of anti-apoptotic members and promoting 
apoptosis. Following the displacement of the BH3 only members, BAX and BAK are 
activated, translocated and inserted in the OMM, creating a platform for the release 
of cytochrome c to the cytosol. Concomitantly, mitochondrial cristae undergo 
remodelling to facilitate cytochrome c release, contributing to an effective induction 
of the intrinsic pathway of apoptosis. Since BH3 mimetics act at the level of 
mitochondria, it is possible that they may induce mitochondrial ultrastructural 
changes. Indeed, as shown in chapter 5, A-1210477 and S63845 induced extensive 
mitochondrial fragmentation in several cell lines. Interestingly, such mitochondrial 
fragmentation does not result in cell death as most cell lines depend on both MCL-1 
and BCL-XL for survival. Inhibition of MCL-1 alone does not result in cell death 
unless BCL-XL is also inhibited. Therefore, the role of MCL-1 inhibitor in regulating 
mitochondrial ultrastructure remains to be characterised. Previous reports link MCL-
1 inhibition to mitochondrial membrane dynamics, by claiming that MCL-1 regulates 
the maintenance of normal IMM structure, mitochondrial fission and the assembly of 
ATP synthase oligomers.62 In chapter 5, I showed that MCL-1 inhibitors can induce 
profound mitochondrial structural changes, ranging from pre-apoptotic cristae 
remodelling and OMM breaks to mitochondrial fragmentation, all of which occurring 
independently of apoptosis, which possibly occurs via off-target effects. 
Mitochondrial membrane dynamics is mediated by a group of fission and 
fusion proteins, which seem to play an important role in apoptosis. Of these, DRP-1 
is widely known for its role as the master regulator of mitochondrial fission. Since 
the early 2000, research involving DRP-1 has been increasing drastically with 
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numerous studies unravelling the role of DRP-1 in mitochondrial division under 
physiological conditions and in drug-mediated mitochondrial fission.294,359 In chapter 
5, I have identified and characterised novel roles of DRP-1 in BH3-mimetic mediated 
apoptosis, cytochrome c release and BAK activation. As previously mentioned, we 
have assessed MOMP via cytochrome c release, which does not comprise the full 
aspect of this process, as other molecules, such as Smac, are also released to the 
cytosol upon MOMP.20 Nevertheless, DRP-1 depletion prevented in great extent 
BH3 mimetic-mediated cytochrome c release in H1299 cells. Indeed, similar results, 
using other apoptotic agents, such as staurosporine and etoposide have been reported 
by other groups.275,290 This, of course it is not without its controversy as another 
report has argued for no role for DRP-1 in BH3 mimetic-mediated apoptosis in 
melanoma cells.360 Furthermore, studies using, mdivi-1, initially considered as a 
DRP-1 inhibitor, showed that DRP-1 is required for tBID-mediated apoptosis and 
that physical topological changes induced by DRP-1 at the mitochondrial membrane 
facilitated BAX/BAK assembly and cytochrome c release.361–363 However, mdivi-1 
effects on DRP-1 are currently attributed to be indirect, as mdivi-1 has been shown to 
be a complex I inhibitor.364 Furthermore, interactions of BAX and BAK with 
mitofusins and their coordination with DRP-1 activity have been proposed as 
possible mechanisms for apoptosis induction.365 The data shown here point in the 
same direction, since silencing of DRP-1 decreases BH3 mimetic-mediated BAK 
activation. It is quite likely that the physical changes at the OMM caused by DRP-1 
oligomerisation facilitates the activation and insertion of BAK at the OMM. 
Recently, post-translational modifications of DRP-1 such as SUMOylation by the 
SUMO E3 ligase MAPL have been elucidated, presenting novel insights into 
understanding of the role of DRP-1 in apoptosis.276,293 This SUMOylation process is 
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thought to stabilise DRP-1 at the OMM to facilitate BAX/BAK assembly. Given the 
fast shuttling of DRP-1 oligomers for the formation of DRP-1 constriction ring in 
mitochondrial fission, this could be a possible explanation on how DRP-1 
stabilisation could facilitate apoptosis. Moreover, other proteins contribute to the role 
of DRP-1 in mitochondrial fission, and possibly apoptosis. 
In addition, there are other proteins involved in the intricate process of 
mitochondrial fission. Dynamin 2, another member of the dynamin family,366 has 
been shown to play a similar role to DRP-1, but its assembly at the fission sites 
occurs after the initial constriction of DRP-1, acting as a final sever for 
mitochondrial fission.307,367 Furthermore, silencing of dynamin 2 has been shown to 
prevent staurosporine-mediated mitochondrial fragmentation and, to some extent, 
cell death.275 On the same note, some reports have shown that naturally formed 
mitochondrial DNA aggregates, also known as mitochondrial nucleoids, signal the 
assembly of the constriction machinery, which occurs in the vicinity of the 
nucleoids.368 In addition, knockdown of DRP-1 has been shown to increase nucleoid 
clustering, which in turn restricts the individual nucleoids from signalling for 
mitochondrial constriction.369 This further strengthens the ties for the role of DRP-1 
in MOMP and apoptosis, as it has been shown that mitochondrial DNA gets released 
from mitochondria following MOMP in a BAX/BAK-dependent manner.370 Another 
protein of interest in this process is the cytoskeleton component septin 2, which has 
been shown to interact with DRP-1 and regulate mitochondrial fission.371 
Interestingly, other components of the cytoskeleton have been shown to play a role in 
mitochondrial fission, such as actin and myosin IIA filaments, bringing together the 




7.5 The role of ER membranes in the induction of apoptosis 
 The crosstalk between ER and mitochondria has been extensively studied in 
the past decades. Besides the already known functions in calcium signalling, protein 
trafficking and lipid exchange, recent studies have added mitochondrial membrane 
dynamics and apoptosis to the list of functions that have been attributed to the 
crosstalk mechanisms between ER and mitochondria.374 In the context of apoptosis, 
widely-studied ER proteins, such as IP3R have been show to regulate ER-derived 
mitochondrial calcium overload and the induction of apoptosis.375–377 In chapter 6, I 
showed that ER shaping proteins such as RTN-4 and CLIMP-63 are required for 
BH3 mimetic-mediated mitochondrial fission and apoptosis. Although the underlying 
mechanism of this anti-apoptotic function is yet to be characterised, there could be an 
important role for ER shaping proteins in ER-mitochondria calcium exchange. 
Studies have shown that RTN-4 couples two important calcium channels, the ER-
resident STIM1 and the plasma membrane-resident Orai1, which act together to 
replenish ER and intracellular calcium stores.378 Thus, silencing of RTN-4 could 
potentially cause a lack of intracellular calcium influx, which could impair ER-
mitochondria calcium transfer and the initial signalling for apoptosis. In fact, 
inhibition of store-operated calcium entry has been associated with cell death 
resistance in prostate cancer379 and also with a poorer prognosis in breast cancer.380 
Although the role of RTN-4 has been extensively studied in neurodegenerative 
diseases,381 in cancer, more studies are required to better understand how this ER 
shaping protein could regulate cell death. 
CLIMP-63 is essential for the interaction of ER with microtubules, hence 
named cytoskeleton-linking membrane protein (CLIMP-63),382 as well as being 
recruited during early stages of the assembly of ER-translocon complexes.383 
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Although the role of CLIMP-63 in apoptosis has not been well characterised, 
enhanced expression of CLIMP-63 has been observed following chemotherapy. For 
instance, inhibition of CDK in leukaemia has been shown to upregulate CLIMP-63, 
which in turn arrests cell growth.384 CLIMP-63 has also been linked to enhanced 
sensitivity to gentamicin in HEK293 cells,385 which enhanced the binding of CLIMP-
63 to 14-3-3 proteins.385 It is possible that this interaction between CLIMP-63 and 
14-3-3 could prevent BAD from being retained in the cytosol by 14-3-3.386 Which in 
turn could enable the mitochondrial translocation of BAD to execute apoptosis. This 
could well be the reason for why silencing of CLIMP-63 prevents BH3 mimetic-
mediated cell death. 
In addition to RTN-4 and CLIMP-63 there are other proteins, such as INF2 
and Spire1C that are involved in mitochondrial fission.277,312,317,372 However the 
specific role of these proteins in apoptosis has not been studied to this date. 
7.6 The role of ER membranes in other cellular functions 
The mitochondria associated membranes (MAMs), especially at the ER, also 
play such an important role in cellular homeostasis that these connective areas are 
often considered as an extra intracellular environment.307,374 Interestingly, some 
reports have shown a connection between MAMs and members of the BCL-2 family 
on the regulation of calcium signalling. For instance, BCL-XL has been shown to 
interact with IP3R channels for the induction of calcium-dependent mitochondrial 
bioenergetics during ER stress,387 or to block VDAC activity for the inhibition of 
ER-derived mitochondrial calcium influx.388 In addition, BCL-2 has also been shown 
to interact with IP3R receptors to block pro-apoptotic calcium signalling to 
mitochondria.389,390 Another important component of the MAMs is MFN2, which has 
been shown to play a crucial molecule in maintaining an appropriate distance 
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between ER and mitochondria. Of interest, it has been reported that knockdown of 
MFN2 reduces the number of ER-mitochondria contact points while not affecting 
calcium exchange.391 The data presented in chapter 6 suggest that DRP-1 also plays 
an important role in maintaining ER-mitochondria contacts, as silencing of the 
GTPase drastically reduced the number of contact points. Although MFN2 and DRP-
1 appear to play opposite roles in mitochondrial membrane dynamics, these data 
indicate that alterations in the fusion/fission balance can deeply affect ER-
mitochondria interactions. 
Despite the initial description of ER and mitochondria contacts in the early 
50s, the importance of these intracellular microenvironment was only further 
explored in the 90s, in a paper describing lipid exchange between these two 
organelles.305 It was demonstrated that lipid-synthesising enzymes were localised at 
the mitochondria-ER contacts, which were later shown to transfer phosphatidylserine 
from the ER.392 Interestingly, lipid transfer has been proposed to play a role in cell 
death393 by mediating the insertion of BAX/BAK and anchoring other BCL-2 family 
members in the OMM, a mechanism that could potentially be affected by silencing 
of ER shaping proteins. Additionally, a recent report has shown that DRP-1 interacts 
with cardiolipin for an effective induction of mitochondrial fission.394 which was 
further backed by an in vitro study showing that cardiolipin is required for proper 
BAX insertion at the OMM and that process is countered by BCL-XL.
395 
Furthermore, one of the only contexts that ER shaping proteins have been associated 
to mitochondria is lipid exchange, by a study with yeast shows that phospholipid 






7.7 Implications and future studies 
 This study reinforces the therapeutic potential and applicability of BH3 
mimetics in various cancers, not only as a stand-alone therapy, but also when used in 
combination with other existing therapies. The data presented here highlights the 
necessity for the assessment of potential off-target or unforeseen effects caused by 
BH3 mimetics, such as the induction of mitochondrial structural changes. The results 
presented in this thesis show that CML cells mainly depend on BCL-XL for survival, 
whereas AML cells depend on BCL-2 and MCL-1 and solid tumours on both MCL-1 
and BCL-XL. This needs to be taken into consideration when prescribing BH3 
mimetics in the clinic as there are side effects, such as thrombocytopenia associated 
with BCL-XL inhibition
152,153 and cardiotoxicity with MCL-1 inhibition.175 
Furthermore, as BCL-XL and MCL-1 play redundant roles in regulating cell survival 
in most solid tumours, concomitant inhibition of these proteins require the 
achievement of a good therapeutic window to minimise side effects. Therefore, 
careful toxicity assessments using these BH3 mimetics alone and in combination are 
required, as well as studies to understand potential mechanisms of chemoresistance 
and drug safety. 
 It has been shown in this study that DRP-1 plays a crucial role in BH3 
mimetic-mediated mitochondrial fragmentation and apoptosis, confirming the role of 
this protein as a master regulator of mitochondrial fission. Although previous studies 
have demonstrated that DRP-1 could play a role in apoptosis,275,290 here it is first 
described that DRP-1 was also required for BH3 mimetic-mediated cell death. These 
findings further open numerous questions regarding the nature of the requirement of 
DRP-1 for apoptosis. For instance, does DRP-1 plays a similar role in alternative cell 
death pathways, such as ferroptosis, necrosis and pyroptosis? Of interest, a report 
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indicates that DRP-1 could also play a crucial role in necroptosis.397 In addition 
further assessment of potential interactions between BCL-2 family members and 
DRP-1 at the OMM would be valuable, as well as identifying the roles of DRP-1 in 
apoptosis. Moreover, more studies are required to identify what mechanisms are 
involved in the recruitment of DRP-1 to mitochondria at the fission sites and how ER 
interplay with DRP-1 could be dictating its activity in mitochondrial membrane 
dynamics and cell death. 
 Also, here it has been shown that RTN-4 and CLIMP-63 play an important 
role for the effective induction BH3 mimetic-mediated apoptosis. The results 
presented in this study open a new avenue for the study of ER-mitochondria 
interactions, as they link ER structural maintenance to mitochondria-induced cell 
death. In the future, focusing on potential interacting partners for RTN-4 and 
CLIMP-63 by techniques such as mass spectrometry could provide a good basis 
towards understanding how these ER shaping proteins could be altering the apoptotic 
pathway and/or related pathways. On that note, it will be important to characterise 
the roles of these proteins in ER-mitochondrial contacts, which can affect several 
other pathways, such as calcium exchange, cell cycle and lipid transfer, as 
exemplified by the association of CLIMP-63 with the cytoskeleton,382 or the role of 











7.8 Concluding remarks 
The main findings presented in this study are: 
• A BCL-XL inhibitor, either alone or in combination with a TKI, could be 
potentially used to treat CML. 
• Combined inhibition of BCL-2 and MCL-1 are effective in promoting 
apoptosis in AML cell lines and primary patient samples. 
• Inhibition of BCL-XL and MCL-1 are highly efficacious in inducing cell 
death in HNSCC cell lines and patient samples. 
• Inhibition of BCL-XL and MCL-1 are highly efficacious in inducing cell 
death in PDAC cell lines. 
• Inhibition of MCL-1 by BH3 mimetics induce DRP-1-dependent 
mitochondrial fragmentation. 
• DRP-1 and CLIMP-63 are required for BH3 mimetic-mediated 
apoptosis, cytochrome c release and BAK/BAX activation. 
• ER shaping proteins, such as RTN-4 and CLIMP-63, play an important 
role in BH3 mimetic-mediated apoptosis and cytochrome c release. 
• DRP-1 and ER shaping proteins regulate ER-mitochondria contacts. 
Taken together these findings have identified several novel aspects of BH3 mimetic 
mediated apoptosis and contributed important new knowledge to the fields of 
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High CIP2A levels correlate with an antiapoptotic phenotype
that can be overcome by targeting BCL-XL in chronic myeloid
leukemia
CM Lucas1, M Milani1, M Butterworth1, N Carmell1, LJ Scott1, RE Clark1, GM Cohen1,2 and S Varadarajan1,2
Cancerous inhibitor of protein phosphatase 2A (CIP2A) is a predictive biomarker of disease progression in many malignancies,
including imatinib-treated chronic myeloid leukemia (CML). Although high CIP2A levels correlate with disease progression in CML,
the underlying molecular mechanisms remain elusive. In a screen of diagnostic chronic phase samples from patients with high
and low CIP2A protein levels, high CIP2A levels correlate with an antiapoptotic phenotype, characterized by downregulation of
proapoptotic BCL-2 family members, including BIM, PUMA and HRK, and upregulation of the antiapoptotic protein BCL-XL. These
results suggest that the poor prognosis of patients with high CIP2A levels is due to an antiapoptotic phenotype. Disrupting this
antiapoptotic phenotype by inhibition of BCL-XL via RNA interference or A-1331852, a novel, potent and BCL-XL-selective inhibitor,
resulted in extensive apoptosis either alone or in combination with imatinib, dasatinib or nilotinib, both in cell lines and in primary
CD34+ cells from patients with high levels of CIP2A. These results demonstrate that BCL-XL is the major antiapoptotic survival
protein and may be a novel therapeutic target in CML.
Leukemia advance online publication, 18 March 2016; doi:10.1038/leu.2016.42
INTRODUCTION
Chronic myeloid leukemia (CML) is a malignant disease of a
primitive hematopoietic cell, characterized by a reciprocal
translocation between chromosomes 9 and 22 and creates the
fusion gene BCR-ABL1, which is a deregulated tyrosine kinase that
drives the leukemia.1 CML treatment has been significantly
improved by the tyrosine kinase inhibitor (TKI) imatinib, but some
patients will eventually fail imatinib treatment and without a
change in therapy, a significant proportion will progress towards
blast crisis (BC), which is usually rapidly fatal.2,3 The kinase activity
of BCR-ABL is opposed by cellular phosphatases, such as protein
phosphatase 2A (PP2A), which is impaired in several malignancies.
PP2A plays an important role in regulating cell proliferation,
differentiation and apoptosis. In CML, PP2A is inhibited by SET4
and cancerous inhibitor of PP2A (CIP2A).5 CIP2A inhibits PP2A
activity and functions by preventing PP2A-driven dephosphoryla-
tion and stabilization of c-Myc.6–8 CIP2A is a strong prospective
predictor of subsequent development of BC in imatinib-treated
CML patients,5 although the underlying mechanisms remain
unclear.
Apoptosis induction is tightly regulated by the BCL-2 family of
proteins, which comprise several antiapoptotic members, such as
BCL-2, BCL-XL, MCL-1, BCL-w and BFL-1, together with proapopto-
tic molecules, such as the multidomain effectors BAX and BAK, as
well as the BH3-only proteins, including the activators BIM,
BID and PUMA, and sensitizers NOXA, HRK, BIK, BMF and BAD.9,10
The BH3-only members can either be promiscuous or selective
with respect to binding their antiapoptotic counterparts.
The activators bind all antiapoptotic BCL-2 family members,
whereas the sensitizers NOXA and HRK are more selective in
binding MCL-1 and BCL-XL, respectively.
11 BCR-ABL modulates the
expression levels and/or the phosphorylation status of several
BCL-2 family members, thus exerting important regulatory effects
on apoptosis.12–15 Furthermore, recent reports suggest important
roles for several antiapoptotic BCL-2 family members in CML
disease progression.16–20 Elevated levels of these proteins in
several cancers make them promising targets for drug therapy.
Small-molecule inhibitors targeting specific members of the BCL-2
family, such as navitoclax/ABT-263 (BCL-2, BCL-XL and BCL-w-
specific) and venetoclax/ABT-199 (BCL-2-specific) are in clinical
trials for several lymphoid malignancies.21,22 Recently, selective
inhibitors of BCL-XL (A-1331852) and MCL-1 (A-1210477) have
been synthesized.23,24 These inhibitors target the antiapoptotic
BCL-2 family members, displacing their sequestered proapoptotic
counterparts, thereby resulting in apoptosis.
In this study, we demonstrate both a novel antiapoptotic role
for CIP2A in CML pathogenesis and a key role for BCL-XL in survival
of CML cell lines and in primary CD34+ cells from patients. These
results raise the possibility that inhibition of BCL-XL may be a
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CA, USA), NOXA from Calbiochem (Darmstadt, Germany), BCL-2 from Dako
(Ely, UK), BAX and BAK from Millipore (Watford, UK), HRK from Aviva
Systems Biology (San Diego, CA, USA) and BID and BFL-1 were from Prof J
Borst (The Netherlands Cancer Institute, Amsterdam, The Netherlands).
All other reagents, unless mentioned otherwise, were from Sigma-Aldrich
(St Louis, MO, USA).
Patient cohort
The study was approved by the Liverpool Central Research Ethics
Committee; all 31 patients gave informed consent and were aged 18 or
over. All have been seen since original diagnosis of chronic phase CML
at our center and have been followed for at least 12 months (median
follow-up: 39 months). Patients’ characteristics are presented in
Supplementary Table S1.
Sample collection, preparation and cell culture
At diagnosis, mononuclear cells from chronic phase CML patients were
separated by density-dependent centrifugation (Lymphoprep Axis-Shield,
Oslo, Norway), washed in RPMI 1640 (BioSera, Uckfield, UK) and
resuspended in 10% dimethyl sulfoxide/10% fetal calf serum (BioSera)/
RPMI at 4 °C and cryopreserved in liquid nitrogen. Wherever possible,
samples were enriched for CD34+ cells using the CliniMACS kit
(Miltenyi Biotec, Auburn, CA, USA). CD34+ cells were cultured using
StemSpan SFEMII media (Stemcell Technologies, Cambridge, UK). K562 and
KCL22 cells were cultured in RPMI 1640 supplemented with 10% fetal calf
serum and 5 mM L-glutamine.
BH3 profiling and flow cytometry
BH3 profiling was carried out using BH3 peptides from New England
Peptide (Gardner, MA, USA) as previously described.25 Loss of mito-
chondrial membrane potential and apoptosis were quantified by flow
cytometry as described.26 Patients with CIP2A levels ⩾ 7.3 mean
fluorescence units by flow cytometry were defined as high CIP2A patients,
as every patient that progressed to BC had CIP2A 47.3 mean fluorescence
units.27 This cutoff value was derived using receiver operating character-
istics (ROC) curve analysis for the prediction of BC based on the diagnostic
CIP2A protein level; minimization of the Euclidian distance between the
receiver operating characteristics curve and the corner (0, 1) was the
criterion used. The optimal cutoff value produced an AUCROC = 0.902 (95%
CI: 0.832, 0.973).
siRNA knockdowns, immunoprecipitation and western blotting
Cells were reverse-transfected with 10 nM of BAK (s1880 and s1881),
BAX (s1888 and s1889), BIM (s195011), PUMA (pool of siRNAs), BMF (pool of
siRNAs), BIK (s1989 and s1990), HRK (s194952), BCL-XL (s1920), MCL-1
(s8583), BCL-w (s1924), BFL-1 (pool of siRNAs) from Life Technologies
(Paisley, UK), BID (SI02654568), NOXA (SI00129430), BAD (SI00299348),
BCL-2 (S100299411) from Qiagen (Manchester, UK) using Interferin
Figure 1. BH3 profiling and RNA interference implicate roles for BCL-2, BCL-XL and MCL-1 in TKI-induced apoptosis. (a) BH3 profiling in K562
cells was carried out using the specified concentrations of different BH3 peptides for 2 h. PUMA-2A was used as the control peptide.
(b) Dynamic BH3 profiling in K562 and KCL22 cells, exposed to increasing concentrations of imatinib for 16 h, was carried out using either
control peptide (bold continuous lines) or BIM peptide (dotted lines) at 1 μM for 2 h. (c) K562 and KCL22 cells, reverse-transfected with the
indicated siRNAs, were exposed for 48 h to dimethyl sulfoxide, imatinib (1 μM), nilotinib (50 nM) or dasatinib (3 nM) and apoptosis assessed by
phosphatidylserine (PS) externalization. Statistical analysis was conducted using one-way analysis of variance applying the Welch correction
and Dunnet’s two-sided multiple comparison test to compare the different treatments to the appropriate control peptide/ siRNA (*P⩽ 0.05,
**P⩽ 0.01, ***P⩽ 0.001). Error bars represent standard error of mean (s.e.m.) from three independent experiments.
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(Polyplus Transfection, NY, USA), according to the manufacturer's protocol
and processed 48 h after transfection. Immunoprecipitation and western
blotting were carried out according to the standard protocols.26
mRNA expression
Quantitative reverse transcription–PCR was performed using cDNA
from total leukocytes. Pre-designed TaqMan real-time PCR assays
were used for BCL2L11 (Hs00708019_s1), BCL2L1 (Hs00236329_m1), BID
(Hs00609632_m1), BBC3 (Hs00248075_m1), HRK (Hs02621354_s1) and BAD
(Hs00188930_m1) and GAPDH (Hs99999905_m1) (Life Technologies). PCR
was performed using a Stratagene MX3005P PCR machine (Agilent
Technologies, Folsom, CA, USA). In evaluating the mRNA expression data,
the comparative Ct method was used, with the 2−ΔΔCt formula to achieve
results for relative quantification. A pool of cDNA from four normal
individuals was used as a calibrator and all samples were normalized to
GAPDH.
Statistical analysis
Statistical analysis was conducted using one-way analysis of variance
applying the Welch correction and Dunnet’s two-sided multiple compar-
ison test to compare the different treatments to the appropriate control
peptide/siRNA (*P⩽ 0.05, **P⩽ 0.01, ***P⩽ 0.001). For continuous variables,
the Mann–Whitney U-test was used for comparisons between independent
samples. For categorical variables, Fisher’s exact test was used.
Progression-free survival functions were estimated by the Kaplan–Meier
estimator and the log-rank test was used for comparisons between groups.
Statistical analysis was performed using GraphPad Prism (GraphPad Prism
Software, Inc., La Jolla, CA, USA).
RESULTS
TKIs prime CML cell lines to undergo apoptosis
Since high levels of CIP2A contributed to imatinib resistance in
CML, we wished to understand the role of BCL-2 family members
in this resistance mechanism. Using BH3 profiling, a peptide-based
technique to determine BCL-2 family dependencies,25 we
observed extensive loss of mitochondrial membrane potential
(φm) in two CML cell lines, K562 and KCL22, following exposure to
increasing concentrations of different BH3 peptides (Figure 1a and
Supplementary Figure S1). Although all BH3-only activators
exhibited extensive mitochondrial depolarization, BH3-only sensi-
tizers demonstrated greater selectivity as demonstrated by a
concentration-dependent loss in φm following BMF, BAD and HRK,
but not NOXA (Figure 1a and Supplementary Figure S1). These
results suggested that the survival of these cells depended more
Figure 2. TKIs induce apoptosis in a BH3-dependent manner. (a, b) K562 and KCL22 cells, reverse-transfected with the indicated siRNAs, were
exposed for 48 h to dimethyl sulfoxide, imatinib (1 μM), nilotinib (50 nM) and dasatinib (3 nM) and apoptosis assessed by phosphatidylserine
(PS) externalization. Statistical analysis was conducted using one-way analysis of variance applying the Welch correction and Dunnet’s two-
sided multiple comparison test to compare the different siRNA transfections to their appropriate control siRNA in each treatment (*P⩽ 0.05,
**P⩽ 0.01, ***P⩽ 0.001). Error bars represent s.e.m. from three independent experiments.
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on BCL-2, BCL-XL and BCL-w, rather than on MCL-1 and BFL-1, as
NOXA was the only sensitizer among the list to specifically target
both MCL-1 and BFL-1 (Figure 1a and Supplementary Figure S1).9–11
In dynamic BH3 profiling studies,28 increasing concentrations of
TKIs resulted in a significant loss of φm, only when the cells were
subsequently exposed to the BIM peptide, suggesting that TKIs
primed these cells to apoptosis and a combination therapy with
another apoptotic stimuli could facilitate rapid apoptosis in these
cells (Figure 1b and Supplementary Figure S2). Since our data
implicated specific members of the BCL-2 family in antagonizing
apoptosis, we performed RNA interference to silence the
expression of different BCL-2 family members to study their
effects on TKI-mediated apoptosis (Figure 1c). The concentrations
of TKIs used in these studies were determined from their
concentration–response curves (Supplementary Figure S3). Down-
regulation of BCL-XL and to some extent BCL-2 resulted in
apoptosis, suggesting that BCL-XL is a critical survival factor in
both CML cell lines (Figure 1c). Furthermore, downregulation of
BCL-XL, and to a lesser extent, BCL-2 and MCL-1, significantly
potentiated TKI-mediated apoptosis in both K562 and KCL22
(Figure 1c), thus confirming an important role for antiapoptotic
BCL-2 family members in TKI-mediated apoptosis.
TKIs induce apoptosis in a BH3-dependent manner
Exposure to TKIs caused a time-dependent decrease in the
expression levels of most anti- and proapoptotic BCL-2 family
members, with the notable exception of BAD, which was
significantly upregulated (Supplementary Figure S4). To under-
stand the relative contribution of different proapoptotic BCL-2
members in TKI-mediated apoptosis, we silenced the expression
of BAX, BAK as well as BH3-only activators and sensitizers in K562
and KCL22 (Figure 2). Although all the proapoptotic effector and
activator proteins were critical for TKI-mediated apoptosis, a
selective dependence on HRK and BAD, but not NOXA, BMF or BIK
was observed in TKI-mediated apoptosis (Figure 2 and
Figure 4. High CIP2A expression levels correlate with an antiapop-
totic phenotype. mRNA expression for BIM, BID, PUMA, HRK, BAD and
BCL-XL in 31 newly diagnosed chronic phase CML patients stratified
by their diagnostic CIP2A status. A pool of four normal healthy
volunteers was used as a calibrator pool. Statistical analysis
was conducted using a Mann–Whitney U-test comparing high and
low CIP2A patients (**P⩽ 0.01). Error bars represent s.e.m.
Figure 3. Expression levels of the proapoptotic BH3-only proteins correlate with progression-free survival in CML patients. Progression-free
survival for patients treated with imatinib at initial diagnosis. PCR was performed using total leukocytes collected at initial diagnosis. Patients
were stratified into high and low expression groups according to the median mRNA expression for BIM, BID, PUMA, HRK and BAD and the
number of cases assessed presented below each graph. The log-rank test was used to determine the significance between high and low
expressers.
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Supplementary Figure S4), thus implicating a regulatory role for
several BH3-only members in TKI-induced apoptosis.
Downregulation of proapoptotic BCL-2 family proteins is
associated with disease progression in imatinib-treated patients
To investigate a possible relationship between these BH3-only
proteins and clinical outcome, we compared the mRNA expression
levels of these proteins with progression-free survival of chronic
phase CML patients, treated with imatinib at diagnosis (Figure 3).
The median expression level for each gene was calculated and
patients were stratified as high or low relative to the median. Low
BIM expression was associated with an inferior progression-free
survival, whereas BID or BAD expression did not correlate with
clinical outcome (Figure 3). Low PUMA and HRK expression were
significantly associated with disease progression to BC (P= 0.03;
Figure 3). In this study, four patients progressed to BC and this
disease progression was not associated with the presence of BCR-
ABL kinase domain mutations. Low expression of BIM, PUMA and
HRK was also associated with poor overall survival but this did not
reach significance (data not shown). Moreover, 50% of patients
with low PUMA or HRK expression at diagnosis had progressed by
36 months (Figure 3). In addition, low diagnostic levels of BIM and
HRK were associated with a slower rate of deep molecular
response (MR5) during the first three years of treatment (data not
shown).
CIP2A levels correlate with the balance between pro- and
antiapoptotic BCL-2 family proteins
Since CML disease progression correlates with high CIP2A
levels,5,29 as well as changes in expression levels of different
BCL-2 family members (Figure 3), we speculated whether CIP2A
levels could correlate with the expression levels of different BCL-2
family members. To investigate this possibility, we assessed mRNA
expression for BIM, BID, PUMA, HRK, BAD and BCL-XL in newly
diagnosed chronic phase CML patients. Expression levels of BIM,
PUMA and HRK were significantly lower in high compared with low
CIP2A patients (Figure 4). A similar trend was observed for BID and
BAD expression but this did not reach statistical significance
(Figure 4). In contrast, patients with high CIP2A levels expressed
high levels of BCL-XL, although this did not reach statistical
significance (Figure 4). Taken together these results suggest that
CIP2A may exhibit its oncogenic activity by altering the balance of
pro- and antiapoptotic proteins resulting in an antiapoptotic
phenotype.
Figure 5. BCL-XL is a critical survival factor and regulates TKI-induced apoptosis in CML cell lines. (a) K562 and KCL22 cells were exposed for
24 h to the specified inhibitors and apoptosis assessed by phosphatidylserine (PS) externalization. (b) Immunoprecipitation of BCL-XL was
carried out in K562 cells, exposed to A-1331852 (100 nM) for 0–2 h, and the eluted complexes were immunoblotted for the indicated proteins.
The input cell lysates and the immunodepleted supernatant (labeled as Flow-through) were immunoblotted to check the efficiency of the
immunoprecipitation. BC represents beads control. (c) K562 cells, exposed for 1 h to 1 nM of ABT-199 or A-1331852, were further exposed in
the presence of the pretreated inhibitors to imatinib (1 μM), nilotinib (50 nM) or dasatinib (3 nM) for 24 h and apoptosis assessed. (d) Same as (b)
but the immunoprecipitation was carried out with antibodies against BCL-XL in K562 cells exposed to A-1331852 (1 nM) with or without
nilotinib (50 nM) for 24 h. Statistical analysis was conducted using one-way analysis of variance applying the Welch correction and Dunnet’s
two-sided multiple comparison test to compare the TKI treatments with the combination treatments of A-1331852, represented by the black
and gray histograms (*P⩽ 0.05). Error bars represent s.e.m. from three independent experiments.
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BCL-XL is a critical survival factor and antagonizes TKI-induced
apoptosis in CML cell lines
Since our initial data identified BCL-XL as a critical survival factor in
CML cell lines, we used a toolkit of selective BCL-2 family
inhibitors, comprising ABT-737 (BCL-2, BCL-XL and BCL-w-specific
inhibitor), ABT-199 (BCL-2-selective), A-1331852 (BCL-XL-specific)
and A-1210477 (MCL-1-selective) to further evaluate the role of
BCL-XL in CML cell survival. In both cell lines, A-1331852 was
extremely potent, inducing apoptosis at low nanomolar concen-
trations, whereas the other inhibitors failed to induce apoptosis
Figure 6. Inhibition of BCL-XL promotes rapid apoptosis in primary CML cells. (a, b) Diagnostic chronic phase CD34
+ cells from high CIP2A
patients were exposed to A-1331852 for 1 h (n= 3) and 4 h (n= 5) and apoptosis assessed. (c, d) Mononuclear cells (MNCs) from healthy
volunteers were exposed to A-1331852 for 1 h (n= 8) and 4 h (n = 6) and apoptosis assessed. (e) Diagnostic chronic phase CD34+ cells from
high CIP2A patients were exposed to imatinib (5 μM), dasatinib (150 nM) and nilotinib (5 μM) for 24 h followed by the addition of A-1331852
(10 nM) to the cells for a further 1 h (n= 5). Statistical analysis was conducted using a Mann–Whitney U-test and P-values specified, where
significant. Error bars represent s.e.m.
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even at 100-fold higher concentrations (Figure 5a). A-1331852 was
efficient in displacing both BIM and BAD from BCL-XL and
releasing them into the cytosol (Figure 5b). Furthermore,
A-1331852, but not ABT-199, was efficacious in potentiating
TKI-mediated apoptosis for 2G TKIs (Figure 5c). A combination of
nilotinib and A-1331852 was more potent than either A-1331852
or nilotinib alone in displacing BIM from BCL-XL (Figure 5d), further
suggesting that A-1331852 can be effective in inducing apoptosis
in CML cell lines, either as a single agent or in combination
with TKIs.
A-1331852 exhibits remarkable potency both as a single agent
and in combination with TKIs in killing primary CD34+ CML cells
We next investigated the ability of A-1331852 to induce apoptosis
in primary CD34+ progenitor cells from high CIP2A patients. In
agreement with our data in CML cell lines, A-1331852 displayed
remarkable potency in inducing apoptosis in these cells at low
nanomolar concentrations as early as 1 h post-treatment
(Figure 6a). Prolonged exposure (4 h) resulted in improved
potency as A-1331852 induced extensive apoptosis (P= 0.002) at
concentrations as low as 1 nM in these cells (Figure 6b). Similar
results were observed in CD34+ progenitor cells from low CIP2A
patients (Supplementary Figure S5). In contrast, mononuclear cells
isolated from healthy volunteers generally remained insensitive to
the treatment (Figures 6c and d). This is particularly significant as
clinically achievable concentrations of imatinib (5 μM), nilotinib
(5 μM) or dasatinib (150 nM) did not induce significant apoptosis in
primary CD34+ cells after 4 h exposure (data not shown).
Even after 24 h exposure, none of these TKIs induced much if
any apoptosis above the high spontaneous apoptosis observed in
the progenitor cells (Figure 6e). However a subsequent and short
exposure to A-1331852 (1 h) following the initial 24 h exposure to
TKIs was sufficient to induce enhanced apoptosis in these
CD34+ cells (P⩽ 0.01, Figure 6e). These data support the possibility
of targeting BCL-XL, as a novel and effective therapeutic strategy
in CML (Figure 7).
DISCUSSION
High expression of CIP2A contributes to imatinib resistance in CML
and is a strong prospective predictor of subsequent development
of BC in imatinib-treated patients.5 However the mechanism(s) by
which CIP2A increases the risk of disease progression is poorly
understood. In this study, we have identified several proapoptotic
BCL-2 family members to be critical in TKI-mediated apoptosis
(Figures 1 and 2). These findings also extended to CML patients, as
decreased expression of specific proapoptotic BH3-only members
PUMA, HRK and possibly BIM correlated with disease progression
in CML patients (Figure 3). To our knowledge, this is the first study
to link several proapoptotic BCL-2 family members to progression-
free survival in imatinib-treated CML patients. We show that high
CIP2A expression levels correspond to low expression of specific
BH3-only proteins, BIM, PUMA and HRK, and an increase in the
expression of BCL-XL (Figure 4), highly characteristic of an
antiapoptotic phenotype.
Recently, we have shown that administration of 2G TKIs, such as
nilotinib and dasatinib, can overcome high CIP2A and prevent
disease progression.5,27 However, this is not without worrying side
effects, as dasatinib has a 25% risk of pleural effusion within ~ 3
years and nilotinib therapy is associated with hyperglycemia in
some patients and a dose-related (8–10%) risk of myocardial
infarction, cerebrovascular event or peripheral arterial occlusive
event by 6 years.30,31 This necessitates research into possible
alternate therapeutic strategies. In this study, using a BCL-XL-
specific inhibitor, A-1331852,23 we demonstrate for the first time,
an effective therapeutic option for CML patients with high CIP2A
expression levels. A-1331852 displayed remarkable potency, both
as a single agent and in combination with TKIs, to induce
apoptosis in cell lines and in progenitor CD34+ primary cells
(Figures 5 and 6) demonstrating the critical importance of BCL-XL
in the survival of CML cells. Although BCL-XL has been associated
with disease progression,12,19,32–34 this is the first study that
demonstrates a novel antiapoptotic role for CIP2A in CML
pathogenesis and how this can be overcome by selectively
targeting BCL-XL. This therapeutic option appears particularly
promising because the CD34+ progenitor cells were highly
sensitive to nanomolar concentrations of A-1331852 but
Figure 7. Selective inhibition of BCL-XL overcomes CIP2A-mediated regulation of BCL-2 family members and disease progression in CML.
The links that we have established/confirmed in this study are presented as bold lines whereas the dashed lines represent findings from
literature. (a) The constitutively active kinase activity of BCR-ABL, antagonized by TKIs, results in phosphorylation of STAT5. (b) p-STAT5 induces
the transcription of BCL-XL. (c) BCL-XL sequesters and inhibits BH3-only proteins. (d) This antiapoptotic activity is abolished by A-1331852.
(e) Failure to achieve effective apoptosis results in disease progression. (f ) High levels of CIP2A correlate with imatinib resistance in CML
patients. (g) This can be overcome by second generation (2G) TKIs. (h) CIP2A expression levels correlate with an antiapoptotic phenotype
characterized by changes in the balance between the pro- and antiapoptotic BCL-2 family members, thus conferring resistance to TKI therapy
in CML. The precise mechanisms by which high CIP2A correlates with the antiapoptotic phenotype is unknown and hence marked with a ‘?’
(i) Selective inhibition of BCL-XL induces rapid apoptosis in CML cells, thus providing a novel and promising therapeutic option.
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insensitive to even prolonged exposure of the TKIs (Figure 6). This
observation is in agreement with previous studies demonstrating
a BCL-XL dependence of stem cell survival for human embryonic
stem cells as well as non-small-cell lung cancer cells.35,36 Thus,
targeting BCL-XL potentially offers great therapeutic benefits in
CML, especially due to the insensitivity of quiescent CD34+
progenitor CML cells to imatinib, which is a major factor in the
recurrence of the disease on discontinuation of therapy,17,37
although it will be necessary to overcome potential toxicities, such
as thrombocytopenia, associated with BCL-XL inhibition.
22,38
In summary, we clearly demonstrate that high CIP2A corre-
sponds to an antiapoptotic phenotype, which may contribute to
the poor prognosis of CML patients. We have also shown that this
antiapoptotic phenotype can be overcome in CML by targeting
BCL-XL, thus identifying an effective therapeutic option for
CML patients with high expression levels of CIP2A (Figure 7). As
high CIP2A levels are also implicated in disease progression in
acute myeloid leukemia, breast, bladder, cervical, colon, hepato-
cellular and lung cancer,39–46 it will be of interest to ascertain if
these tumors also exhibit an antiapoptotic phenotype. Targeting
this antiapoptotic phenotype with selective BCL-2 family antago-
nists may offer novel therapeutic approaches to these
malignancies.
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DRP-1 is required for BH3 mimetic-mediated
mitochondrial fragmentation and apoptosis
Mateus Milani1,4, Dominic P Byrne2,4, Georgia Greaves1, Michael Butterworth1, Gerald M Cohen1,3, Patrick A Eyers*,2 and
Shankar Varadarajan*,1,3
The concept of using BH3 mimetics as anticancer agents has been substantiated by the efficacy of selective drugs, such as
Navitoclax and Venetoclax, in treating BCL-2-dependent haematological malignancies. However, most solid tumours depend on
MCL-1 for survival, which is highly amplified in multiple cancers and a major factor determining chemoresistance. Most MCL-1
inhibitors that have been generated so far, while demonstrating early promise in vitro, fail to exhibit specificity and potency in a
cellular context. To address the lack of standardised assays for benchmarking the in vitro binding of putative inhibitors before
analysis of their cellular effects, we developed a rapid differential scanning fluorimetry (DSF)-based assay, and used it to screen a
panel of BH3 mimetics. We next contrasted their binding signatures with their ability to induce apoptosis in a MCL-1 dependent cell
line. Of all the MCL-1 inhibitors tested, only A-1210477 induced rapid, concentration-dependent apoptosis, which strongly
correlated with a thermal protective effect on MCL-1 in the DSF assay. In cells that depend on both MCL-1 and BCL-XL, A-1210477
exhibited marked synergy with A-1331852, a BCL-XL specific inhibitor, to induce cell death. Despite this selectivity and potency,
A-1210477 induced profound structural changes in the mitochondrial network in several cell lines that were not phenocopied
following MCL-1 RNA interference or transcriptional repression, suggesting that A-1210477 induces mitochondrial fragmentation
in an MCL-1-independent manner. However, A-1210477-induced mitochondrial fragmentation was dependent upon DRP-1, and
silencing expression levels of DRP-1 diminished not just mitochondrial fragmentation but also BH3 mimetic-mediated apoptosis.
These findings provide new insights into MCL-1 ligands, and the interplay between DRP-1 and the anti-apoptotic BCL-2 family
members in the regulation of apoptosis.
Cell Death and Disease (2017) 8, e2552; doi:10.1038/cddis.2016.485; published online 12 January 2017
Targeting the diverse anti-apoptotic BCL-2 family of proteins
offers substantial promise for cancer treatment and has the
potential to be valuable in overcoming tumour recurrence and
chemoresistance. In particular, the BCL-2 selective inhibitor,
ABT-199 (Venetoclax) and ABT-263 (Navitoclax), which also
targets BCL-2, BCL-XL and BCL-w, have been employed
successfully for treating haematological malignancies.1–3
However, these inhibitors are ineffective in treating solid
tumours, whose survival often depends on the overexpression
of the anti-apoptotic protein MCL-1. MCL-1 is one of the most
widely expressed pathologic factors in human cancers,4 and
many putative MCL-1 inhibitors have been synthesised,
several of which have demonstrated selectivity in different
types of in vitro assays.5–13
Inhibitors of the BCL-2 family of proteins, widely referred to
as BH3 mimetics, elicit their pro-apoptotic roles by activating
BAX and or BAK, which perturbs mitochondrial integrity
resulting in the release of cytochrome c and caspase
activation.14 The putative inhibitors of MCL-1 evaluated in
the current study have all been designed to function as BH3
mimetics, and a variety of analytical data from different in vitro
studies has demonstrated their ability to target MCL-1.5–13
However, the lack of a single benchmarked binding assay to
evaluate compound binding and reproducibility has hindered
compound comparisons, with most assays relying upon
fluorescence polarisation, which is subject to signal-to-noise
artefacts and potential interference from the compounds.
Indeed, many described MCL-1 inhibitors have failed to enter
clinical trials, potentially due to a lack of specificity and
potency.
In this study, we purified recombinant human MCL-1 from
bacteria and developed a rapid, simple differential scanning
fluorimetry (DSF) assay, which we exploit to screen a broad
panel of BH3 mimetics. Using a thermostability protocol, we
validate A-1210477 as a potent and selective MCL-1 ligand
in vitro. We corroborate our DSF assay in a series of cellular
experiments, showing that A-1210477 induces rapid apopto-
sis in an MCL-1-dependent cell line. Furthermore, we observe
rapid and extensive mitochondrial fission following A-1210477
that occurs in a DRP-1-dependent manner. Finally, we
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characterise roles for DRP-1 in A-1210477-mediated mito-
chondrial fragmentation as well as in BH3 mimetic-mediated
apoptosis. Thus, our report identifies A-1210477 as a bona
fide MCL-1 inhibitor that not only facilitates apoptosis but also
grossly perturbs mitochondrial membrane dynamics.
Results
Most described MCL-1 inhibitors fail to potently induce
apoptosis in a MCL-1 dependent cell line. The literature
contains numerous examples of small molecule MCL-1
inhibitors that exhibit a wide range of reported binding
affinities for MCL-1 (Figure 1). These have been calculated
using a variety of in vitro approaches, including fluorescence
polarisation (FP), surface plasmon resonance (SPR), ELISA
and time-resolved fluorescence resonance energy transfer
(TR-FRET; Figure 1). The first selective inhibitors of the
BCL-2 family of proteins, ABT-737 and its orally available
analogue, ABT-263 (Navitoclax) target BCL-2, BCL-XL and
BCL-w, but not MCL-1, at low nanomolar concentrations.1
These compounds have been followed by ABT-199 (Veneto-
clax), A-1331852 and A-1210477, which, respectively, target
BCL-2, BCL-XL and MCL-1.
2,5,15 The MCL-1 ligand ‘Com-
pound 9’ was generated as a result of a HTS strategy coupled
to direct hit optimisation,6 while MIM-1 was identified by a
stapled peptide-based competitive screen.7 A series of
3‑substituted‑N‑(4-Hydroxynaphthalen-1-yl) arylsulphona-
mides, including compounds 10 and 36, have been reported
to bind and inhibit MCL-1.8 Obatoclax mesylate is a pan-
BCL-2 inhibitor with reported specificity for MCL-1.9 Marito-
clax (marinopyrrole A1) is a natural product that directly binds
MCL-1 and targets it for proteasomal degradation.10 Removal
of the toxic aldehyde groups in the naturally occurring
polyphenol, gossypol, resulted in apogossypol, which upon
further substitution yielded BI97C1 (Sabutoclax) and
BI112D1, both of which are claimed to target all members
of the BCL-2 family.11,12 TW-37 is a benzenesulphonyl
derivative of gossypol reported to bind to MCL-1 with a
higher affinity than BCL-2 or BCL-XL (Figure 1a).
13
To investigate whether these compounds induce cellular
apoptosis by inhibiting MCL-1, we exposed MCL-1-addicted
H929 cells to this broad panel of putative inhibitors (Figure 1a)
and assessed the extent of apoptosis induction. Also included
in our panel as negative controls were ABT-737, ABT-263,
ABT-199 and A-1331852, which were assessed alongside the
stabilised alpha-helix of BCL-2 domains (SAHBs), which were
designed to mimic the BH3 binding helix of MCL-1 and NOXA,
respectively.16 Remarkably, only A-1210477 induced exten-
sive concentration-dependent apoptosis in H929 cells follow-
ing a brief (4 h) exposure (Figure 1b). Both apogossypol and
ABT-737         ABT-263              ABT-199              A-1331852         A-1210477
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Figure 1 Reported in vitro binding constants of MCL-1 inhibitors correlate poorly with the ability to induce apoptosis in a cellular context. (a) Chemical structures of reported
BH3 mimetics used in this study along with literature binding affinities (μM), assessed by fluorescence polarisation (FP), surface plasmon resonance (SPR) or time-resolved
fluorescence resonance energy transfer (TR-FRET). (b) Analysis of concentration-dependent effects of MCL-1 inhibitors on cellular apoptosis, assessed by the extent of
phosphatidylserine (PS) externalisation following 4 and 24 h of exposure in MCL-1 addicted H929 cells. Statistical analysis was conducted using one-way ANOVA and P-values
depicted as ***P⩽ 0.001. Results are shown as the mean± S.E.M. (standard error of the mean) from at least three independent experiments
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BI97C1 (Sabutoclax) induced apoptosis at high micromolar
concentrations, whereas all other inhibitors failed to exhibit
any enhanced apoptosis (Figure 1b). In contrast, a prolonged
exposure (24 h) to several compounds, including ABT-199,
A-1331852, Obatoclax, Maritoclax, gossypol derivatives and
compounds 9, 10 and 36, resulted in a marked increase in cell
death (Figure 1b), suggesting that they function through an
indirect or off-target effect.
Design and validation of a new assay to evaluate MCL-1
compound binding. Since in vitro binding assays for these
drugs were carried out using different assays under distinct
experimental conditions, it is impossible to correlate dis-
crepancies between reported in vitro binding affinities
(Figure 1a) and quantified cellular effects (Figure 1b) without
introducing some form of standardisation. To overcome this
technical challenge, we developed and validated a new
in vitro assay that enabled us to compare, under identical
experimental conditions, the relative effects of putative
MCL-1 inhibitors. DSF is a biophysical method that can be
used in a thermostability assay (TSA) workflow to monitor
shifts in unfolding parameters as a measure of ligand binding
affinity.17–22 We initially isolated a recombinant truncated
version of human MCL-1 (amino acids 172-329, correspond-
ing to the BH1-3 domains) as well as a R263A mutant to
serve as negative control, as the conserved arginine at
position 263 of MCL-1 is critical for ligand and substrate
binding in all BCL-2 family members (Figures 2a and b).23
Both wild-type (WT) and R263A MCL-1 exhibited similar
folded secondary structure profiles (assessed by circular
dichroism) and thermal unfolding profiles (assessed by DSF;
Figures 2c and d), although R263A MCL-1 (Tm ~66 °C) was
slightly less stable than WT MCL-1 (Tm ~67.5 °C). To
validate whether recombinant MCL-1 proteins were function-
ally relevant for screening putative MCL-1 inhibitors, we
assessed the ability of different synthetic BH3 peptides to
bind WTand R263A MCL-1. As expected, the MCL-1 specific
synthetic peptide, MS-1, and a peptide corresponding to the
BH3 domain of BIM, were both very efficient MCL-1 binding
partners, with temperature shifts of ~ 10 °C recorded at
equimolar peptide and MCL-1 protein concentration. In
contrast, PUMA and NOXA peptides showed more modest
MCL-1 binding signals, even at high concentrations
(Figure 2e). Under identical conditions, no detectable
MCL-1 binding was observed for BAD (which binds specifi-
cally to BCL-2, BCL-XL and BCL-w but not MCL-1), HRK
(BCL-XL-specific) and PUMA-2A (a negative control) syn-
thetic peptides (Figure 2e). These results were entirely
consistent with the extent of mitochondrial depolarisation
induced by these peptides in a cellular BH3 profiling assay
using H929 cells (compare Figures 2e and f). Furthermore,
none of the BH3 peptides bound/stabilised the R263A
mutated MCL-1 protein (Figure 2g), validating the importance
of this highly conserved basic residue for peptide binding,
and creating a powerful dual recombinant protein screening
system for further mechanistic analysis of MCL-1 ligands.
DSF identifies A-1210477 as a MCL-1 specific inhibitor.
Next, we next used DSF to screen 18 compounds that have
been reported to be MCL-1 inhibitors, concluding that
A-1210477 elicited the most marked thermal shift (ΔTm value
of 6–8 °C), in contrast to the weak thermal shifts observed
with other inhibitors of o2 °C, which is within the cut-off for a
weak or nonspecific binding event, as defined for ligand
binding to protein kinases and bromodomains.22 MCL-1
SAHB was the next-best inducer of MCL-1 stabilisation,
exhibiting a thermal shift of ~ 4 °C at a concentration of 10 μM
(Figure 3a). Interestingly, the BCL-XL ligand A-1331852
consistently destabilised MCL-1 protein at concentrations of
10 μM and above (Figure 3a). This effect was specific to
MCL-1 protein, and did not occur with any other proteins
tested. However, destabilisation also occurred with MCL-1
R263A, suggesting a nonspecific interaction elsewhere on
the MCL-1 protein (data not shown). In contrast, MCL-1
thermal shifts with A-1210477 and MCL-1 SAHB were both
concentration-dependent and completely abolished in MCL-1
R263A (Figure 3b and c). Finally, we directly measured the
affinity of the interaction between MCL-1 and A-1210477
using Microscale Thermophoresis (MST), which confirmed a
sub-micromolar Kd value of ~ 740 nM (Figure 3d). Taken
together, these data strongly suggest that A-1210477 is a
bona fide MCL-1 inhibitor in a cellular context (Figure 1b) and
represents the most potent MCL-1 ligand evaluated using our
thermal shift assay, with concentration-dependent ΔTm
values suggestive of high-affinity (nM) binding, corroborated
by MST analysis.24–26
A-1210477 synergises with a BCL-XL inhibitor to induce
the intrinsic apoptotic pathway. Next, we wished to
confirm whether A-1210477 could synergise with distinct
BH3 mimetics to induce apoptosis in cells that depend on
another BCL-2 family member, in addition to MCL-1.
Individual exposure of H1299 cells, which depend on both
MCL-1 and BCL-XL for survival,
27,28 to either A-1210477 or
A-1331852 (a specific BCL-XL inhibitor) had little effect on
apoptosis, whereas a combination of the two compounds
resulted in a marked induction of apoptosis (Figure 4a). This
was accompanied by a concomitant loss of the mitochondrial
membrane potential, activation and oligomerisation of BAK
and release of mitochondrial cytochrome c (Figures 4b–f).
A-1210477 induces DRP-1-mediated mitochondrial fission.
The exposure of H1299 cells to A-1210477 resulted in a highly
fragmented mitochondrial network, whereas the cells exposed
to A-1331852 retained normal mitochondrial structure
(Figure 4f). A-1210477-mediated mitochondrial fragmentation
was observed in multiple cancer cell lines (Figure 5a) but these
mitochondrial changes did not result in apoptosis (data not
shown). Interestingly, neither genetic MCL-1 silencing (RNA
interference) nor transcriptional MCL-1 repression (using the
CDK inhibitor dinaciclib) phenocopied A-1210477-mediated
mitochondrial fragmentation (Figure 5b), strongly suggesting
that these effects occurred in a MCL-1-independent manner.
As the length and continuity of the filamentous mitochondrial
network is regulated by specific fission and fusion proteins, we
speculated that A-1210477 may alter expression levels of
mitochondrial fission and/or fusion GTPases. However,
A-1210477-mediated mitochondrial fragmentation was not
accompanied by a loss of fusion proteins, such as MFN1 or
MFN2 and/or enhanced OPA1 proteolysis (Figure 5c), almost
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certainly excluding a fusion defect. In contrast, inactivation of
the fission protein, DRP-1 using either a siRNA or a dominant-
negative DRP-1 mutant (K38A) efficiently reduced mitochon-
drial fragmentation following A-1210477 exposure (Figure 5d),
confirming the absolute requirement of DRP-1 in A-1210477-
mediated mitochondrial fission.
DRP-1-is required for BH3 mimetic-mediated apoptosis.
Although A-1210477-mediated mitochondrial fragmentation
did not directly result in apoptosis, it remained possible that
such major structural alterations could sensitise cells to
apoptosis. Interestingly, downregulation of DRP-1 not only
prevented mitochondrial fragmentation but also markedly
reduced the extent of apoptosis, following exposure to the
combination of A-1210477 and A-1331852 (Figures 6a–c).
Silencing the dual expression of BCL-XL and MCL-1 resulted
in extensive apoptosis (Figure 6d), independent of any
mitochondrial fragmentation (data not shown). DRP-1 defi-
ciency also diminished apoptosis in these cells (Figure 6d)
suggesting that the protective effect of DRP-1 siRNA was
independent of mitochondrial fragmentation, and occurred
most likely due to its known effects on mitochondrial outer
membrane permeabilisation (MOMP; Figure 6e).29 Taken
together, these results strongly suggested that DRP-1 was
required both for BH3 mimetic-induced mitochondrial frag-
mentation as well as apoptosis.
Discussion
Several promising small molecule inhibitors reported to target
MCL-1 in vitro have been largely ineffective in a cellular
context.27 The failure to convert a ‘high-affinity’ (often reported
as nM) in vitro MCL-1 binding affinity into an enhanced
apoptosis phenotype in a physiological context might be partly
due to the lack of accessibility of the drugs at sites of action,
thus rendering it more difficult to treat solid tumours than
circulating B cells in lymphoidmalignancies. Alternatively, high
expression levels of additional BCL-2 family members in solid
tumours could result in functional target redundancy, raising
the prospects of a requirement for pan-BCL-2 family inhibition
as a therapeutic strategy. With the exception of A-1210477,
most of the other putative MCL-1 inhibitors tested here
induced cell death in a MCL-1-dependent cell line only after
prolonged cellular exposure (Figure 1b). This is in stark













































































































































Figure 2 Analysis of purified recombinant WTand R263A MCL-1 (E173-R329) proteins. (a) Modelled binding mode of NOXAB peptide engaged with MCL-1 BH3 domain
(PDB: 2JM6) with the critical Arg 263 side-chain highlighted. (b) SDS-PAGE and Coomassie blue staining of gel filtered, purified recombinant WT and R263A MCL-1 (2 μg)
proteins. (c) Circular dichroism spectra showing similar secondary structures of WT (red) and R263A (blue) MCL-1 (E173-R329) proteins. (d) TSA comparing thermal
denaturation (unfolding) profiles for WT (red) and R263A (blue) MCL-1 (E173-R329) proteins. (e) Validation of a MCL-1 TSA using synthetic BH3 peptides, demonstrating
concentration-dependent binding, characterised by a positive shift of change in the unfolding temperature (ΔTemperature). (f) BH3 profiling in H929 cells reveals an enhanced
loss in mitochondrial membrane potential (φm) following exposure to BIM, PUMA, NOXA and MS-1 peptides, consistent with their ability to bind to MCL-1. (g) ΔTemperature
(ΔTm) values for R263A MCL-1 confirms little, or no, detectable binding of MCL-1 to the indicated synthetic peptides. Mean ΔTm values± S.D. (n= 2) were calculated by
subtracting the control Tm value (buffer, no peptide) from the measured Tm value. The TSA graphs are plotted as duplicate data points (0.3 °C separation per point) and are
representative of a single experiment performed in duplicate, which was repeated at least three times
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other potent clinical BH3 mimetics, such as ABT-263 and
ABT-199.2,27,30 Indeed, the induction of cell death at these
later timesmight be attributed to either other indirect measures
of downregulating MCL-1 (such as transcriptional or transla-
tional repression and NOXA upregulation) or other off-target
effects associated with these inhibitors.27,31
In this study, we developed a novel DSF approach to
evaluate the effects of a panel of putative MCL-1 inhibitory
ligands, characterising A-1210477 as the only compound in
our panel that boundMCL-1 in a R263-dependent manner and
induced concentration-dependent apoptosis (Figures 1–3).
Although MCL-1 SAHB also bound MCL-1 rather specifically
(Figure 3), it was inefficient in inducing apoptosis in a cellular
context, either due to weak target engagement or weak cell
permeability. In contrast to most other putative inhibitors
tested, A-1210477 also readily perturbed the thermal-induced
unfolding of MCL-1 at concentrations consistent with high-
affinity binding to MCL-1 (Figure 3), providing strong support
for the exploitation of this assay for the identification and
benchmarking of other MCL-1 ligands. We believe that this
simple and rapidmethod could readily be exploited to compare
and contrast both potency and mechanistic aspects of
compound binding for MCL-1, circumventing issues
associated with data comparison and poor reliability
demonstrated for more complex fluorescence assays
(most of which involve FRETor FP).
Indeed, there is now an urgent need for specific and potent
small molecule inhibitors of MCL-1 that efficiently target
cancer cells while sparing physiological cellular functions of
MCL-1. While this manuscript was in preparation, a new
single-digit nanomolar MCL-1 inhibitor, S63845, which
induces rapid apoptosis in MCL-1-dependent cells, was
reported.32 It will be interesting to assess whether S63845
exhibits mitochondrial structural changes similar to those
observed with A-1210477. Nonetheless, of all the compounds
tested in the current study, only A-1210477 was prominent in
terms of MCL-1 binding in DSF assay and rapid induction of
apoptosis in cellular assays. However, A-1210477 still
requires micromolar concentrations in a cellular context to
exert apoptotic effects, and is predicted to lack the potency for
in vivo efficacy, where nanomolar compounds are likely to be a
prerequisite. The discovery of high-affinity compounds such
as S63845 that reportedly possess this higher cellular
efficacy in tumour models might help alleviate this issue in
the clinic.
Materials and Methods
Cell culture. The H929 cells from ECACC (Salisbury, UK), H23 and H1299 cells
from ATCC (Middlesex, UK) were cultured in RPMI 1640 medium supplemented
with 10% fetal calf serum (FCS) from Life Technologies, Inc., (Paisley, UK). HeLa
and MCF7 from ATCC were cultured in DMEM medium supplemented with 10%
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Figure 3 Inhibitor screening using differential scanning fluorimetry (DSF) reveals that A-1210477, but not other BH3 mimetics, exhibit marked MCL-1 binding and thermal
stabilisation. (a) MCL-1 TSA screen of BH3 mimetics evaluated in the study reveals marked stabilisation of MCL-1 by A-1210477 and MCL-1 SAHB. In contrast, A-1331852
exhibits a negative perturbation (destabilisation) in thermal stability, possibly suggesting either nonspecific binding or an unusual binding mode to MCL-1. (b) A-1210477 exhibits a
concentration-dependent increase in MCL-1 stabilisation. (c) A-1210477 and MCL-1 SAHB exhibit concentration-dependent binding to WT but not R263A MCL-1. (d) MCL-1
protein (173–329) was covalently labelled with the fluorescent red dye NT-647 and binding to A-1210477 analysed using microscale thermophoresis. The TSA graphs are plotted
as duplicate data points (0.3 °C separation per point) and are representative of a single experiment performed in duplicate, which was repeated at least three times
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BCL-2 family inhibitors. ABT-737, ABT-263, ABT-199, A-1331852 and
A-1210477 were kindly provided by AbbVie Inc. (North Chicago, IL, USA).
Compounds 10, 20, 21, 22, 36, 37 and 41 were provided by Dr. Z Nikolovska-
Coleska (University of Michigan, Ann Arbor, MI, USA).8 Compound 9 was custom-
synthesised and purchased from Molport (Riga, Latvia).6 MIM-1 and the stapled
peptides against MCL-1 and NOXA were kindly provided by Dr. L Walensky (Dana-
Farber Cancer Institute, Boston, MA, USA).7,16 Maritoclax was provided by Professor
H-G Wang (Pennsylvania State University College of Medicine, Hershey, PA, USA).10
Apogossypol, Sabutoclax and BI112D1 were provided by Professor M. Pellecchia
(Sanford-Burnham Institute, La Jolla, CA, USA).11,12 Gossypol, Obatoclax and
TW-37 were obtained from Selleck Chemicals Co. (Houston, TX, USA).
Reagents and plasmids. Peptides for BIM (MRPEIWIAQELRRIGDEFNA),
BID (EDIIRNIARHLAQVGDSMDRY), NOXA (AELPPEFAAQ LRKIGDKVYC), PUMA
(EQWAREIGAQLRRMADDLNA), HRK (WSSAAQLTAARLKALGDE LHQ), MS-1
(RPEIWMTQGLRRLGDEINAYYAR), BAD (LWAAQRYGRELRRMSDEFEGSFKGL)
and PUMA-2 A (EQWAREIGAQARRMAADLNA) were from New England Peptide
(Gardner, MA, USA) or GenScript (Piscataway, NJ, USA). Antibodies against
MCL-1, BAK and GAPDH from Santa Cruz Biotechnology (Santa Cruz, CA, USA);
OPA1, DRP-1, HSP60 and Cytochrome C from BD Biosciences (Oxford, UK);
Tubulin, MFN1, MFN2, Caspase-3, MCL-1 (RC-13) from Abcam (Cambridge, UK);
BAK (Ab-1) from Merck Chemicals Ltd (Nottingham, UK) were used. For bacterial
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Figure 4 Inhibition of both BCL-XL and MCL-1 is required to release mitochondrial cytochrome c in H1299 cells. (a) H1299 cells were exposed to A-1210477 (10 μM),
A-1331852 (100 nM) or both compounds. Only the combined treatment lead to a time-dependent increase in apoptosis, as assessed by (a) PS externalisation, (b) mitochondrial
depolarisation, (c) BAK activation, (d) BAK oligomerisation and (e and f) mitochondrial cytochrome c release. For cytochrome c release, the cells were immunostained with
cytochrome c antibody (scale bar, 10 μm) and ~ 100 cells for each treatment in three independent experiments were quantified for the loss of mitochondrial cytochrome c.
Statistical analysis was conducted using one-way ANOVA and P-values depicted as *P⩽ 0.05 and ***P⩽ 0.001
Interplay of DRP-1 and BCL-2 family members in apoptosis
M Milani et al
6
Cell Death and Disease
amino acids E173- R329 was amplified using the primer sets, 5′-AAGTTCTG
TTTCAGGGCCCGGAGTTGTACCGGCAGTCG-3′ and 5′-ATGGTCTAGAAAGCTTT
ACCTGATGCCACCTTCTAGGTC-3′ and cloned into pOPIN F (OPPF-UK, Oxford,
UK) to generate N-terminally His6-tag fusion protein. This was used as a template
to generate the R263A mutant using site-directed mutagenesis with the primer sets,
5′-CGTAACAAACTGGGGCGCGATTGTGACTCTC-3′ and 5′-GAGAGTCACAATCG
CGCCCCAGTTTGTTACG-3′. GFP-DRP-1 K38A plasmid was described
previously.33 All other reagents, unless mentioned otherwise, were from Sigma-
Aldrich Co. (St. Louis, MO, USA).
Protein purification. WT MCL-1 fusion protein (N-terminal His6-tag fused to
amino acids Glu173-Arg329, containing the BH3, BH1 and BH2 domains) and an
R263A substitution in the WGRIV motif found in the MCL-1 BH1 domain were
produced in BL21 (DE3) pLysS E. coli cells (Novagen, Nottingham, UK), induced
with 0.4 mM IPTG for 18 h at 18 °C and purified by immobilised metal affinity
chromatography (IMAC) using Ni-NTA agarose (Qiagen, Manchester, UK) and size
exclusion chromatography using a HiLoad 16/600 Superdex 200 column (GE
Healthcare, Chicago, IL, USA), equilibrated in 50 mM Tris HCl, pH 7.4, 100 mM
NaCl, 10 % (v/v) glycerol and 1 mM DTT. Secondary structure compositions of WT
and R263A MCL-1 proteins (0.9 mg/ml) were analysed by circular dichroism in the
far UV range (180–260 nm) using a Jasco 1100 CD spectrometer with a path length
of 0.1 cm, following buffer exchange into 10 mM sodium phosphate (pH 7.4) and
25 mM NaF.
DSF assays. Thermal shift assays (TSA) were performed using a StepOnePlus
Real-Time PCR machine (Life Technologies, Paisley, UK) using Sypro-Orange dye
(Invitrogen, Paisley, UK). Thermal ramping (0.3 °C per min between 25 and 94 °C)
was used to generate thermal denaturation curves for purified MCL-1 proteins
(10 μM) in the presence or absence of the indicated concentrations of ligand (final
DMSO concentration 4% v/v). Data were processed using the Boltzmann equation
to generate sigmoidal denaturation curves, and average Tm/ΔTm values calculated
as previously described,26 using GraphPad Prism software.
Microscale thermophoresis. MCL-1 protein (173–329) was covalently
labelled with the fluorescent red dye NT-647, which reacts with primary amines
present on MCL-1 Lys residues to form a stable dye–protein conjugate before
analysis. The concentration of MCL-1 was kept constant in the assay and the
concentration of the unlabelled A-1210477 ligand diluted in buffer was varied
between 6 nM and 200 μM. The assay was performed after loading into capilliaries
25 mM HEPES, pH 7.4 containing 0.05% Tween-20. MST analysis was performed
using the Monolith NT.115 instrument and data were plotted using Monolith
software.
BH3 profiling and flow cytometry. BH3 profiling was carried out as
previously described.34 In brief, the cells were permeabilised with digitonin
(0.002 %) in DTEB buffer (10 mM HEPES, 135 mM Trehalose, 20 μM EDTA, 20 μM
EGTA, 5 mM succinic acid, 0.1 % BSA, 50 mM potassium chloride, pH 7.5)
containing oligomycin (10 μg/ml) and incubated for 2 h with varying concentrations
of BH3 peptides. The loss of mitochondrial membrane potential (φm) was measured
by observing the loss of TMRE (200 nM) using an Attune NxT flow cytometer
(ThermoFisher Scientific, Paisley, UK). The extent of apoptosis in cells following
different treatments was quantified by FACS following staining of the cells with
Annexin V-FITC and propidium iodide to measure phosphatidylserine externalisa-
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Figure 5 A-1210477 induces extensive mitochondrial fragmentation in a DRP-1-dependent manner. (a) H23, HeLa and MCF7 cells exposed to A-1210477 (10 μM) for 2 h
resulted in extensive mitochondrial fragmentation, as assessed by immunostaining with HSP60 antibody (scale bar, 10 μm). (b) H1299 cells were either transfected with control
siRNA, two different MCL-1 siRNAs for 72 h or exposed to Dinacilib (30 nM) for 4 h and assessed for mitochondrial integrity by immunostaining with HSP60 antibody (scale bar,
10 μm). The blots show knockdown efficiency of MCL-1 siRNAs and downregulation of MCL-1 by Dinaciclib. (c) Western blot of H1299 cells exposed to A-1210477 (10 μM) for
the indicated times revealed no major changes in total expression levels of mitochondrial fission or fusion proteins. Tubulin was used as a loading control. (d) H1299 cells were
either transfected with control siRNA, DRP-1 siRNA or GFP-DRP-1 K38A plasmid, then exposed to A-1210477 (10 μM) for 2 h and the decrease in the extent of mitochondrial
fragmentation was quantified by assessing ~ 100 cells from each treatment in three independent experiments (scale bar, 10 μm). Statistical analysis was conducted using one-
way ANOVA (***P⩽ 0.001). The blots show the knockdown efficiency of DRP-1 siRNA and the overexpression of GFP-DRP-1 K38A (denoted by*)
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with Z-VAD(OMe).fmk (Selleck Chemicals) for 30 min were exposed to the indicated
drugs, fixed in 1 % (w/v) paraformaldehyde and stained with conformation-specific
AP-1 BAK antibody (1 μg/ml), corresponding fluorophore- conjugated secondary
antibody and quantified by FACS.
siRNA knockdowns. For transient transfections, the cells were transfected
using TransIT-LT-1 transfection reagent (Mirus Bio LLC, Madison, WI, USA) and left
for 48 h, according to the manufacturer's instructions. For siRNA knockdowns, the
cells were transfected for 72 h with DRP-1 siRNA (S104274235; Qiagen), MCL-1
siRNA (s8585; Ambion and SI02781205; Qiagen) or BCL-XL siRNA (s1920;
Ambion) using Interferin Reagent (Polyplus transfection Inc, NY, USA), according to
the manufacturer's protocol.
Gel filtration and western blotting. For gel filtration experiments, the cells
were lysed in CHAPS lysis buffer containing 1 % CHAPS, 20 mM Tris HCl (pH 8),
150 mM NaCl, 20 μM MG132 and protease inhibitor cocktail, incubated on ice for
30 mins, and centrifuged at 14 000 × g for 3 min at 4 °C. The pellet was discarded
and supernatant (500 μl; 25 mg of protein per ml) was injected onto both Superose
6 and Superdex S200 size exclusion columns (GE Healthcare) and eluted using a
running buffer containing 50 mM Tris HCl (pH 8), 150 mM KCl, 1 mM EDTA,
5 % glycerol, 1 mM DTTand 1 mM PMSF. 500 μl fractions eluted from the columns
were collected for immunoblotting. Western blotting was carried out according
to standard protocols. Briefly, 50 μg of total protein lysate was subjected to
SDS-PAGE electrophoresis. Subsequently proteins were transferred to nitrocellulose
membrane and protein bands visualised with ECL reagents (GE Healthcare).
Microscopy. Bright-field microscopy of cells was performed using EVOS FLOID
cell imaging station (ThermoFisher Scientific). For immunofluorescent staining, the
cells grown on coverslips were fixed with 4 % (w/v) paraformaldehyde,
permeabilised with 0.5 % (v/v) Triton X-100 in PBS and followed by incubations
with primary antibodies, the appropriate fluorophore-conjugated secondary
antibodies, mounted on glass slides and imaged using a 3i Marianas spinning
disk confocal microscope, fitted with a Plan-Apochromat × 63/1.4 NA Oil Objective,
M27 and a Hamamatsu ORCA-Flash4.0 v2 sCMOS Camera (all from Intelligent
Imaging Innovations, GmbH, Gottingen, Germany).
Statistical analysis. For time-course studies, a two-way ANOVA was
performed and other studies were analysed for statistical significance with one-
way ANOVA and the asterisks depicted correspond to the following P-values:
*P⩽ 0.05, **P⩽ 0.005 and ***P⩽ 0.001.
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Figure 6 BH3 mimetics induce apoptosis in a DRP-1-dependent manner. (a) H1299 cells, transfected with DRP-1 siRNA and exposed to a combination of A-1210477
(10 μM) and A-1331852 (100 nM) demonstrate a marked decrease in apoptosis at 4 and 24 h. Statistical analysis was conducted using one-way ANOVA (**Po0.005,
***P⩽ 0.001). (b) Bright-field microscopy of H1299 cells transfected with control or DRP-1 siRNA and treated with A-1210477 (10 μM) and A-1331852 (100 nM) for 4 h reveals
the extent of DRP-1-dependent cell death (scale bar, 30 μm). (c) Immunoblots showing the knockdown efficiency of DRP-1 siRNA as well as its anti-apoptotic effects, as evident
from the decrease in the processing of pro-caspase-3 following DRP-1 downregulation. (d) H1299 cells were transfected with siRNAs against both BCL-XL and MCL-1 in the
absence or presence (Triple si) of DRP-1 siRNA for 36 h and the extent of apoptosis assessed by PS externalisation. Blots showing the knockdown efficiency of the siRNAs and
the anti-apoptotic effects associated with DRP-1 deficiency, as evident from the decrease in the processing of the caspase substrate, PARP. Statistical analysis was conducted
using one-way ANOVA (***P⩽ 0.001). (e) Scheme representing the distinct functions of A-1210477 in apoptosis induction (by releasing BH3-only members from the hydrophobic
groove and causing mitochondrial outer membrane permeabilisation; MOMP) as well as increased mitochondrial fission in a DRP-1 dependent manner
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DRP-1 functions independently of
mitochondrial structural perturbations to
facilitate BH3 mimetic-mediated apoptosis
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Abstract
Maintenance of mitochondrial integrity is critical for normal cellular homoeostasis. Most cells respond to stress stimuli
and undergo apoptosis by perturbing mitochondrial structure and function to release proteins, such as cytochrome c,
which are essential for the execution of the intrinsic apoptotic cascade. Cancer cells evade these events by
overexpressing the anti-apoptotic BCL-2 family of proteins on mitochondrial membranes. Inhibitors of the anti-
apoptotic BCL-2 family proteins, also known as BH3 mimetics, antagonise the pro-survival functions of these proteins
and result in rapid apoptosis. Although the precise mechanism by which BH3 mimetics induce apoptosis has been
well characterised, not much is known in terms of the structural changes that occur in mitochondria during apoptosis.
Using a panel of highly selective BH3 mimetics and a wide range of cell lines, we demonstrate that BH3 mimetics
induce extensive mitochondrial fission, accompanied by swelling of the mitochondrial matrix and rupture of the outer
mitochondrial membrane. These changes occur in a BAX/ BAK-dependent manner. Although a major mitochondrial
fission GTPase, DRP-1, has been implicated in mitochondrial apoptosis, our data demonstrate that DRP-1 might
function independently/downstream of BH3 mimetic-mediated mitochondrial fission to facilitate the release of
cytochrome c and apoptosis. Moreover, downregulation of DRP-1 prevented cytochrome c release and apoptosis even
when OPA1, a protein mediating mitochondrial fusion, was silenced. Although BH3 mimetic-mediated displacement
of BAK and other BH3-only proteins from BCL-XL and MCL-1 was unaffected by DRP-1 downregulation, it prevented
BAK activation significantly, thus placing DRP-1 as one of the most critical players, along with BAX and BAK, that
governs BH3 mimetic-mediated cytochrome c release and apoptosis.
Introduction
Most chemotherapeutic agents kill cancer cells by
executing the intrinsic apoptotic pathway, which is char-
acterised by mitochondrial outer membrane permeabili-
zation (MOMP), release of cytochrome c from the inner
mitochondrial membrane (IMM) and formation of the
apoptosome that activates the initiator and effector cas-
pases. MOMP is regulated by the BCL-2 family, whereby
BAX and BAK, undergo specific conformational changes
to form oligomeric pores that insert into the outer
mitochondrial membrane (OMM) to release cytochrome
c1,2. Activation of BAX and BAK is achieved by several
pro-apoptotic BH3-only members, which are generally
rendered ineffective by sequestration with specific anti-
apoptotic BCL-2 family of proteins, such as BCL-2, BCL-
XL and MCL-1
3,4. These anti-apoptotic proteins are
highly expressed in many cancers and inhibitors known as
BH3 mimetics have been designed to target them in order
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to displace the BH3-only proteins, activate BAX and BAK,
thereby inducing MOMP and apoptosis of cancer cells5.
ABT-737, and its orally available analogue, ABT-263
(Navitoclax) were the first bona fide BH3 mimetics
developed to target BCL-2, BCL-XL and BCL-w
6,7. Sub-
sequently, BH3 mimetics that specifically target BCL-2
(ABT-199 (Venetoclax), S55746), BCL-XL (A-1331852)
and MCL-1 (A-1210477, S63845, AMG 176 and
AZD5991) have been synthesised8–14. These inhibitors, as
single agents, have demonstrated much promise in treat-
ing a wide variety of haematological malignancies, and
have had limited success in combination with conven-
tional chemotherapy against several solid tumours8,12–17.
BH3 mimetics induce apoptosis primarily by targeting
protein–protein interactions between the anti- and pro-
apoptotic BCL-2 family members18. Subsequently, BH3
mimetics have been shown to induce significant structural
changes in the mitochondria, ranging from mitochondrial
matrix swelling to discontinuities in the OMM, upstream
of caspase activation19,20. Furthermore, BAX and BAK
localise to the breakpoints in OMM and may facilitate
cytochrome c release at such breakpoints19. Although
BCL-2 family members have been implicated in regulating
mitochondrial membrane dynamics and functions21–24,
putative inhibitors of MCL-1 have often resulted in
extensive mitochondrial fission in various cell lines25–27.
The regulation of this fission and its relationship to BH3
mimetic-mediated apoptosis remains to be determined.
Mitochondrial structure is maintained through an
intricate balance between the activities of several fusion
and fission proteins, which belong to a conserved family
of GTPases that reside in the OMM or IMM. Mitofusins 1
and 2 (MFN1/ 2) and optic atrophy 1 (OPA1) are essential
for mitochondrial fusion, whereas dynamin related pro-
tein 1 (DRP-1) is essential for mitochondrial fission28.
Defects in mitochondrial fusion and fission have been
implicated in a range of pathophysiological conditions
including poor brain development, optic atrophy, cardi-
omyopathy and neurodegenerative diseases29,30. Mount-
ing evidence now suggests the involvement of several
members of BCL-2 family members, particularly MCL-1,
in the regulation of mitochondrial structure and func-
tion22–25,29. However, the mechanism by which MCL-1
regulates mitochondrial membrane dynamics and the
potential cross-talk with its conventional role in antag-
onising apoptosis remain to be characterised.
In this study, we use a panel of highly selective BH3
mimetics together with cell lines that depend on specific
BCL-2 family members for survival to demonstrate that
BH3 mimetics induce significant ultrastructural mito-
chondrial changes upstream of caspase activation. DRP-1
plays a role downstream of these changes but upstream of
MOMP to facilitate cytochrome c release and apoptosis,
following exposure to BH3 mimetics.
Results
BH3 mimetics induce marked mitochondrial structural
changes
Previously, we have reported that BH3 mimetics induce
a novel paradigm of apoptosis characterised by marked
ultrastructural changes in the mitochondria, involving the
loss of mitochondrial cristae and the appearance of breaks
in the OMM, resulting from mitochondrial matrix swel-
ling19,20,31. In cell lines that depend for survival almost
exclusively on BCL-2 (MAVER-1), BCL-XL-(K562) and
MCL-1 (H929)32, exposure to the relevant BH3 mimetics,
such as ABT-199, A-1331852 and A-1210477, respec-
tively, resulted in similar mitochondrial matrix swelling
and rupture of the OMM (Fig. 1a–c). Such mitochondrial
changes were also evident in H1299 cells following
exposure to a combination of A-1331852 and A-1210477,
as these cells depend on both BCL-XL and MCL-1 for
survival (Fig. 1d). These mitochondrial ultrastructural
changes were independent of effector caspases, as they
were observed in cells pre-treated with Z-VAD.fmk, a
broad-spectrum caspase inhibitor (Fig. 1). Exposure of the
different cells to their appropriate BH3 mimetic resulted
in mitochondrial membrane depolarisation, loss of cyto-
chrome c and induction of apoptosis, as assessed by
phosphatidylserine externalisation (Supplementary Fig.
S1). Exposure of the cells to Z-VAD.fmk almost com-
pletely inhibited BH3 mimetic-mediated apoptosis,
assessed by PS externalisation, whereas little if any inhi-
bition of cytochrome c release was observed (Supple-
mentary Fig. S1). Taken together these results suggested
that the mitochondrial structural changes occurred
upstream of effector caspase activation and accompanied
cytochrome c release, as well as a loss of mitochondrial
membrane potential.
BH3 mimetic-mediated mitochondrial perturbations occur
in a BAX/BAK-dependent manner
To assess whether BAX and BAK play crucial roles in
BH3 mimetic-mediated ultrastructural changes in mito-
chondria, we exposed HCT-116 WT and BAX/BAK
double knock-out (DKO) cells to a combination of A-
1331852 and A-1210477, as HCT-116 cells also depend
on both BCL-XL and MCL-1 for survival
33. Exposure of
the HCT-116 WT cells to the BH3 mimetics resulted in
significant mitochondrial matrix swelling accompanied by
a loss of mitochondrial cristae, although rupture of the
OMM was not readily apparent (Fig. 2). However, all
these mitochondrial changes were clearly prevented in the
HCT-116 BAX/BAK DKO cells, demonstrating a
requirement for BAX and/or BAK for the perturbation of
the mitochondria. Since BH3-only members are generally
required to activate BAX and BAK, we wished to assess
whether BH3 mimetics could induce mitochondrial
structural perturbations in the absence of all known pro-
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Fig. 2 BH3 mimetics disrupt mitochondria in a BAX- and BAK-dependent but BH3-independent manner. HCT-116 WT, DKO (BAX/BAK
deficient) and OctaKO cells were exposed to Z-VAD.fmk (30 µM) for 0.5 h, followed by a combination of A-1331852 (100 nM) and A-1210477 (10 µM)
for 4 h and assessed for mitochondrial structural changes by electron microscopy. Scale bars: 500 nm
Fig. 1 BH3 mimetics induce marked ultrastructural changes in mitochondria of different cells. a MAVER-1, b K562, c H929 and d H1299 cells
were exposed to Z-VAD.fmk (30 µM) for 0.5 h, followed by ABT-199 (100 nM), A-1331852 (100 nM), A-1210477 (10 µM), or a combination of A-1331852
(100 nM) and A-1210477 (10 µM), respectively, for 4 h and assessed for mitochondrial structural changes by electron microscopy. Yellow arrowheads
indicate regions of breaks at the outer mitochondrial membrane. Scale bars: 500 nm
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apoptotic BH3-only members. For this, we used HCT-116
OctaKO cells, which lack the BH3-only members namely,
BIM, BID, PUMA, BAD, BIK, HRK, BMF and NOXA33.
Exposure of these cells to a combination of A-1331852
and A-1210477 resulted in mitochondrial structural
changes, characteristic of significant cristae remodelling
(Fig. 2). However, the swelling of mitochondrial matrix
and the accompanying loss of cristae observed in the
HCT-116 WT cells following BH3 mimetics were not
apparent in HCT-116 OctaKO cells (Fig. 2). This is con-
sistent with earlier findings demonstrating that the pro-
apoptotic BH3-only members are dispensable for BH3
mimetic-mediated apoptosis34. Taken together, our data
demonstrated that the activation of BAX and/or BAK,
either in a BH3-dependent or independent manner, is
essential for the ultrastructural changes observed in the
mitochondria, following exposure to BH3 mimetics.
DRP-1 is not required for the mitochondrial structural
changes that occur during the onset of apoptosis
We previously reported that putative inhibitors of
MCL-1 induced extensive mitochondrial fission and
suggested that this could be a prerequisite for the ensuing
apoptosis in MCL-1-dependent cell lines25–27. In support
of this suggestion, exposure of A-1210477 but not A-
1331852 resulted in extensive mitochondrial fission that
resembled mitochondrial fragmentation in H1299 cells
(Fig. 3a, Supplementary Fig. S2). The ability of A-1210477
to induce mitochondrial fission was also clearly evident
when used in combination with A-1331852 to induce
apoptosis in these cells (Fig. 3a, Supplementary Fig. S2).
However, mitochondria in this instance appeared swollen,
potentially indicating swollen matrix and loss of cristae
that were previously observed at the level of electron
microscopy (compare Figs. 1d and 3a). In marked con-
trast, S63845 at a concentration (100 nM) sufficient to
induce apoptosis in a MCL-1-dependent manner34 failed
to demonstrate mitochondrial fission (Fig. 3a, Supple-
mentary Fig. S2). However, S63845 (100 nM) when used
in conjunction with A-1331852 resulted in mitochondrial
structural changes that resembled the swollen mito-
chondria observed following a combination of A-1210477
and A-1331852 (Fig. 3a, Supplementary Fig. S2). Taken
together, our results suggested that mitochondrial fission
DMSO                          A-1331852                       A-1210477             A-1331852+A-1210477               S63845                  A-1331852+S63845
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Fig. 3 Mitochondrial fission mediated by A-1210477 and S63845 occurs in a DRP-1-dependent manner. a H1299 cells were exposed to Z-
VAD.fmk (30 µM) for 0.5 h, followed by either A-1331852 (100 nM), A-1210477 (10 µM), S63845 (100 nM), or a combination of the different inhibitors
for 4 h and assessed for mitochondrial integrity by immunostaining with HSP70 antibody. b H1299 cells were transfected with control or DRP-1 siRNA
for 72 h and exposed to A-1210477 (10 µM) or S63845 (1 and 10 µM) for 4 h and assessed for mitochondrial integrity. The extent of mitochondrial
fragmentation was quantified by analysing ~100 cells for each condition in three independent experiments. Scale bar: 10 µm. Error bars=mean ±
SEM. Statistical analysis was conducted by one-way ANOVA (***P ≤ 0.001)
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mediated by A-1210477 versus a combination of MCL-1
and BCL-XL inhibitors was distinct. Moreover, while
S63845 failed to exhibit mitochondrial fission at low
concentrations (100–1000 nM), higher concentrations
(10 μM) of S63845 resulted in significant mitochondrial
fission, which mimicked A-1210477-mediated mitochon-
drial fragmentation (Fig. 3b).
We previously reported that A-1210477-mediated
mitochondrial fission occurred in a DRP-1-dependent
manner27. A similar dependence on DRP-1 was also
observed in cells exhibiting extensive mitochondrial fis-
sion, following exposure to high concentrations of S63845
(Fig. 3b). Thus both the MCL-1 inhibitors, A-1210477 and
S63845, induced mitochondrial fission, which was clearly
dependent on DRP-1 (Fig. 3b). We wished to assess if
such mitochondrial fission was a prerequisite for apop-
tosis induction. Since H1299 cells depend on both BCL-
XL and MCL-1 for survival, we exposed cells to either A-
1210477 or A-1331852 and simultaneously silenced the
expression levels of either BCL-XL or MCL-1 to facilitate
apoptosis. Although downregulation of BCL-XL or MCL-
1 did not result in mitochondrial fission and maintained
the filamentous structure, exposure of the cells to A-
1210477 resulted in significant mitochondrial fission,
which resembled fragmented mitochondria (Fig. 4a–d,
Supplementary Fig. S3). In the MCL-1-downregulated
cells, A-1210477 still retained its ability to cause mito-
chondrial fragmentation (Fig. 4e), but when BCL-XL was
downregulated, A-1210477 resulted in mitochondrial
structural changes that resembled matrix swelling (Fig. 4f,
Supplementary Fig. S3), as previously described (Fig. 1d).
In contrast, exposure to A-1331852 only resulted in
similar mitochondrial swelling when MCL-1 was also
downregulated (Fig. 4g–I, Supplementary Fig. S3). These
results suggested that mitochondrial fission, mediated by
MCL-1 inhibitors, appeared to exhibit a distinct mor-
phology from that observed following the induction of
apoptosis. This was more apparent following DRP-1
downregulation, which prevented A-1210477-mediated
mitochondrial fission (Fig. 4m, n), but did not appear to
alter mitochondrial swelling observed during apoptosis
induction (Fig. 4o, q, Supplementary Fig. S3). Taken
together, these results exclude an involvement of DRP-1
in the early mitochondrial structural changes including
mitochondrial swelling associated with the onset of
apoptosis (Fig. 4).
Consistent with the above hypothesis, electron micro-
graphs revealed marked structural alterations of the
mitochondria in cells exposed to both A-121077 and A-
1331852, characterised by breaks in the OMM (denoted
by the yellow arrowheads), mitochondrial matrix swelling
and a concomitant loss of cristae (Fig. 5a). Down-
regulation of DRP-1 alone resulted in elongated mito-
chondria, consistent with its known role in mitochondrial
fission (Fig. 5a). However, the mitochondria in the DRP-1-
downregulated cells following exposure to BH3 mimetics
Fig. 4 DRP-1 is not required for mitochondrial fission during BH3 mimetic-mediated apoptosis. H1299 cells were transfected with control,
MCL-1, or BCL-XL siRNAs, either alone or in combination with DRP-1 siRNA for 72 h, then exposed to Z-VAD.fmk (30 µM) for 0.5 h, followed by A-
1210477 (10 µM) and/or A-1331852 (100 nM) for 4 h and assessed for mitochondrial integrity by immunostaining with HSP70 antibody. The boxed
regions in the images are enlarged to show mitochondrial structural changes in the indicated cells. Scale bar: 10 µm
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appeared visibly swollen with intact cristae and few if any
breaks in the OMM (Fig. 5a). Taken together, our data
suggested that mitochondrial fission observed following
exposure to MCL-1 inhibitors was distinct from the
structural perturbations (characterised by OMM breaks
and IMM swelling) observed as a result of apoptosis
induction.
DRP-1 is critical for the release of cytochrome c from
mitochondria during apoptosis
Permeabilisation of the OMM, otherwise known as
MOMP, occurs as a consequence of BAX and/or BAK
oligomerization and is generally accompanied by the
release of mitochondrial cytochrome c into the cytosol.
Exposure of cells to a combination of A-1210477 and A-
1331852 resulted in an almost complete release of mito-
chondrial cytochrome c into the cytosol (Fig. 5b, c). This
was markedly inhibited in cells, following inactivation of
DRP-1 using siRNA or overexpression of the DRP-1 K38A
plasmid (Fig. 5b, c), thus placing DRP-1 upstream of
cytochrome c release. While cytochrome c was still
retained in mitochondria following DRP-1 down-
regulation, mitochondria in these cells appeared swollen
(Fig. 5b), consistent with those observed in the electron
micrographs (Fig. 5a). As cytochrome c release occurs as a
consequence of mitochondrial cristae remodelling35,
exposure to BH3 mimetics not only resulted in the release































































































































































































Fig. 5 DRP-1 regulates BH3 mimetic-induced cytochrome c release and apoptosis downstream of mitochondrial cristae remodelling. a
Electron microscopy of H1299 cells, transfected with DRP-1 siRNA for 72 h in the presence or absence of the indicated BH3 mimetics for 2 h. Breaks in
the outer mitochondrial membrane are indicated by the yellow arrowhead. Scale bars= 10 nm. b H1299 cells were transfected with DRP-1 siRNA or
GFP-DRP-1 K38A plasmid for 72 h, exposed to Z-VAD.fmk (30 µM) for 0.5 h, followed by a combination of A-1331852 (100 nM) and A-1210477 (10 µM)
for 4 h and the extent of cytochrome c released from mitochondria assessed by confocal microscopy. The boxed regions in the images are enlarged
to show mitochondrial structural changes in the indicated cells. The extent of cytochrome c release was quantified by counting at least 100 cells from
three independent experiments. c Same as b, but the extent of cytochrome c release as well as OPA1 processing and the silencing efficiency of DRP-
1 siRNA were analysed by western blotting. d H1299 cells were transfected with the indicated siRNAs for 72 h, treated as described in b and the
extent of cytochrome c release assessed and quantified. The extent of cytochrome c release was quantified by counting at least 100 cells from three
independent experiments. e Same as d but the cells were exposed to BH3 mimetics in the absence of Z-VAD.fmk and the extent of apoptosis
assessed by PS externalisation from at least three independent experiments. All scale bars, unless indicated: 10 µm. Error bars=mean ± SEM.
Statistical analysis was conducted by one-way ANOVA (***P ≤ 0.001)
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the high molecular weight isoforms of OPA1, character-
istic of mitochondrial cristae remodelling (Fig. 5c). While
downregulation of DRP-1 markedly diminished BH3
mimetic-mediated release of cytochrome c, it did not
prevent BH3 mimetic-mediated loss of OPA1 (Fig. 5c),
thus placing DRP-1 upstream of cytochrome c release but
downstream of mitochondrial cristae remodelling. This
was further confirmed following exposure of DRP-1 and/
or OPA1-downregulated cells to BH3 mimetics. While
downregulation of OPA1 resulted in significant mito-
chondrial fission, as well as a near-complete release of
cytochrome c following BH3 mimetics, a simultaneous
downregulation of DRP-1 diminished these effects (Fig.
5d). Similarly downregulation of DRP-1 prevented BH3
mimetic-induced apoptosis, even in the absence of OPA1
(Fig. 5e), thus placing DRP-1 downstream of OPA1 pro-
teolysis but upstream of cytochrome c release in BH3
mimetic-mediated apoptosis.
DRP-1 is critical for BAK activation during BH3 mimetic-
mediated apoptosis
Our results indicated that BH3 mimetics could induce
structural perturbations in the mitochondria, char-
acterised by OPA1 proteolysis, cristae remodelling and the
accompanying redistribution of cytochrome c from cristae
to mitochondrial inner membrane space, all irrespective of
the presence or absence of DRP-1. Since the role of DRP-1
was placed upstream of cytochrome c release, we wished
to assess whether DRP-1 impacted on any upstream events
during BH3 mimetic-mediated apoptosis. The primary
function of BH3 mimetics is to disrupt the protein–protein
interactions between the anti-apoptotic (BCL-XL and
MCL-1, in this instance) and pro-apoptotic members of
the BCL-2 family. The released pro-apoptotic proteins
could then activate the effector proteins (BAK, in H1299
as these cells lack BAX) to oligomerise on mitochondrial
membranes to subsequently release cytochrome c (Fig. 6a).
Fig. 6 DRP-1 regulates BH3 mimetic-induced activation of BAK. a Scheme demonstrating the primary mechanism of action of BH3 mimetics and
the downstream events that culminate in apoptosis. b Immunoprecipitation of BCL-XL and MCL-1 was carried out in H1299 cells, transfected with
control or DRP-1 siRNA, followed by exposure to Z-VAD.fmk (30 µM) for 0.5 h and a combination of A-1331852 (100 nM) and A-1210477 (10 µM) for
4 h, and the eluted complexes were immunoblotted for the indicated proteins. c H1299 cells were treated as b and the extent of BAK activation was
assessed by flow cytometry from at least three independent experiments. Error bars=mean ± SEM. Statistical analysis was conducted by one-way
ANOVA (***P ≤ 0.001). d Western blots of different molecular weight fractions from size exclusion chromatography showing BAK oligomerisation in
H1299 cells upon exposure to A-1331852 (100 nM) and A-1210477 (10 µM) for 2 h. e Immunoprecipitation of active BAK in H1299 cells treated as b,
and the eluted complexes were immunoblotted for the indicated proteins. f Representative images of cells showing BAK activation and DRP-1
distribution in H1299 cells treated as b. Scale bar: 10 µm
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Immunoprecipitation of BCL-XL and MCL-1 to identify
their associated pro-apoptotic proteins revealed that in
H1299 cells, BIM and BAK were bound to both BCL-XL
and MCL-1, whereas NOXA and BAD exclusively bound
to MCL-1 and BCL-XL, respectively (Fig. 6b). Exposure of
these cells to a combination of A-1331852 and A-1210477
resulted in displacement of most of these pro-apoptotic
proteins from their corresponding ant-apoptotic partners
(Fig. 6b). Importantly, none of these interactions/dis-
placements were altered in cells following DRP-1 down-
regulation, thus suggesting that DRP-1 played no role in
the early events of BH3 mimetic-mediated apoptosis. Since
BAK and other BH3-only proteins were released following
BH3 mimetics, we next wished to assess if BAK activation
was altered in the absence of DRP-1. Downregulation of
DRP-1 resulted in a significant decrease in BH3 mimetic-
mediated activation of BAK (Fig. 6c), suggesting that DRP-
1 was critical in the activation of BAK during BH3
mimetic-mediated apoptosis. Although the requirement of
DRP-1 for BAK activation could be demonstrated, no
binding of DRP-1 to the oligomerised/active BAK was
observed in these cells (Fig. 6d–f), thus suggesting the
involvement of other protein(s) in BAK activation imme-
diately preceding cytochrome c release. Taken together,
our data confirm that DRP-1 plays a critical role at the
level of BAK activation, facilitating OMM breaks, cyto-
chrome c release and apoptosis.
Discussion
BH3 mimetics, in particular ABT-737 and ABT-199,
induce a novel paradigm of cell death, characterised by
excessive swelling of mitochondrial matrix and dis-
continuities in the OMM in BCL-2-dependent chronic
lymphocytic leukaemia cells19,31. BH3 mimetics targeting
BCL-XL and MCL-1 also induce similar mitochondrial
ultrastructural changes in cells that exclusively depend on
BCL-XL and MCL-1, respectively (Fig. 1)
20. However, cells
exposed to the MCL-1 inhibitor, A-1210477, exhibit
marked mitochondrial changes, in particular mitochon-
drial fission, irrespective of their dependencies on a spe-
cific BCL-2 family member for survival (Fig. 3). This is in
agreement with our previous findings27. Mitochondrial
fission mediated by A-1210477 alone did not result in
apoptosis in these cell lines, even after prolonged expo-
sure27. This was most probably because most cell lines
derived from solid tumours depend on both BCL-XL and
MCL-1 for survival, and inhibition of MCL-1 alone was
not sufficient to result in apoptosis. This was further
supported by our observation that inhibition of MCL-1
using A-1210477 while resulting in extensive mitochon-
drial fission did not induce OMM breaks and cell death,
unless the activity of BCL-XL was also neutralised.
Although A-1210477-mediated mitochondrial fission
did not necessarily result in apoptosis, it was difficult to
ascertain whether such fission was a prerequisite for
apoptosis. This difficulty was partly because DRP-1
appeared to play important but distinct roles both in A-
1210477-mediated mitochondrial fission and BH3
mimetic-mediated apoptosis27. Moreover, DRP-1 also
interacted with MCL-1 and BCL-XL, thus coupling
mitochondrial fission and apoptosis23,27,36. However, with
the development of more potent inhibitors, such as
S63845, we have demonstrated that mitochondrial fission
does not occur at concentrations sufficient to inhibit
MCL-1 (Fig. 3). Furthermore, while mitochondrial fission
induced by A-1210477 and high concentrations of S63845
was mediated by DRP-1, mitochondrial swelling that
occurred at the onset of apoptosis induction was largely
independent of DRP-1 (Figs. 3 and 4), thus differentiating
the distinct types of mitochondrial fission.
Our data in the HCT-116 WT and BAX/BAK DKO
cells convincingly demonstrate that BH3 mimetic-
mediated OMM breaks and swelling of matrix compart-
ment are essential for BAX/BAK to facilitate cytochrome
c release (Fig. 2). The inability of HCT-116 OctaKO cells
to prevent BH3 mimetic-mediated mitochondrial changes
further supports our findings that BAX and BAK but not
the known BH3-only members are critical for BH3
mimetic-mediated apoptosis33,34. How BAX and BAK
localise to the sites of OMM breaks to facilitate cyto-
chrome c release is not entirely known. The involvement
of DRP-1, Dynamin-2, and even membranes of the
endoplasmic reticulum in these events have been pre-
viously proposed37–42. Downregulation of DRP-1 or its
receptors, MID49 and MID51, have been shown to
antagonise cytochrome c release and apoptosis in
response to a wide variety of apoptotic stimuli43. DRP-1
functions downstream of OPA1-mediated cristae remo-
delling (Fig. 5), to activate BAK (Fig. 6), which in turn
precedes BAK oligomerisation and membrane insertion
for the execution of MOMP and apoptosis. However,
mitochondrial cristae remodelling requires the presence
of BAX and BAK (Fig. 2)44. Thus DRP-1 could function
either downstream or independent of OPA1 proteolysis to
activate BAK and ensuing apoptosis. Taken together, our
data suggest that BH3 mimetics most likely activate BAX/
BAK independently of the eight known BH3-only mem-
bers, which further results in OPA1-mediated cristae
remodelling to redistribute cytochrome c within the
mitochondria, thus priming the mitochondria to undergo
MOMP, upon sensing the stress signal. DRP-1 plays a
critical role at this stage to activate BAK and/or BAX to
insert these effector proteins on mitochondrial mem-
branes. This along with the constriction of the primed
mitochondria by DRP-1 constitute the so-called stress
signals that cause OMM breaks, efficiently releasing the
redistributed cytochrome c into the cytosol and initiating
apoptosis.
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Materials and methods
Cell culture
H1299 (purchased from ATCC), K562 (provided by
Prof. R. Clark, University of Liverpool) and MAVER-1
cells (provided by Dr. J. Slupsky, University of Liverpool)
were cultured in RPMI 1640 medium (Life Technologies).
H929 cells (purchased from DMSZ, Braunshweig,
Germany) were cultured in RPMI 1640 medium supple-
mented with 0.05 mM β-mercaptoethanol (BME). Colon
cancer cell lines HCT-116 (wild-type and DKO) (from R.
J. Youle, National Institute of Health, USA) and HCT-
116-OctaKO33 were cultured in McCoy’s 5A Modified
media. All culture media were supplemented with 10%
FBS (Life Technologies) and maintained at 37 °C in a
humidified atmosphere of 5% CO2. All cell lines used in
this study were subjected to short tandem repeat (STR)
profiling to ensure quality and integrity.
Reagents
ABT-199, A-1210477 and Z-VAD.FMK from Selleck
(Houston, TX, USA), S63845 from Active Biochem
(Kowloon, Hong Kong) and A-1331852 from AbbVie Inc.
(North Chicago, IL, USA) were used. Antibodies against
HSP70 (cat#ab2799) from Abcam (Cambridge, UK),
OPA1 (cat#612607), cytochrome c (cat#556432) and
DRP-1 (cat#611113) from BD Biosciences (San Jose, CA,
USA); BCL-XL (cat#2762), BIM (cat#2933) and BAD
(cat#9292) from Cell Signalling Technology (MA, USA);
BAK (AB-1) (cat#AM-03) and NOXA (cat#OP180) from
Millipore (Watford, UK) and MCL-1 (cat#sc-819), BAK
(cat#sc-832) and GAPDH (cat#sc-25778) from Santa Cruz
Biotechnologies (Santa Cruz, CA, USA) were used. All
other reagents were obtained from Sigma Aldrich (St.
Louis, MO, USA).
Overexpression and genetic silencing
For transient overexpression studies, cells were trans-
fected with GFP-DRP1 K38A plasmid (provided by Dr. E.
Bampton, University of Leicester, UK), using TransIT-LT-
1 transfection reagent (Mirus Bio LLC, Madison, WI,
USA), according to the manufacturer’s protocol. For RNA
interference, cells were transfected with 10 nM of siRNAs
against DRP-1 (s104274235), MCL-1 (s8585 or
SI02781205) or BCL-XL siRNA (s1920) purchased from
Qiagen Ltd (Manchester, UK) or ThermoFisher Scientific
(Waltham, MA, USA). Cells were transfected using 0.33%
(v/v) Interferin reagent (Polyplus Transfection Inc., NY)
to culture media, according to the manufacturer’s proto-
col and processed 72 h after transfection.
Microscopy
For electron microscopy, cells were fixed in 2.5% (w/v)
glutaraldehyde and 2mM calcium chloride in 0.1M
cacodylate buffer (pH 7.4). This was followed by heavy
metal staining, which consisted of two consecutive
osmium tetroxide steps (2% (w/v) OsO4 in ddh2O), fol-
lowed by 1% (w/v) aqueous uranyl acetate. To prevent
precipitation artefacts, the cells were washed copiously
with ddH2O between each staining step. All fixation and
staining steps were performed in a Pelco Biowave®Pro
(Ted Pella Inc., Redding, California, USA) at 100w 20Hg,
for 3 min and 1min, respectively. Dehydration was in a
graded ethanol series before filtration and embedding in
medium premix resin (TAAB, Reading, UK). Seventy to
74 nm serial sections were cut using a UC6 ultra micro-
tome (Leica Microsystems, Wetzlar, Germany) and col-
lected on Formvar (0.25% (w/v) in chloroform (TAAB,
Reading, UK) coated Gilder 200 mesh copper grids
(GG017/C; TAAB, Reading, UK). Images were acquired
on a 120 kV Tecnai G2 Spirit BioTWIN (FEI, Hillsboro,
Oregon, USA) using a MegaView III camera and analySIS
software (Olympus, Germany). For immunocytochem-
istry, cells grown on coverslips were fixed with 4% (w/v)
paraformaldehyde, permeabilised with 0.5% (v/v) Triton
X-100 in PBS, followed by incubations with primary
antibodies (diluted 1:250 in 3% BSA in PBS), the appro-
priate fluorophore-conjugated secondary antibodies
(diluted 1:1000 in 3% BSA in PBS), mounted on glass
slides and imaged using a 3i Marianas spinning disk
confocal microscope, fitted with a Plan-Apochromat ×63/
1.4 NA oil objective, M27 and a Hamamatsu ORCA-
Flash4.0 v2 sCMOS Camera (all from Intelligent Imaging
Innovations, GmbH, Germany).
Cytochrome c release assay
Approximately 106 cells were washed in cold PBS and
resuspended in mitochondrial isolation buffer (250 mM
sucrose, 20 mM HEPES, pH 7.4, 5 mM MgCl2 and 10mM
KCl) containing 0.01% digitonin. Cells were left on ice
for 5 min followed by centrifugation at 13000 g for 3 min
at 4 °C. Subsequently, the supernatant (cytosolic fraction)
and pellet (mitochondrial fraction) were processed for
western blotting.
Size exclusion chromatography, immunoprecipitation and
western blotting
Size exclusion chromatography and immunoprecipi-
tation experiments were carried out as previously
described16,27. Western blotting was carried out
according to standard protocols. Briefly, 50 μg of total
protein lysate was subjected to SDS-PAGE electro-
phoresis. Subsequently proteins were transferred to
nitrocellulose membrane, probed with appropriate pri-
mary antibodies (diluted 1:1000 in Tris-buffered saline
with 0.1% Tween-20), species-specific secondary anti-
bodies (diluted 1:2000 in Tris-buffered saline with 0.1%
Tween-20) and protein bands visualised with ECL
reagents (GE Healthcare).
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Flow cytometry
The extent of apoptosis in cells following different
treatments was quantified by using an Attune NxT flow
cytometer (ThermoFisher Scientific, Paisley, UK) follow-
ing staining of the cells with AnnexinV-FITC and propi-
dium iodide to measure phosphatidylserine
externalisation, as previously described45. Loss in mito-
chondrial membrane potential (ψm) was assessed as
described previously19 by staining cells with TMRE, a
lipophilic fluorescent dye that accumulates in the mito-
chondria in relation to the membrane potential, and
quantified by flow cytometry. For BAK activation, cells
were fixed with 2% paraformaldehyde at room tempera-
ture for 10 min, washed with PBS and resuspended in a
buffer containing 0.1% saponin and 0.5% BSA in PBS for
10min. The cell suspension was then incubated with
0.1 mg/ml of anti-BAK AB-1 (Calbiochem Research Bio-
chemicals—now Merck, cat#AM-03) antibody for 1 h at
4 °C, followed by further incubation with goat-anti-mouse
IgG-AlexaFluor-488 conjugated secondary antibody for
1 h at 4 °C, before being subjected to flow cytometry.
Statistical analysis
Statistical analysis was conducted by using one-way
ANOVA with Bonferroni’s multiple comparison test was
performed to evaluate differences between numerical
variables. Asterisks depicted correspond to the following p
values: *p ≤ 0.05, **p ≤ 0.005 and ***p ≤ 0.001.
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